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clinical problems.
Since the early 1900*s, many investigators have studied the effects of pituitary
ablation and the mode of action of the hypophyseal hormones. Initltally, work was
mainly directed towards the purification and bioassay of the various hormones, although
the effects of hormone administration were also studied. Recently, attempts have been
made to synthesise some of the hormones. The aim of this thesis is to describe a
series of studies undertaken in an attempt to develop new assay methods for growth
hormone and the gonadotropins and the application of these procedures. (89)
An investigation of the bioassay for growth hormone depending on the increase in
tibial epiphyseal cartilage width in immature hypophysectomised rats has shown that
the method is not specific and is of low sensitivity. The procedure has been used to
compare the potency of pituitary extracts from different species and to provide a
measure of the effect on body growth and on cartilage width of two synthetic compounds
and of nerve section. A dithiocarbamoylhydrazine derivative, Compound 33» 828 (I.C.I.)
was found to have a markedly inhibitory effect on general body growth and cartilage
width, possibly due to the toxicity of the compound. A synthetic polypeptide, Ciba
50920-Ba which is claimed to have an adrenocorticotrophic hormone-like action on the
adrenal, had no marked effect on cartilage growth. It has also been shown that the
artificial induction of muscular atrophy in young rats by section of the sciatic nerve
did not interfere with cartilage growth and that the administration of pituitary hormones
to animals treated in this way was without effect. (166)
A haemagglutination-inhibition method has been developed for the assay of growth
hormone and has proved to be sensitive and highly specific. When estimates of the
growth hormone potency of standard pituitary preparations were made by both the bioassay
described above and the immunological method, similar results were obtained. The
immunological procedure was, however, found not to be sufficiently sensitive for
clinical application. A latex particle agglutination-inhibition method for the
quantitative determination of human chorionic gonadotrophin has also been developed.
Use other side if necessary.
This again proved to be unsuitable for clinical application. (88)
The pyruvic acid oontent of the immature rat ovary, both prior to and following
gonadotrophic stimulation, was estimated by two different methods. A marked rise in
pyruvic acid was noted following initial stimulation with pregnant mare serum
gonadotrophin, but this rapidly fell to a low level which could not be altered by
further gonadotrophic stimulation. The relationship between pyruvic acid and
gonadotrophic stimulation is discussed. (65)
The studies reported in this thesis have shown that the methods available for the
quantitative determination of growth hormone and gonadotrophins axe not entirely
satisfactory because of poor sensitivity or lack of specificity. However, despite
these limitations, useful information can be obtained by these procedures although it
is clear that they are not suitable for clinical application. The development of more
sensitive and specific methods for the estimation of these hormones is therefore
necessary and it is suggested that future work in this field should be directed
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As far back as 1886, Marie defined the disease state of
acromegaly and Minkowski, (1887) noted that it was usually
associated with an enlargement of the pituitary. It was, however,
not until Ashner (1909, 1910 & 1912) observed that hypophysectomy
in young animals resulted in dwarfism, that the existence of a
pituitary secretion which enhanced body growth was recognised;
at the same time, atrophy of the genital organs in hypophysectom-
ised dogs established the presence of a gonadotrophic secretion
from the pituitary (Aschner, 1912). The first definite proof of
the existence of this growth hormone came in 1921 when Evans and
Long produced giant rats by daily injections, over long periods, of
an extract of ox pituitary. In 1922, these workers reported that
in their crude pituitary extracts, the growth promoting factor was
chemically distinct from the gonadotrophic factor.
Over the next 30 - 40 years work was mainly directed
towards the development of assay methods and to the purification
of growth hormone. During the last 5-10 years attempts have
also been made to synthesise the hormone and to develop more
sensitive methods of assay which could be applied to its measure¬
ment in body fluids.
Assays Dependant on Weight Gain
The elaseieal methods for the assay of growth hormone
•» 2 —
depend on its ability to cause growth. Thus, as early as 1931,
Evans and Simpson suggested that a possible procedure was to
measure the increase in body weight of normal 'plateaued* rats
following the administration of growth hormone. Details of sen¬
sitivity and precision were not, however, reported. Full method¬
ological details were latex given by Marx, Simpson and Evans in
1942. They reported that good results were obtained when young
adult rats of between 5-6 months in age and weighing 220 - 280 g.
were used. The hormone was administered daily for 15-20 days
and the minimum effective dose was 250 |ig. /day. It was shown
tnat tire 20-day injection period gave a slightly steeper dose res¬
ponse curve, but figures for the index of precision^ X) were not
quoted. The method was subsequently shown to be reasonably
satisfactory with regard to its precision and specificity (F^asa-
Bech, 1947; Greenspan, Li, bimpson and Evans, 1950). The chief
disadvantages of the procedure are its high degree of insensitivity
and the lengthy injection period required, while its main advantage
is that the adsay requires intact rather than hypophyn ec tomis ed rats.
In 1942, Marx and his co-workers reported that the
weight gain test as described by Evans and Simpson (1931) could be
made more sensitive by the use of immature hypophy -sec tomis ed
rats instead of adult animals. In this proecure approximately 28
day old rats were hypophysectomised, rested for 10-12 days and
then given daily intraperitoneal injections of growth hormone for 15-20
3 -
days* The minimum effective dose was 30 ^.g. /day and as with the
original technique the 20-day injection period was found to give a
steeper dose response curve than did the 15-day period. Figures
for the index of precision were not quoted, but the method was
considered to be somewhat lees precise than that using plateaued
rats. Its main disadvantages lie firstly in the use of hypophy-
sectomised animals and secondly, in its lack of sensitivity which
makes it unsuitable for clinical application.
Attempts have also been made to develop a similar assay
method using intact dwarf mice by F^nss-Bech (1947) and Kemp
(1948). It is difficult to estimate the sensitivity of the procedure
because the results were expressed in terms of animal units. It
is clear, however, that thyroid-stimulating hormone (TSH) inter¬
feres with the method. A 2-3 week injection period is required.
More recently, Lostroh and Li (1957) noted that the hypophy-
sectomised mouse increased in weight when growth hormone was
administered daily for 17 days. The minimum effective dose was
15 tjig. I day. No attempt has, however, been made to develop this
as an assay method.
Increase In Tail Length
In 1938, Freud and Levie suggested that the increase in tail
length of the hypophycectomised rat might form the basis of an
assay for growth hormone. In this procedure the animal was
X-rayed before and after the administration of the hormone and
from the resultant skiagrams the increase in tail length, from the
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beginning of the first caudal vertebra to the tip of the tail was
measured. Eater, F^nss-Bech (1947) made a careful study of
this method and Dingeman&e, Freud and Uyldert (1948) used it to
measure the 'chondotrophin' (i. e. growth hormone) content of
human seriim. From these studies it is difficult to estimate the
sensitivity of the method, it would, however, appear to be low and
there is every indication that it is not specific. More recently, de
Groot (1963) has developed a modified method based on the syner¬
gistic effects of thyrozine and growth hormone. She claimed that
using a 3 week injection period, the effective dose range was
5-20 pg. GH/ day when administered together wife 6 y.g, thyrozine/
day.
Tibial Test
In 1941 Kibrick, Becks, Marx and Evans noted that if growth
hormone was administered to hypophysectomised immature female
rats at dose levels which did not have a significant effect on body
weight, a significant increase in the width of the epiphyseal carti¬
lage could be detected. It was, however, not until 1943 that this
method which is known as the 'tibial test* was first cited as a
possible bioassay for growth hormone by Evans, Simpson, Marx
and Kibrick. At this time it was considered to be more specific,
sensitive and practicable than the weight gain test in plateaued or
hypophysectomised rats. It was also shown feat with a 4-day
injection period the minimum sensitivity was approximately 40 ug. I
«• 5 —
rat. A full investigation of the assay was not carried out until
1949 when Greenspan, Li, Simpson and Evans studied the specifi¬
city of the procedure and attempted to define the limits within which
■
the assay could be successfully used. In the original method, a
lengthy staining technique was employed prior to the measurement
of the epiphyseal cartilage width. This was successfully simpli¬
fied by Greenspan et al. (1950) and their method is still the pro¬
cedure of choice.
By 1953, it had become apparent that the tibial test was too
insensitive for clinical application and was probably not specific.
Li (1953) suggested that the ideal test animal should be thyroidec-
tomised, adrenalectomy ed, gonadectomised and hypoph.yseetom.ieed
Such animals are, however, extremely difficult to obtain and to
keep alive and although the precision of the assay was greatly
improved, its sensitivity was considerably reduced. For this
reason animals of this type have not been used for routine clinical
studies.
Work in this field continued in the hope that greater sensi¬
tivity and precision would be obtained if the conditions of assay and
parameters measured could be correctly adjusted. In 1957,
Lostroh and Li reported a non-specific assay method using hypophy-
sectomised mice in. which greater sensitivity ( ^ 1 ytg. / day) was
obtained, but only at the expense of a much longer injection period.
The procedure has, however, not been widely used. The response
was still affected by other hormone preparations.
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Denko and Bergenetal (1955) explored the possibility of
measuring the uptake of C-35 into the chondroitin sulphate of the
tibial epiphyseal cartilage, and in i960, Collins and Baker
described an assay method for growth hormone depending on the
uptake of S-35 by the costal cartilage. Collins, Lyster and
Carpenter (1961), in a comparison of their E-35 uptake method
and the tibial test, claimed that the former technique was more
sensitive, precise and specific. The effective dose range was
3-20 yig. / day and 5 - 80 |ig. /day respectively! the index of
precision was 0.25 ana 0.45 respectively. It is,however of
interest to note that Tweed and MeCullagh (1962) in a careful study
of the same two assay techniques found very poor correlation
between the results obtained by the tibial test and the method
dependant ora 5-35 uptake.
A further modification of the tibial test is the P-32 uptake
technique of Hamori and Mess (1962). This autoradiographic
procedure appears to be somewhat simpler to carry out than the
£-35 method. It is claimed to be specific and to be three times
more sensitive than the tibial test. Its great advantage lies in the
use of intact neo-natal rats instead of hypophyeectomised animals.
Eats of this age have virtually no calcified bone ceils in the epi¬
physes and a comparison of the conventional tibial test and the P-32
method cannot be undertaken in the same animal.
In the first section of this thesis are presented the results
of a study on the tibial test (Chapter 2). The specificity of the
method has been reappraised with particular reference to the
effect of the other anterior pituitary hormones,, to adrenalectomy
and to the food intake of the test animals. The procedure lias
been applied to tne quantitative estimation of the potency of
various pituitary extracts obtained from different species, to
assessing the biological effects 01 two new synthetic compounds,
and to a study of die effects of certain surgical procedures on
growth of the tibial cartilage.
Cellular Growth
In 1962, Moon, Jentoft and Li showed that when human
liver cells were grown in a culture medium, they multiplied more
rapidly in the presence of human growth hormone, HGH, and that
the iaciease in the number of cell nuclei was proportional to the
amount of growth hormone used; the minimum dose being 75 ug. /
culture flask. The increase in nitrogen which was also measured
did not provide such a good index.
The procedure was said to be highly specific for HGH,
growth hormone from other species being ineffective. Attempts
to repeat this work in this laboratory were unsuccessful due to tire
failure to establish a viable culture of human liver cells. Although
highly insensitive it was hoped that this method might have provided
a means of standardising HGH preparations which would have
obviated toe use of hypophysectomised animals.
Chemical Methods
Several workers have attempted to develop chemical methods
» 9 »
of assaying growth hormone. These have all depended on the
ability of the hormone to alter certain metabolic reactions which
could be measured chemically. The moat frequently studied have
been t
a) the retention of nitrogen,
b) the reduction in blood - non - protein - nitrogen,
c) the rise in plasma non-esterified fatty acids (NEFA),~
- ■:* ' ' ' '• ' ' ■
d) the hypoglycaemic effect.
None of these procedures has provided a sensitive,
accurate or specific measure of growth hormone. Some of the
methods have, however, been used clinically to ascertain the
effectiveness of administered growth hormone. Thus It has been
assumed that a patient receiving growth hormone in whom a rise
in plasma NEFA or a nitrogen retention has been noted, showed an
anabolic response to the administered hormone.
It can be seen that the detection and assay of growth hormone
by biological methods is usually a long process involving laborious
and often non-specific techniques, and is quite unsuitable for appli¬
cation to the measurement of the hormone in body fluids. How¬
ever, in recent years the development of new and sensitive immun¬
ological techniques has opened up a new and promising field of
investigation. For these reasons attempts have been made to
develop sensitive immunological assays for growth hormone some
of which will be discussed below.
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£ Production of Antisera to Pituitary Extracts
During the 193Q's, Witebsky and Behreae (1932) and Kestaer
(1938) attempted to obtain antisera to anterior lobe pituitary
extracts. They were successful in obtaining low tifcre antisera
which were, however, not specific. This lack of specificity was
primarily due to the use of crude pituitary hereogenates as the
antigen. Work of this type has been continued in recent years by
Cruickshank and Currie (1958) who also failed to obtain specific
antisera and by Anigstein, Whitney and Rennels (1958) and by
Anigstein, Rennels and Anigstein (I960) who succeeded in charact¬
erising some of the antibodies present in an antiserum prepared
against the anterior lobe of the rat pituitary. In particular, they
found antibodies specific to growth hormone and to gonadotropins,
and suggested that weaker antibodies to ACTH and TEH might be
present.
Apart from this work on crude pituitary extracts, antisera
have also been prepared to highly purified pituitary extracts, in
order to ascertain the immunological homogeneity of such prepar¬
ations and as an index of the structural similarity of extracts from
different species.
Immunological Assay of Growth Hormone
Hayashida and Li (1958 abc) carried out anaphylactic shock
experiments, precipitin tests and an antihormonc experiment based
on the tibial tes^. in an attempt to study the immunological
properties of beef and human growth hormone antisera. These
-10-
wcrkers suggested that the development of a precipitin test might
provide an alternative as a ay method for growth hormone which
would be more sensitive and specific than the tibial test. They
claimed to be able to detect as little as I pg. beef growth hormone
and 0,1 fig. human growth hormone by such a procedure.
At the same time Head and Stone (1958) developed an
immunological method based on a haemagglutination-iuhibition
technique, using the ultra-sensitive antigen-tagged red cells
prepared according to the method of Boycea (1951). They claimed
to be able to detect as little as 0.001 jig. of a human growth hormone
preparation supplied by Raben (Boston, U.S.A.). Further papers
by Read and Bryan (i960 ab) gave details of the method, the
statistical method used to evaluate the results, specificity tests
employed and the values for human sera obtained.
Read and Stone's preUminary report proved to be a great
impetus to other workers, and in the years immediately following
there have been an increasing number of reports on the immunolo¬
gical assay of growth hormone. Initially, the method used was
Read's haemagglutiaatiae.-inhibition assay and serum growth
hormone levels estimated in this way have been reported by Boucher
and Mason (1961), Domiagues and Pearson (1962), Ehrlich and
Handle (1961 abc), Hartog and Russell Tracer (1961), Hayashida.
(1962) and Kaplan and Grumbach (1962 . The results obtained by
these workers, while in general agreement, show considerable
variability, the actual values obtained are quoted in Chapter 3
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Table 29. It is of interest that *11 the workers who used this pro¬
cedure find it to be unsatisfactory.
When it became apparent that the haemagglutination-
inhibition method was not satisfactory for the estimation of growth
hormone in biological fluids, other immunological techniques were
tried. In 1961, Trenkle, Moudgal, Sadri and Li imported that
human growth hormone could be estimated by a complement
fixation technique. This did not, however, prove sensitive enough
for clinical application.
More recently, radio-immunological assays have been
developed. In these assays, radio-isotopes are used to define the
end-point of antigen/ antibody reactions instead of the more conven¬
tional immunological end-points such as the formation of a visible
precipitate, agglutination or haemolysin reactions. The principle
behind this assay lies in the fact that the antibodies present in
antiserum react quantitatively with the appropriate antigen. If
the antigen present comes from more than one source the antigens
from the different sources will compete with each other for the
binding sites in proportion to the amounts originally present. A
source of antigen is therefore labelled with a radio-isotope (usually
1-131), and the amount of this required to give 80 - 100^ binding
of the antibodies ascertained. This amount of activated antigen
is then incubated with the test sample and a predetermined amount
of antiserum. At the end of the incubation period the free and
bound antigen fractions are separated and counted. The amount of
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added unactivated antigen can then be calculated by reference to a
standard curve.
Using this basic theory two different methods of assay have
been developed. The first to be described were those of Greenspan,
Cofell, Lew and Peng (1962) and Utiger, Parker and Daughaday
(1962) in which the end-point is an activated precipitin reaction.
The bound antigen is obtained in the form of a precipitin complex,
while the free antigen remains in the supernatant. This method
has a minimum sensitivity of about 3 mug. and a working range of
up to 400 mug. • it has been applied to clinical problems. The
second method is derived from the Yalow and Berson (I960)
technique for insulin. In this method the free and bound antigens
are separated from each other by electrophoresis on cellulose
acetate. It has been developed independently by Glick, Roth,
Yalow and Berson (1963) and Hunter and Greenwood (1962). A
more detailed report by the later workers was published two years
later (Greenwood, Hunter and Klopper, 1964). This procedure has
a minimum sensitivity of about 1 mug. and a working range of
between 1-20 mpg. i it gives results which correspond well with
the tibial test and has been applied to clinical problems.
Application of Immunological Techniques to Endocrinology.
Immunological techniques were first applied to the field of
endocrinology by Stavitsky and Arquilla (1953) who were trying to
establish the presence of insulin antibodies in patients exhibiting
insulin resistance, and subsequently developed the first hormone
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immunological assay. In the years following the publication of
Read1® method for the immunological assay for growth hormone,
in addition to the work on growth hormone and insulin many workers
have reported the successful production of antisera to other
hormones. Thus, antisera have been prepared to ACTH (Fishman,
McGarry and Beck, 1959; McGarry, Ballantyne and Beck, 1962),
Prolactin (I»aron and Asa, 1963; Levy and Sampliner, 1961, 1962),
TSH (Fishman et al.. 1959; Hayashida, Rankin, McCleland and
Contopoulos, 1961) and the gonadotrophins (Gold, Castillo, Baram
and Scommegna, 1962 and Segal, Laurence, Perlbachs and Hakim,
1962 who worked with NIH - FSH & LH; Moudgal and Li, 1961 abc
- sheep and human LH; McGarry and Beck, 1963 - human FSH;
Butt, Crooke, Cunningham and Gell, I960 and Butt, Crooke and
Cunningham, 1961 - HMG and HCG; Brody and Carlstrom, I960,
1961 & 1962, Lunenfield, Isersky and Shelesnyak, 1962, Taymor,
Goes and Buytendorp, 1964, Wide and Gemzell, I960 and Wide,
1962 v/ho all wo rked with HCG).
Immunological A spects of Hitman Chorionic Gonadotrophin
This hormone is produced in large quantities during early
pregnancy and the immunological work in this field has been
concentrated on firstly, the production of a rapid qualitative test
for pregnancy and secondly, the development of a rapid quantitative
method for the measurement of HCG in normal and abnormal
pregnancy.
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In 1959, Got, Levy and Eourrillcn published their findings
on the preparation of anfcisera to HGG. Three preparations
exhibiting different levels of purity were used and it appeared that
fee antigenic impurities present (in the aatisera formed) were of
human protein origin and could be eliminated by prior absorption of
fee antisera with normal human serum.
Since i960, Brody and Carlstrom Lave published a series of
papers dealing with the immunological assay of HCG by a modified
complement fixation test. These workers have estimated (1962)
the serum HCG in 474 subjects at intervals from the 5 - 4Gfch week
of pregnancy, and claim that their values are in agreement with
those of Loraine (1957). It would appear, however, feat the results
obtained were in general higher than those of Loraine (1957). In
IS patients with threatened abortions who subsequently aborted and
5 subjects with ectopic pregnancies abnormally low HCG levels
were found, while in 15 patients with threatened abortions but good
prognosis and subsequent normal pregnancies, HCG levels which
were within the normal range were observed.
Over the same period of time. Wide and Gemzell, (i960,
1962) have attempted to prepare an antiserum to HCG and to esti¬
mate HCG in urine using a haemagglutination-inhibition technique.
Their antiserum was not as pure as that of Brody and Carlstrom
and fee results obtained by these workers, which are probably
inaccurate, appear to be marked over estimates. Their immuno¬
logical values are four times higher than fee value obtained by
- 15 -
bioaeeay, although the overall pattern of their results is similar
to that of other workers, with peak levels of excretion occuring
between the seventh and the twelfth week of pregnancy. They
reported values below the normal range in 33 cases of spontaneous
abortion and levels within the normal range in 39 cases of threatened,
abortion.
Unlike Wide and Gems ell, Keele, Remple, Bean and Webster
(1962) were able to prepare a very pure HCG antiserum which
showed no cross reactions with human FEH or LH, although it did
show a cross reaction with human seromucoid. This antiserum was
capable of neutralising the biological activity of HCG both in vivo
and in vitro. When used to diagnose pregnancy, 26 cases were
studied and all gave positive reactions when tested between the 6th
and 14th weeks.
At the same period of time, Lunenfeld and his co-workers
studied the immunological properties of HCG. In 1962, they
reported the preparation of an antiserum to HCG which was capable
of neutralising the biological activity of HCG both in vitro and also in
vivo. This antiserum contained antibodies to serum proteins which
were serologically active but incapable of neutralising the biological
activity of HCG. It was suggested that this contamination could
cause the results obtained foy immunological means to be considerable
overestimates of the true potency. In a later study (Issersky,
Lunenfeld and Sheleenyak, 1963) they prepared an HCG antiserum
which was capable of neutralising the follicle-stimulating activity of
16
a human post-menopausal urine gonadotrophs (HMG) preparation
and an HMG antiserum which was able to neutralise the follicle-
stimulating activity of HCG. This means that both HCG and HMG
have a common follicle-stimulating antibody but whether this is due
to a contamination of both these preparations by FSH or indicates
the presence of a common follicle-stimulating principle inherent
in the molecule was not established by the experiments reported.
Immunological Pregnancy Tests
At least three such tests are now commercially produced.
A test based on the agglutination of latex particles is marketed by
Ortho Pharmaceutical Ltd. while tests based on the agglutination
of prepared red cells are marketed by Organon Laboratories Ltd.
under the name 'PregnaB^con* and by Burrough - Welcome under
the name •Puerpuerin*.
The Ortho Company elate, an accuracy of 97. 77 ♦ 0. 8%
in a series of 1,390 cases, which agrees well with the figures of
97. 99% and 94. 80% obtained by the Xenopuc toad test (1,193 cases)
and the rabbit (328 cases) respectively. Unlike the toad and
rabbit tests, the incorrect results were mainly due to false
negatives (2. 09%). This test has been used by a number of groups
in the U.S.A. and found to be a satisfactory method for the diag¬
nosis of pregnancy. Goldin (1962) reports 94.9% accuracy in
39 cases; Henry and Little (1962) 95% accuracy in 40 cases, the
latter workers got no false positive results in 48 non-pregnant
- 17 -
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women ranging in age from under 18 to over 50, while in a series
of 54 men, the 2 subjects presenting false positive results had
scrotal abcesses.
Raj, Bayron, Waltman and Green (1963) claimed 100%
.. ... .. ... * ... . . - "
accuracy using the 'Pregnosticon1 test as against 93, 5% accuracy
using the rat ovarian hyperaemla test. They reported that in a
series of 545 pregnant subjects and in 560 non-pregnant subjects
no inaccurate results were obtained by the immunological diag¬
nostic test while only 422 correct pregnancy results and 506
correct non-pregnancy results were obtained by the rat ovarian
hyperaemia test in the same subjects.
While immunological pregnancy tests appear to be an
inexpensive, rapid, simple to perform and reasonably accurate
method of diagnosis; it must, however, be emphasised that in
.
their present form only qualitative and no quantitative results can
... ......
'•' ' M ,; ' ' ' " ;• • • • . - .... •
be obtained.
In the second part of this thesis is presented the results of
an immunological study of growth hormone and of the gonadotrophiia,
Attempts were made to raise antisera to these hormones. The
haemagglutination-inhibition assay was established for growth
hormone and applied to the estimation of the growth hormone
potency of human pituitary fractions and human serum. The result
of an attempt to modify the qualitative latex agglutination-inhibition
pregnancy diagnosis test to form a quantitative assay for HCG are
also presented.
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Immunological Assay of FSH and LH
A number of workers have attempted to prepare antisera to
FSH and LH of both human and ovine origin. The work in this field
has been badly hampered by the lack of pure human or ovine FSH
and LH preparations.
Moudgal and Li, (1961 abc) have prepared specific antieera
to highly purified preparations of human and ovine LH, while Segal
et al (1962) have prepared reasonably specific antisera to NIH-
FSH- i and NIH-LH-SI. In spite of the preparation of these highly
specific antisera, reliable immunological assay methods for FSH
and LH have not yet been established, although Goss and Taymor
(1962) claim to be able to measure human LH quantitatively using
the Ortho Pregnancy Kit. They report good agreement between the
restilts obtained by the ventral prostate and immunological methods
when pituitary extracts are assayed, but not with urinary extracts;
they also claim that human FSH and ovine LH do not interfere in
this system.
At the present time, the most sensitive and specific methods
of estimating FSH and LH are biological in nature. The most
satisfactory of these are the ovarian augmentation test in intact
weanling mice (Brown, 1955) which is claimed to be specific for
FSH (Simpson, 1961) and has a sensitivity of approximately 15 ag.
NIH-F5H-SI, the ovarian ascorbic acid depletion test (Parlow, 1958,
1961) and the ovarian cholesterol depletion test (Bell, Mukerji and
Loraine, 1964) which are both performed in intact immature rats
- 19
and claimed to be specific for LH, they have an effective doee range
of 0.4 - 2.0 ijig. and 0.06 - 0.3 upg. NIH-LH-S3 respectively.
Biosynthesis of Cholesterol
By I960, the biosynthetic pathway for cholesterol had been
established (see Cornforth, I960 and fig. 1). Most of this work
had been done in vitro, by following the metabolism of labelled
(C*"13, C-14) substrateE by yeast cultures and liver slices (amongst
other references see Cornforth, Hunter and Popjack, 1953 abi
Cornforth, Gore and Popjack, 1957i Crosselin and Lynen, 1964 and
Woodford and Bloch, 1955). Claesson and Hillarp had demonstrated
the presence of a cholesterol-like oestrogen precursor in the ovar¬
ian tissue of rabbits (1947a) and of rats and guinea-pigs (1947b) by
histochemical means, while quantitative estimations of the choles¬
terol content of the ovaries of immature rate both before and after
gonadotrophs stimulation have been made by Mukerji, Bell and
Loraine (1965). Since the production and metabolism of choles¬
terol had proved to be highly sensitive to the administration of
exogenous gonadotrophs (Bell et al., 1964; Mukerji et ah. 1965)
it was thought that an investigation of some of the earlier steps of
the biosynthetic pathway for cholesterol might prove rewarding. It
was hoped that as well as obtaining quantitative information about the
presence of cholesterol precursors in the ovary, new assay methods
for the quantitative measurement of the gonadotropic hormones
might be developed.
The method of Searcy and Berquist (I960) is not specific for
Fit* It* toe BIOSYNTHETIC PATHWAY of CH0LE8TKB0L» TOGETHE1
WITH THE FORMULAS OF SOME OF TEE OOMFOUNQB*
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cholesterol, but is a colour reaction which gives an estimate of all
compounds present which have a similar ring A and ring B structure
to cholesterol. In view of the fact that this method of cholesterol
estimation was used by Bell and hie colleagues, it was thought that
a specific investigation into the two immediate precursors, lano-
sterol and desmosterol would not yield any further information.
It had been suggested (Robinson, 1932) that the straight
chain, isoprenoid compound squalene might px-ovide the carbon
skeleton of the cholesterol molecule. Laugdon and Bloch (1953)
showed that acetate could be metafeolically converted to squalene
and squalene to cholesterol, while the work of Cornfcrth and
Popjack (1954) appeared to confirm the rcle of squalene as an
intermediate in the production of cholesterol. Initially it was
thought that the most active biological precursor of cholesterol was
the isopreno id compound, the C$ acid - dimethylacrylic acid.
However ieotopic experiments have shown that the compound,
mevalonic acid is a much better precursor of cholesterol than
dimethylacrylic acid (Tavormiha, Gibbs and Huff, 1956). While .it
would have been interesting to investigate the mevalonic acid
content of the ovaries, it was found that the specific methods of
assay were too laborious and time-consuming for inclusion into a
bioassay procedure and no attempts were made to measure the
mevalonic acid content of ovarian material.
The acetyl co-enzyme A used in cholesterol biosynthesis
can be derived from either the break down of fatty acids or from
- 21 -
pyruvic acid. Pyruvic acid is a general metabolic precursor with
a very rapid rate of turnover and destruction following the removal
of tissues from the body (Neieh, 1957). It was thought, however,
that an investigation into the ovarian content of pyruvic acid
particularly following gonadotrophic stimulation might yield
interesting information about the general metabolic effects of the
goaadotrophins on ovarian material; especially as the most
sensitive available methods (Katsuki, Kawano, Yoshida, Kanayuki
and Tanulca, 1961; Bucher, Caok, Lampred-it and Latzko, 1963)
have a sensitivity of about 0.1 - 0,2 p moles pyruvic acid. In the
final section of this thesis is described a study of the pyruvic acid
content of ovarian tissue from immature rats and of the effects of
gcnadotrophin administration on the level of pyruvic acid.
- 22 -
CHAPTER II
TIBIAL TEST """"" "
INTRODUCTION
The first bioassay method for growth hormone was developed
in 1931 by Evans and Simpson and depended on the increase in total
body weight of plateaued rate, i, e, adult animals which had virtually
ceased to grow. Later various modifications such as the use of
hypophyeectomised immature rats were introduced in an attempt to
increase the sensitivity of the procedure. In the early 1940*8 a
test based on the increase in width of the proximal epiphyseal
cartilage of the tibia in hypophysectomised immature rats was
devised by Evans and his co-workers (1943), This method was
about three times more sensitive, was considerably more practi¬
cable than previously described assays, then became the assay of
choice for growth hormone. When first developed, this assay was
thought to be specific for growth hormone, but as purer hormone
preparations were made available it became apparent that this was
not the case, although little quantitative data on the subject has been
quoted in the literature. In the present study, conditions of assay
such as the length of the injection period, the minimum permissible
post-hypophysectomy rest period and the specificity of the method
were reinvestigated, with a view to using the assay for the quanti¬
tative determination of growth hormone.
The assay method is however, neither sensitive nor specific
enough, to be used for the direct measurement of growth hormone
-23 -
activity in body fluids. Nevertheless it provides an excellent method
for comparing the potency of different pituitary growth hormone pre¬
parations and the best method of comparing growth hormones from
different animal species, it also appeared possible that it could
be used as an index of body growth and in this form the assay was
applied to the assessment of two new synthetic compounds. It was
also used to investigate the condition of the epiphyseal cartilage in
animals suffering from artificially induced muscular atrophy.
MATERIALS AND METHODS
1. Hormones and Synthetics
The preparations used in this study will be discussed under
three headings, a) growth hormone standards, b) test preparations
including synthetics and c) the hormones used in specificity tests.
All the hormones were of pituitary origin,
a) Standards
The international standard replaced the Armour material and
.
both are of bovine origin. M. R. C. standard 'A* is a first attempt
.... '■■■'■ , u' .....
to supply a standard growth hormone preparation of human origin.
1. The International Standard - This is a growth hormone
preparation of bovine origin supplied by the Department of Biological
Standards, National Institute for Medical Research (N. I.M. R. )
London. This preparation consists of three batches of hormone
each of 25 g. ; two obtained from workers in the U.S.A. and one
from Canadian manufacturers. Mixing was carried out by dissolv¬
ing all the material together and then lyophilising the resultant
- 24
solution. Ampoules, which each contain 30 mg, of lyophilised
material were filled with dry nitrogen, prior to sealing and are
maintained at - 1G°C.
By definition of the Expert Committee on Biological Stan*
dardization of the World Health Organisation (W. H. O.) the growth
hormone activity represented by 1 i,u. is contained in 1 mg. of
this material. Contamination is as follows:-
TSH - 0.034 i.u./mg.
ACTH*<0.01 i.u./mg.
Prolactin - < 0.25 i. u, / mg.
2. The Armour House Standard 'Somar 'A1 - a growth
hormone preparation of bovine origin prepared by the Armour
Pharmaceutical Co. Ltd. and distributed by the Endocrinology
Study Section of the National Institutes of Health (N.I.H.), Bethesda,
Maryland, U.S.A. This is a lyophilised preparation and each
sterile ampoule contains 50 mg. The estimated potency of this
preparation is about 1.3 i.u./mg.
Contamination is as follows:*
TSH - <0.06 i. u. / mg.
ACTH - <0.02 i,u./mg.
Prolactin - <0.5 i.u./mg.
Gonadotrophin - <10.0 units/mg.
3. M.R. C. * Standard 'A* - a growth hormone prepar¬
ation of human origin supplied by N. I. M. R. Preliminary estima¬
tions of potency suggest that each ampoule has an activity equal to
- 25 -
,
about 0.14 i.u. (increase in body weight in hypophysectomised rats).
4. NIH -Beef and Sheep Pituitary Growth Hormones - Three
such preparations were supplied at different times by the N. I. H. I
two were of bovine and one of ovine pituitary origin. They are:-
NIH - GH - B2)
) beef
NIH - GK - B4)
NIH - GH - S3 eheep
Each preparation is claimed to be approximately equipoteat
with the International Standard and the contamination data is as
follows
< 0.01 i.u. /mg,
< 0.001 i.u./mg,
< 0.05 i. u. /mg.





FSH no detectable activity could be
found in 1.8 mg. of the growth
hormone preparation.
b) Test Preparations
The test preparations studied herein may be divided into
three groups. The first consists of a growth hormone of bovine
pituitary origin. The second of eight growth hormone fractions
prepared from human pituitaries, and the third of two synthetic
compounds.
1. 'KWA* Growth Hormone - this preparation was extracted
from bovine pituitaries by Dr. Kwa of the Antoni van Leeuwenhoek-
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Huis, Amsterdam. It is prepared from a sub-cellular pituitary
fraction according to the method of Tuynman, Kwa and Bloemendal
(1962).
2, Human Growth Hormone Preparations - All the human
growth hormones used were prepared by initial extraction with hot
glacial acetic acid according to the method of Raben (1957, 1959).





One, designated the Cambridge preparation, was prepared
in the Department of Biochemistry, Cambridge, U.K. The three
remaining preparations were supplied by the Imperial Cancer
Research Fund, and are>
ICRF 6
ICRF 6, peak 1
ICRF 6, peak 2
The two ICRF sub-fractions were obtained by fractionation
of a Raben-type growth hormone preparation (ICRF 6) on a G200
Sephadex Column; buffer 0.05 M borate, 0.05 M KC1, pH 8.6.
3. Synthetics -








b) Synacthen - Ciba 30920 - Ba - a synthetic polypeptide.
This synthetic compound consists of the ftl~24 amino
acid sequence of natural ACTH. It has a molecular
weight of 3,294 and an ACTH - like activity of about
100 i, u. /mg. (Schuler, Schar and Desaulles, (1963),
c) Hormones Used in Specificit y Tests
Only hormones derived from the anterior lobe of the
pituitary were used in the specificity studies. These were as
follows
1, Adrenocorticotropic Hormone - Two commercial
preparations available for clinical use were used in this study:
a) 'Zinc corticotrophin' supplied by Organon Laboratories Ltd,
This preparation had an activity of 100 i. u, / ampoule.
b) 'Acthar', manufactured by Armour Pharmaceutical Co,, Ltd,
Two preparations with activities of 40 and 70 i. u. I ampoule
were used.
2, Follicle-Stimulating Hormone (Ovine NIH - fsh - Si) -
This is distributed by the Endocrinology Study Section of the
National Institutes of Health (Bethesda, U.S.A.) and is contami¬
nated with 0,6% LH as estimated by the ovarian ascorbic acid
depletion test (Pariow, unpublished data).
- 2.8 m
Other contamination data:-
ACTH - 0.00044 i. u. / mg. (adrenal ascorbic acid depletion
method).
Prolactin - < 0. 15 i.u. /mg. (pigeon crop assay)
TSH - <0.01 U.S.P. units/mg. (F^ uptake)
GH - no detectable growth hormone activity in ten-day
weight teste following daily administration of 2. 5mg.
3. Luteinising Hormone (ovine NIH - .LH - SI) - This
preparation is distributed by the N. I. H. and total doses of up to 6 mg.
show no significant FSH contamination (increase in ovarian weight
assay).
Other cantanxination data :»
ACTH - 0.00025 i.u./mg.
Prolactin - no detectable activity following
administration of 25 mg. total
dose.
TSH - 0.015 U.S.P. units/mg.
GH - no detectable activity in tea-day
weight tests following daily
administration of 1. 0 mg.
4, Prolactin (ovine - NIH - P - S3 - This preparation,
distributed by the N. I. H. is said to have a potency of 15 i. u. / mg.
Contamination data is as follows
ACTH - 0.00025 i.u./mg.
GH - >0.1 and < 1,0%, i.e. less than
0.01 i. u. I mg.
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No detectable FSH and LH activity in amounts
of up to 8 mg. and 10 mg. respectively.
5. Thyroid-Stimulating Hormone - The following two
preparations were used in this study
a) NIH - TSH - BI. A preparation of bovine origin distributed by
the NIH for experimental purposes. It contains approximately
0.07 i.u./mg.
b) Ambinon. A preparation supplied by Orgasoa for clinical use,
with an activity of 10 u. s.p. units/ ampoule.
2, Animals
Two separate strains of rats were used in these studies.
Animals of the Wistar strain were bred in a closed colony main¬
tained in the laboratory in Edinburgh, while the Sprague-Dawley
rats were obtained from the Charles River Breeding Laboratories
Inc., Boston, Mass., U.S.A.
All hypophysectorais ed animals were of the Sprague-Dawley
strain and were hypophysectomised in the U.S.A.. before dispatch
to Edinburgh
3. Method in Detail
The tibial assay used was based on the method described by
Evans, et al. (1943), together with the modifications suggested by
Greenspan, et al. (1950). The assays were of a 4 - or 6 - point
design and the results were analysed according to the simplified
method of Gaddum (1953b) (See Appendix),
i) Procedure
Immature female rats were hypophys ectorais ed at age 21 -
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25 days when weighing 50 jh 2. 0 g. The rate were rested for
between 10 and 12 days after lrypophysectomy before receiving four
daily subcutaneous injections of the test preparation (dissolved and
made up to the required concentration in 0.9% saline). Twenty-
four hours after receiving the last injection the rats were killed
with ether and the tibiae dissected free. The pituitary fossa was
examined macroscopically for signs of pituitary remnants; the
tibiae from any rats exhibiting signs of pituitary remnants were
discarded. The tibiae were stored in 10% formol saline (10%
formaldehyde solution w/v in 0. 9% saline) until cartilage width
measurements could be made,
ii) Staining Procedure
a. Each tibia was halved longitudinally through the condylar groove
and down the tibial crest.
b. Cut halves were soaked in water for 10 minutes.
c. Sections transferred to acetone and left for 6 minutes,
; ' ' '
d. Sections washed in water for 3 minutes.
e. Sections transferred to freshly prepared 2% silver nitrate
solution and left cut surface uppermost for 2 minutes.
f. £Sections were then rinsed in water before being exposed under
water to a strong light for about 3-5 minutes (until calcified
portions were suitably darkened).
g. The sections were then thinned by further longitudinal sectioning
and the cartilage area between the stained calcified portions
measured with a Watson binocular microscope. Ax 10 objec-
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tive and a x6 micrometer eyepiece were used. The mean
epiphyseal cartilage width was calculated for each section
from the ten estimations made across each section .
iii) Histological Procedures
Histological sections were prepared in the following manner.
The tibiae were decalcified; median longitudinal sections were cut
and stained with haematoxylinjeosin to show the condition of the
cartilage plate and the surrounding bone. Photomicrographs of the
tibiae have been mounted, together with an arbitrary scale to
emphasise the difference in cartilage widths.
iv) Comment
In the majority of the experiments reported herein the
experimental conditions were identical to the above, however, in
some of the experiments described, the conditions have been
slightly altered. In particular, th® sex, age and weight range of
the rats, and the injection period, have been adjusted to meet the
requirements of particular experiments and these modifications are
detailed in the appropriate places,
RESULTS
The results presented herein will be considered under the
i . .... ...... ... >. •- - .
following headings. A) Tibial Test, B) Hormone Assays and
G) Applications of the Procedure.
The first section comprises the results of a typical growth
hormone assay by the tibial test, some experiments in which the
conditions of assay, i.e. the length of the post-hypophysectomy
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rest period and she length of the injection period, were examined
and the results of specificity tests which included some experiments
on feeding.
In the second section are reported the results obtained from
some experiments in which the potency of a number of growth
hormone preparations from different animal species was estimated
in terms of the International Standard.
The final section comprises the results of experiments hi
which two new synthetic compounds were tested for effects on body
growth and the effect of artificially induced muscular atrophy on
cartilage width was also examined.
A) Tibial Test
1} Typical growth hormone assay.
The results from a typical 6-pcinc assay of growth hormone
are shown in Table X. It will be seen that a four-fold dose interval
gives a reasonable inter-dose increase in cartilage width.
As will be seen from these results, each mean width shows
a very high standard deviation. This is the inevitable consequence
of the immense variability in inter-animal response and is the major
cause of the lack of precision in this assay.
It can also be seen that this assay method is highly insensi¬
tive, In the standard curve shown here a daily injection of 12. 5 ^ig.
for 4 days causes an increase in cartilage width which is not signi¬
ficantly greater than the mean control width. This indicates that
samples with concentrations of less than 50 jug. cannot be estimated
TABLE1
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accurately. None of the tibial assays carried out has proved to be
statistically invalid and so, where large quantities of material are
available, reliable estimations of potency can be made.
2) Modifications to the me tliod
The method, as described previously, is the standard pro¬
cedure used by most workers in this field. It was felt mat some of
the conditions - in particular, the length of the post-hypophysectomy
rest period, i.e. the period between hypophysectomy and commence¬
ment of growth hormone treatment; and the actual length of the
injection period - required investigation in order to establish the
optimal conditions for the assay in the colony of animals used,
a) The Effect on Tibial Epiphyseal Cartilage W idth of Altering the
Length of the Post-Hypophysectomy Rest Period
Introduction
The rest period of 10 - 12 days advocated by Evans
et al. (1943) in their original paper on the tibial assay has been
generally adopted by all subsequent workers in this field (e. g. Greenspan
et al., 1949; Li, 1953; Lostroh. and Li, 1957). The rest period
t . . .. • : '
not only allows the cartilage time to regress, but aiso enables
one to detect &:>imals in which the removal of the pituitary has not
"... ' • .
been complete.
The present study was undertaken in order to determine how
': '
quickly cartilage regression starts, and the earliest period after
hypophysectomy that cartilage regression can be said to be complete.
Method: ~
Bats were sampled at approximately daily intervale after
hypophys ectomy, and cartilage width measur eraexits made in the
usual way.
Results
The results of this experiment are shown in Table 2.
From the results it can be seen that there is a steady
depression of cartilage width over the first 6 days after hypophy-
s ectomy, thereafter no marked changes occur after the 8th day.
The width (228. 51 8, 55 p.) noted on the fourth day after hypophy-
sectomy is still significantly higher (P < 0. Ql) than, the width
(197.98 _+ 5. 11 ji) of the 'control1 animals which were killed on
the fifteenth day. The cartilage widths obtained from the lulled
6 days and more (e::cept animals killed on day 9) after hypophy-
s ectomy are not significantly different from those killed on the
fifteenth day. The animals lulled on day 9 had cartilage widths
which were significantly lower than those of the control animals.
9
Discuss ion
From this experiment it would appear that cartilage regres¬
sion is complete by 6 - 3 days after hypophyeectomy, and that the
12-day rest period recommended by Evans and his co-workers
(1943) is not really essential. If, however, the material to be
assayed is scarce, use of the 12-day rest period permits one to
reject with some certainty unsuitable animals such as weaklings and
incompletely hypophysectomised rats* However, if one is confident
TABLE 2.
The effect of hypophyseetomy on the width of the tibial
epiphyseal cartilage of immature female rats.











Intact1 6 304.27 - 13.59 <0.001
1 2 297.86 i 5.85 ^ 0.001
3 2 263.00 1 2.69 < 0.001
4 4 228.51 - 8.55 0•0V
6 2 174.52 - 3.90 0.0s\
8 2 205.24 - 4.39 N 0.50
9 2 169.16 1 8.29 < 0.05
10 2 191.59 - 12.19 > 0.50
11 6 180.86 1 9.09
• V-:-:i * $ ''
s 0.10
15* 8 197.98 - 5.11
(control) : , 5 '• • ' i
•
. ; ; . ; i '•/ . '' ;
- ' -i ' i ■' vi :' S
4 • , : ' • ? • • ;• • '• '■>
' Animals set aside before hypopfayaectoEy and killed immediately
on arrival in Edinburgh i.e. equivalent to the animals killed
1 day after hypophyseetoay.
rt ' -1 5 • ' ' ' . . »
* Standard control animals injected with 0.5 ml./day 0.95* saline
from day 11 to 14 inclusive and killed on day 15.
O 4 ' *
Significantly lower than the control value.
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that all the animals will prove to be satisfactory, and time is at a
premium, a shorter rest period can be used. This observation has
been used to reduce the experimental period of some long-term
studies reported hereafter.
b) The Effect of Length of the Injection Period en Cartilage Width
Introduction
Greenspan et ai. (1949) found that when the same total dose
was given over a three or four day period either intraperitoneal!'/,
subcutaneouely or intravenously, there was no significant difference
in the cartilage width response noted. If however this total dose
was given as a single injection or over a two day period, maximal
response by the cartilage was not attained. Increasing the frequen¬
cy of administration to two injections per day did not affect the
response.
In the present experiment the daily dose was kept constant,
but injection periods of four and fourteen days, with consequent
differences in total dose, were compared.
Method
The injection schedule is shewn in Table 3. Animals were
killed one day after the final injection and cartilage width measure¬
ments made in the usual manner.
Results
The results obtained ?re shown in Table 4. It will be seen
that there was no significant difference in the cartilage widths of
animals which had received four or fourteen daily injections, although
TABLE 3
Injection schedule showing dose / day and the total dose received
over a 4- and 14- day period.
Growth Hormone Total Dose Total Dose
Dose/Day over 4. days over 14 days
5 ;ttg. 20 jag. 70 jig.
10 jig. 40 jig. 140 jig.



















































































the total amount of growth hormone administered in each case was
widely different.
Discus e ion?-
From this experiment it would seem that a maximal increase
in cartilage width is attained after a four day infection period* a
finding in agreement with that of Greenspan ct ai.« (1949). These
workers, however, had kept the total dose administered constant,
so it was somewhat surprising to find, that, when in fact the total
dose administered was more than trebled during the 14 day injection
period, no significant difference in cartilage width was noted.
This implies that the cartilage responds to a daily stimulus, rather
than to a total stimulus.
It is possible that over a long period, the growth promoting
effect of the hormone diminishes and thus an apparently stable
width is obtained. It is also possible that continuous injections of
the hormone cause the formation of weak antibodies and that these
inhibit slightly the growth promoting activity of the hormone,
thereby producing an apparently constant cartilage width.
A four day injection period is therefore sufficient for assay
work. If, however, the injection period is extended to fourteen
days, it is possible that, while the growth hormone response remains
constant, hidden growth promoting contaminants may appear in
unknown substances. It may thus be advisable to prolong the
injection period when examining substances for non-specific effects
on cartilage width.
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3* Specificity of the k-ethod
introduction:
Following the development of increasingly pure hormone
preparations it became apparent that this test was not as specific
for growth hormone as had originally been thought. It was also
known that a reduction in food intake ox growing animals will prevent
an increase in weight, and even cause a weight lose if the reduction
in feeding is very severe. Becks, Simpson, Li and Evans (1944)
and Wyraan and Tu-n-Suden (1945) have observed that in normal
rats a reduction in cartilage width followed a period of reduced
feeding.
it has been suggested that the ideal test animal for the tibial
assay is one which is not only hypophysectomised but also adrenal¬
ectomy ed, thyroidectomy ed and gonadectomised (li, 1953). ACTH
is known to inhibit cartilage width (Becks, Simpson, Li and Evans,
194<ti but the effect of adrenalectomy per se is still in dispute.
The experiments in this group were designed therefore to
a) compare the effect of the anterior pituitary hormones ACTH,
FSH, LH, prolactin and TSH either alone or in comoination
with growth hormone on the epiphyseal cartilage width of the
tibia. The effect of these hormones on total body weight during
the experimental period was also noted.
b) compare the effect of starvation with the effect of hypopnysec-
tomy on the proximal epiphyseal cartilage of the tibia of both
sexually immature and mature rats; the histological appearance
of the cartilage was also examined,
c) study the effect on cartilage width of adreaaiecfcomising both
intact and hypophysectomised rate. The effect of adreaaiec-
tomy on body weight was also noted and a comparison of the
effects made.
a. The Effect of Anterior Pituitary Hormone
Method:-
In this experiment slightly older hypophysectornised male
rate weighing 100 10 g. were used. The hormones were admin¬
istered twice daily according to the schedule contained in Table 5
and the injection period lengthened to fourteen days. Animals were
weighed at the commencement of the injection period and again on
the final day of the experiment. The alteration in body weight
the treatment period was noted. Cartilage width measurements and
....... ... ..... .. . ;. .. . . .... ■
_ •
histological sections w . re prepared as previously described.
Results
The effect of hormone administration on both body weight and
on the width of the tibial epiphyseal cartilage are shown in Tables 6
and 7 and figure 2. The histological sections arc compared in Figs.
3 and 4.
Control Rats
A group of hypophysectomioed rats treated with saline was
used as controls. The final mean cartilage width was 132 +_ 5.34^u
and there was a mean increase of 3. 75 +_ 1.7 g. in body weight
during the injection period (Table 6).
TABLE 5.
Injection schedule for experiment to determine the effect






1. Saline 0.9^ 1.0 ml. 28.0 ml.
2. Growth Hormone «2i) NIH-B2 0.5 tag. 14..0 mg.








5. TSH •Aabinon1 0.5 i.u. 14.0 i.u.
6. AGTH 'Zinc Corticotrophin•
'Acthar'
1.0 i.u. 28.0 i.u.







































The effect of hormone administration on tibial epiphysis









£>•<$ Saline 4 132.0 ~ 5.34* 3.75
+
Ml 1.7*
AGTH 6 85.c£ 4.09* - 3.83 +«• 1.68*
Tm 7 177.4- 9.24* 17.0
♦
Ml 1.23*
Prolactin 7 192.8 * 5.34* 15.0 +m 1.17*
LH )





Hormone 7 292.0 - 6.18* 47.14
+
6.6*
Combined 1 6 268.3 - 10.47* 70.33
+
2.79*
Combined II 7 282.7 - 9.15* 67.43
+
2.72*
* Mean - Standard Error
TABLE 7
Effect of ACTS on the width of the Tibial
Epiphyseal Cartilage Plate and Body Weight







ju Mean - S.D.
Decrease in Total body
weight liean - S.D.
0.9%
saline 11 122.26 t 4.94 - 4*0 £ 3.15
AfiSi
■
12 100.30 £ 7.24 - 5.0 i 3.49
THE EFFECT OF HORMONE TREATMENT ON TIBIAL EPIPHYSEAL
CARTILAGE WIDTH AND ON 3Q0f WEIGHT IN THE INTACT AND
HYPOPHYSECTOMISED RAT,
























The administration of ACTH caused a reduction in cartilage
width (P< 0. 001) in two experiments but in body weight (P A 0. 02)
only in the animals which had been treated with the 'zinc cortico¬
tropin'.
Thyroid-stiinulating hormone
The administration of TSH caused significant increases in
body weight (P < 0.001) and in cartilage width (P C 0.01).
Gonadotropins
When LH and FSH were administered together a significant
increase in body weight {P C 0.001) was observed. Cartilage
width was however unaffected.
Growth Hormone
The animals treated with growth hormone alone showed an
increase in body weight of 47.14 + 6.6 g. and a mean cartilage
width (292. 0 +_ 6.13 fx ) which is more than twice the mean control
width.
Combined Hormones
When the hormones were administered together, the
increase in body weight was greater (P C 0.02) than the increase
in the group treated with growth hormone alone. There was no
significant difference between the two groups receiving the com¬
bined hom-onee although in one group of animals the dose was
double that in the other.
The combined hormones also produced a marked increase in
•« «
cartilage width} the effect observed was approximately the same
at both dose levels. No significant difference was fouac when the
mean cartilage width of the animals receiving the combined hormone
was compared with that of intact animals and animals receiving
growth hormone alone.
Histology
Figure 3 shows that in the hypophysectomised rat# AGTI-I
caused a considerable reduction in cartilage width {reading 2-3
scale units). Growth, hormone caused a marked increase over the
saline-treated control animals, the read-digs were respectively
10 - 11 and 4-5 scale units.
Figure 4 shows the effect of the administration of 'combined
hormones' at two dose levels to hypophysectomieed rats (see Tables
5 and 6). It will be noted that although the dosage in one group of
animals was half that in the other group, the effect on cartilage
width was approximately the same (reading 6 scale units in each
case).
Discussion
It was interesting to note that significant alterations in
cartilage width occurred following the administration of all the
hormones except the gonadotrophins LH and FSH. Except for A
which caused a significant depression in cartilage width, this alter¬
ation took the form of an increase in cartilage width. V hen the
experiment with ACTH was repeated using a completely different
preparation (ARMOUR's - AGTHAK), a marked depression of
\
Fig. 3»- PHOTOMICROGRAPH SHOWING THE EPFSCT OF GROWTH 30RMOWS
AND ACTII ADMINISTRATION ON THE CARTILAGE WIDTH OP THE










Fig. 4» - PTIOTOm CROGRAFHS SHOWING THE EFFECT OF GROWTH HORMONE
AND COMBINED HORMONE ADMINISTRATION ON THE CARTILAGE
WIDTH OF THE TIBIAE OF HYPOPinTSECTOMlSED RATS.
TIBIALEP PHYSEALCART LAGE HYPOPHYSECTOMIZEDANIMALS COMBINEDSALIGROWTHI HORMONESE IZEE Fig.4-.
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cartilage width was again seen. In this repeat experiment,
however, the lose ia total body weight noted was not significanjtly
different from the control value; this is probably due to the fact
that the saline-treated control group of hypophysectomised animals
also showed a slight loss in weight during the experimental period.
A significant loss in weight had been noted in the first experiment
when Organon's Zinc Corticotrophin was uoecl, but in this study
the control animals showed a slight gain in weight during the
experimental period. Cortisone is known to have a marked depres¬
sant effect on actively growing tissues (Ragan, Howed, Plotz, Meyejf
and Blunt, 1949; Sobel 1958; and Sayeed, Blumenthal and
Blumenthal, 1962, amongst others) and it is possible that ACTH
acts on cartilage growth by stimulating cortisone production from
the adrenal cortex; Angervall and Lundin (1962) have noted an
increase in adrenal weight following the administration of ACTH to
hypophysectomised pregnant rats; they alec observed a slight loss
in body weight during the experimental period.
The TSH used was a commercial preparation and not of a
particularly high standard of purity, so that its stimulating effect
on cartilage and body growth may be partly ascribed to this. Li
(1953), however, has found that thyroxine caused a considerable
increase in cartilage width (which also had a synergistic effect with
growth hormone) so it is possible that the effect noted here was
caused by increased liberation of thyroxine following stimulation of
the thyroid gland by the administered TSH.
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The percentage growth hormone contamination for the
prolactin preparation used is known and claimed to be more than
0.1% but less than 1%, i. e. in this study more than 1 yg, but less
than 10 tig./day. In a previous experiment (see length of injection
period) it had been found that while a daily Injection of 10 ug. /day
growth hormone caused an increase in cartilage width, this was
not, however, significantly different from the control value (P } Q. 1)l
It •would seem, therefore, that the marked effect of prolactin on
cartilage width cannot be entirely ascribed to growth hormone con¬
tamination, but must be, in part, an intrinsic property of the hor¬
mone. This would appeer to be a feasible hypothesis in view of the
present controversy as to whether human prolactin exists as a
separate entity or ac an additional biological effect of growth
hormone (Chadwick, Foley and Gemzell, 1961; Wallace and
Ferguson, 1961. .Recently, however, Apostolalds (1965) has
claimed that he has isolated human prolactin and shown it to be a
separate hormone. He has prepared human pituitary fractions
which have a relatively high prolactin activity and a low growth
hormone activity (about 0.3 i.u./mg.) but he considers that the
growth hormone activity is due to contamination of the fraction
rather than an intrinsic growth promoting activity of the prolactin
hormone.
When the two gonadotropins were administered together,
they had no effect on cartilage width although they caused a small
but significant rise in body weight. These were the only hormones
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to show different effects in the two assay methods and it was
interesting to see that they had a positive effect in the body weight
test which has been claimed to be the more specific and precise,
if les6 sensitive of the two bioassays for growth hormone (li, 1953).
It would appear, therefore, that all the anterior pituitary
hormones cause a significant alteration in body weight. It was
interesting to note that when the hormones were administered
separately, the animals receiving growth hormone showed the
greatest increase in body weight, approximately three times
that seen in the animals treated with TSH and Prolactin. If,
however, the hormones were administered jointly there was a
marked synergistic effect, the body weight increase being approx¬
imately 50% greater than that seen in animals treated with growth
hormone alone, even when the growth hormone content of the
mixture was half the amount given to growth hormone treated
animals. Synergistic effects of anterior pituitary hormones upon
body weight in the pigeon have also been noted by Bates, Miller
and Garrison (1963).
Similarly, significant alterations in cartilage width were
noted following the administration of all the hormones except the
gonadotrophins LH and FSH. A synergistic effect was not noted as
a maximal tibial response appears to have been obtained with the
dose of growth hormone administered. While the conditions of
this experiment would mask the appearance of a synergistic effect
- 44 -




Two groups of Spragtte-Dawley rate with mean body weights
of 100 g. and 250 g. respectively were used. The rats in the lower
weight range were then sub-divided into three groups, one group
was hypophysectomised and maintained on an unrestricted diet, the
remaining intact animals were divided into two groups, one of which
was allowed to feed ad libitum, the other group was placed on
reduced feeding so that the body weight was maintained at the same
level as that of the hypophysectomised rats. The older rats were
also sub-divided into two groups. One group consisted of hypophy-
sectomised animals fed ad libitum; the other, of intact animals,
was fed sufficient to maintain the body weight at the same levels as
that of the hypophysectomi6ed animals.
One tibia from each animal was prepared for cartilage
width measurements as previously described. For the histological
examination, sections were made from tibiae selected at random
from each of the subgroups and prepared as described earlier.
Results:
The results are shown in Table 8 and in Fig. 5.
Effect on body weight and cartilage width
Where the body weight of intact animals was maintained at
the same level as that of the comparable hypophysectomised group,
\
TABLE 8
The effect of feeding on the tibial epiphysis and body weight
in hypophysectoralsed and intact rats.
Feeding No. of Width of Tibial Increase in





Hypophysectoralsed Unlimited 4 132.0 ± 5.34 * 3.75 ± 1.7 *
Intact Reduced
food 6 149.2 + 10.25 * 3.0 + 1.9 *
Intact Unlimited 6 276.3 £ 11.64 * 104.1 £ 3.8 *
Initial Weight
250 g.
Completely Unlimited 5 81.9 ± 4.39 * -16.4 + 5.3 *
hypophysectoralsed
nypopityl^ctoini sed Unlimited 2 149.3 ± 15.97 * +49.0 - 3.0 *
Intact Reduced 7 97.9 + 3.43 * -12.9 + 2.6 *
* Mean + Standard Error
\
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the cartilage width ox the intact animals was found to be of the same
order as that of the hypophysectomised rats. There was no differ-
■ ■
... A ^ ^ m .
ence at the lower weight range, although a slight but insignificant
difference (P > 0. 1) was apparent in the animals from the higher
weight range.
Histology
The sections shown in Fig. 5 were taken 1) from an intact
rat on reduced food, 2) from a partially, and 3) a completely
hypophys ectomis ed rati the latter two animals were on unlimited
food. The sections show that although the widths of the intact and
of the completely hypophyseetomised cartilages were almost the
same (readings approximately 3 scale units), the cartilage cells
*■
from the hypophysectoraised rat appeared to be much more atroph¬
ied than those from the intact animal. The section from the par¬
tially hypophysectomised rat showed a similar atrophy of the
.
cartilage cells but an increase in plate width (4-5 scale units)
suggesting that the pituitary was still partially functional.
Discussion
Both Becks et al. (1944) and Wyman and Turn-Sudan (1945)
had noted a reduction in cartilage width in animals following reduced
feeding. This observation was confirmed in the present study where
in both intact immature and intact mature rats fed sufficient to main-
tain, but not to increase the body weight, the cartilage width was
reduced to the same level as that seen in the hypophys ectomis ed
group, whose growth had been arrested by removal of the pituitary.
5f PBOTOMICROGRAPH SHOWING 1!IE EFFECT OF FEEDING ON TBI
CARTILAGE >YIDTfi OF THE TIBIAE OF PITUITARY INTACT
AND HfPOPHYSECTOMISED SATS.
TIBIALEPIPHYSEALCARTILAGE INTACTHYPOPHYSECTOM1ZED PARTIALCOMPLETE REDUCEDFOOADLIBD Fig.5.
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However, it was observed in the present experiments that the
cartilage cells of the hypophys ectomis ed group showed a consider¬
able degree of atrophy not seen in the 'starved1 group, suggesting
that the 'growth arrest' of these animals was only temporary and
could be reversed again by unlimited feeding.
It would appear, therefore, that over - or under-feeding
of rats being used for a tibial assay might materially affect the
final result obtained. It is to be hoped that if animals have
unlimited access to a balanced diet and an adequate fluid supply




Young male rats (100 + 10 g. ) hypophysectomised 24 hoi*.rs
before air transport and intact animals of a similar weight range
imported at the same time, were unilaterally nephrectomyed 4-5
days after hypophysectomy. The animals were unilaterally neph¬
rectomy ed in order to study the effect of hypophysectomy and
adrenalectomy on Iddney growth, but as this procedure appeared to
have no effect on tibial cartilage growth it can be dismissed from
further consideration. Half the intact and half the hypophysecto¬
mised rats were bilaterally adrenalectomyed at the same time.
The rats were lulled 14 days after adrenalectomy and the tibiae
treated in the usual manner.
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Results
From Table 9 it would appear that adrenalectomy per se
had no effect on the cartilage width of intact animals although the
weight gain observed during the experimental period was less
(P < 0. 01) than that of the intact animals. A group of hypophy-
sectomised rats was also adrenalectomised, but only two out of
twelve survived the double operation. The difference in cartilage
width between this latter group and the hypophyeectomised group is
not significant, but whether the result is meaningful, in view of the
extensive mortality of the adrenalectomised animals, is question¬
able.
Discussion
The effects of adrenalectomy and ACTH on cartilage width
and body weight noted by various workers are highly contradictory.
Buffet and Wyman (1955) observed that there was a significant
increase in cartilage width following adrenalectomy in intact rats
(ages 80 - 200 days), a finding which supported that of Maasen (1951)
who considered that adrenalectomy stimulated epiphyseal growth.
The claims of Maasen were based on somewhat flimsy evidence
gathered from measurements of tibial length; not cartilage width
measurements. On. the other hand Wyman and Tum-Suden (1945)
and Ingalle and Hayes (1941) observed a reduction in cartilage width
following adrenalectomy. Wyman and Tum-Suden ascribed this to
•self-starvation* in their young animals as cartilage width was
restored to control levels following salt treatment and restoration
TABLE 9
Effect of bilateral adrenalectomy and hypophysectomy
and ACTS administration on the body weight and the width
of the tibial epiphyseal cartilage of












Pituitary intact 12 301.27 ± 12.09 62,05 + 5.29
Pituitary intact/
adrenalectomised 11 296.42 + 11.32 41.18 £ 3.46
Hypophysectomised/
adrenalectomised 2 132.47 + 20,84 1.0 + 0
Hypophysectomised 11 122.26 + 4.94 -4.0 + 3.15
Hypophysectoraised,
2 i.u. ACTH/day 12 100.30 ± 7.24 —5,0 + 3.49
Hypophysectoiaised/
adrenalectomised,
2 i.u. ACTfl/day 3 119.06 + 8.25 -10.6 + 6.44
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of appetite. The observations of Wyirian and Tum-Suden appear to
be confirmed in this experiment in which adrenalectomy per se did
not appear to affect cartilage growth in either intact of hypophy-
sectomised rats. Adrenalectomy did, however, appear to have a
deleterious effect on the general health of hypophysectomised rats,
and few survived the double operation.
It would seem, therefore, that routine tibial assays would
not appreciably benefit by the use of test animals which had been
both hypophysectomised and adrenalectomyed.
B. Hormone Assays
Comparison of the Potency of Various Growth Hormone
Preparations.
Introduction
The growth hormone content of all but one of the preparation:
listed at the beginning of the chapter have been estimated in terms
of the international standard. Wherever possible 6 *• point assays
were performed, but in some cases of duplication and shortage of
material 4 - point assays were used.
ResrJts
The results of sixteen such assays are shown in Tables
10, 11 and 12. All assays were proved to be validj the five 4-
point assays showed no significant deviation from parallelism,
while the remaining eleven 6-point assays showed, in addition, no
significant curvature of the dose response curve.
TABLE 10
comparison of ftrtoraattonal §tafl4arfl witfr Armour










3*3 0.744 40 - 125% 0.235 Edinburgh
0.75
; . X
52 - 98% Standards*
Committee
The assay used is described as depending on the growth rate of
hyper-thyroid mixed animals. It probably means the increase in
body weight rather than the tibial assay.
While the International Standard therefore has a potency of only
75% of that of the Armour Standard, it was decided that 1 i.u.
Growth Hormone represents the activity contained in 1 mg. of the
International Standard.
TABLE11



















































































Armour House Standard - Sornar A
A comparison of the International Growth Hormone Standard
with the Armour House Standard (Somar A) shows that the Inter¬
national Standard has an activity of only 74.4% (fiducial limits
40 - 125%) of that of the Armour material (Table 6). This result
agrees with the findings of the biological standards committee
which accepted a final figure of 75% (95% confidence limits 52 - 98*
obtained using the growth hormone assay based on the increase in
body weight of hypophysectomised immature rats. As the Comm¬
ittee agreed to define the International Unit of Growth Hormone as
the activity contained in 1 mg. of the prepared International
Standard, this means that 1 mg. of Armour Standard has an acti¬
vity equal to 1.34 i.u. growth hcrmone.
Beef and Sheep Pituitary Growth Hormone Preparations
As will be seen from Tables 10 and 11, except for the
recently prepared Kwa 'soft' preparation of growth hormone this
makes the Armour material the most potent preparation of growth
hormone tested. It is interesting to note the very high level
(1.63 i.u. /mg. ) of activity obtained in material which has not been
subjected to harsh chemical procedures.
Using a preparative system based on the Cohn fractionation
technique, which involves alcohol precipitation at low temperatures,
the beef and sheep growth hormones supplied by the National
Institute of Health, U.S.A., were approximately equipotent with
each other, but had a somewhat lower activity (approximately 0.7 -
- 50 -
0. 8 i. u, / mg, ) than the International Standard.
Human Pituitary Growth Hormone Preparations
The even harsher technique of pituitary extraction used by
Raben, which involves extraction of the pituitary material with
glacial acetic acid at ?0°C, has resulted in preparations with a
relatively low activity (about 0.4- i.u./mg.). It is possible that a
high proportion of the growth hormone material consists of dena¬
tured protein formed during extraction by the Raben method and
therefore biologically inactive.
The ICRF material which was also prepared according to the
Raben method is approximately twice as active (0.8 i. u. / mg, ),
the result of further purification procedures aimed at producing a
highly purified preparation. It was interesting to note that when
this preparation was subjected to further separation on a G 200
S ephadex column (buffer 0. 05 M bo rat e, 0, 05 M KC1, pH 8.6)
two distinct fractions were obtained. These were designated Peak
1 and Peak 2. Peak 2 appeared to have a high biological activity
(1.14 i.u. /mg) while Peak 1 had a very low activity (0. 16 i.u. /mg.).
The estimates of biological activity in each fraction agree with the
estimates of immunological potency made by Dr. Hunter, who found
that the respective immunological estimates of the growth hormone
activity of Peaks 2 and I wore one-and-a-half and one-fifth the
activity of the initial material. It is not yet clear as to whether
Peak 1 is mainly denatured protein or a 'prolactin1 fraction with
only a low biological activity.
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The material supplied by the Medical Research Council *
MRC Standard A - also shows a high activity (0. 11 i. u. I ampoule,
i. e. approximately 1.0 i.u./mg. ). It also has been subjected to
stringent purification procedures, as it has been prepared for
clinical use and as a U.K. standard for human growth hormone.
The Cambridge human growth hormone was prepared for
immunological work, and therefore submitted to stringent purifi¬
cation procedures before assay. This material was also found to
have a high biological activity (1.17 i. u./mg. }.
Discussion
The fiducial limits of the tibial test are usually wide and the
lambda figures frequently high. Lambda figures of 0.225 (Binge-
manse et al., (1943) to 0.330 (Gemzell and Heijkenskjold, 1956)
have been reported in the literature; the lambda figures obtained
in these experiments have usually been much higher (range 0. 197 -
1. 09). High lambda figures are usually taken to indicate a lack of
precision, but here they simply reflect the combination of a high
standard deviation and a reiatively shallow slope, la the tibial
assay, high standard deviations are the inevitable consequence of
the variability of animal response and groups of 5 - 6 animals have
been used wherever possible, in order to minimise this effect.
As the fiducial limits of all the assays overlap, it seems
reasonable to conclude that the test preparations have common
identity and are in fact growth hormone.
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C. Applications of the Tibial Test
Effect of Dithiocarbamoylhydrazine derivative - Co i poand
33,828 (I.C.I.) on Cartilage Growth
Introduction
This dithiocarbamoyl derivative, compound 33,828
(Imperial Chemical Industries) had been shown to inhibit pituitary
gonadotrophs function in rats (Paget, Walpole and Richardson,
1961), Brown (1963) considers that compound 33,828 reduces the
formation of pituitary gonadotrophin, but whether it acts as a
selective or total pituitary depress eat was not however determined.
In this study, the effect of the compound, when administered
alone or in combination with growth hormone (NIK - B - 2), on
growth-promoting activity as judged by the tibial test in hypophy-
eectomised rats was examined.
Materials and Methods
1, Compound 33, 328
2. Growth hormone - beef - (NIH-B-2),
Both compounds were dissolved in 01N NaOK and made up to
the desired concentration with 0,9% saline. The injection schedule
is shown in Table 13, The dose of growth hormone (50 ug/day)
used was selected because it was known to have a marked effect on
cai-tilage width. The doses of compound 33, 828 (1, 5, o, 0 and
24,0 mg,/kg.) administered to the rata were comparable to tho6e
given to human subjects (Bell, Brown, Fotherby, Loraine and
Robson, 1962), A standard four-day tibial assay was carried out.
TABLE13



















































































The effects of growth hormone and compound 33, 828
separately and in combination onthe width of the tibial epiphyseal
cartilage and on body weight of hypophysectomised immature female
rate are shown in Table 13. It can be seen that the lowest dose of
the compound had no effect (P > 0. l)m on cartilage width, although
the two higher doses caused considerable reductions in cartilage
width (P <1 0.001 in both cases). When administered together with
beef growth hormone, all three doses inhibited the action of the
hormone (PC 0.001 in all cases), the degree of inhibition depending
on the amount of the compound administered.
Although only the short four day assay period was used, the
effects on body weight show a similar trend. Only the animals
treated with the highest dose of the compound showed significant
differences. A small overall loss in weight (mean - 2,4 g.) was
observed in the treated animals, and when compared with the
animals receiving saline this loss was significant (P < 0.01).
Weight gain in the rats treated with the compound plus growth
hormone was no different (P > 0.1) from that of the control animals,
but was significantly less than that of animals treated with hormone
alone (P <0.001).
Discussion
These results indicate that in the rat compound 33, 828 is
capable of inhibiting growth. While its action on body growth is
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similar to that of ACTH (see page ), weight loss and cartilage
regression also occur during reduced feeding experiments. From
this experiment, it was not possible to decide whether the growth-
.
inhibiting effect of this compound was mediated through the adrenal
.
gland (although it was noted that the mean adrenal gland weight -
Table l^t - of animals treated with 1200 ^.g,/day of the compound
together with 50 p.g/day of growth hormone was significantly greater-
P CO. 001 in both cases - than that of either the saline or growth
hormone treated animals, implying increased adrenal activity in
' ' " • ; ■ • " -• * '
this group) or simply a self-imposed starvation effect resulting
from a general toxicity inherent in the compound. Brown (1963)
had observed general toxic effects with high doses of the compound,
.
but considered that the depression of pituitary FSH noted could not
be entirely ascribed to toxicity. It is probable therefore that some,
.
if not all, of the growth inhibition seen hi this study reflects a true
biological effect of this dikuccarbamoylhydrazine derivative,
6, Effect of a Synthetic Polypeptide - CJBA 30920 - BA. on
Cartilage Width.
Introduction
This synthetic polypeptide is a straight chain compound
consisting ox the j3 1-24 amino acids found in natural ACTH, it
has been shown to have ACTH-like activity and it is claimed that
0, 01 mg. of this compound has an activity comparable to 1 i. u. of
natural ACTH (Schuler, Schar and Desaulles, 1963),
TABLE M
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0.9?' saline 6 9.16
♦
0.60
23,828 (75 i|g) 5 8.60
♦
0.81
33,828 (300 yg) 5 8.80
♦
0.73
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In this experiment, the effect of the compound in a dose said
to be equivalent to 1 i.u./day (-which in the natural ACTH was known
to have a marked depressant activity on cartilage width) was studied.
Results
The results of this experiment are shown in Table 15. It
will be seen that, while there is apparently a slight increase in the
cartilage width of animals treated with the Ciba synthetic, there is
no significant difference in the cartilage response of this group and
the saline control group.
Discussion
The results of this experiment were completely unexpected.
Schuler et al., (1963) had shown that the material depleted adrenal
ascorbic acid (Sayer's test for ACTH) and had melancyte activity.
By 1962 Li had shown that natural ACTH consisted of a 39»amino
acid polypeptide; the 25 - 39 amino acid sequence being variable
between species and considered by him to be non-essential for
hormonal activity. He had also examined a synthetic polypeptide
consisting of the ^ 1-19 amino acids and shown, it to have both
high ACTH and melanocyte activity. Thus it was expected that the
Ciba synthetic compound would have had a marked depressing effect
on cartilage growth.
Several explanations are available. The first and simplest,
is that not enough of the compound was administered. In the two
experiments in which natural ACTH was used a total dose of 28 i.u./
animal over a 14-day period was administered as against 4 i.u./
TABLE 15.
tt nf ml line










0.9^ saline 8 197.98 - 5.11 1.1846 >0.2
Gibs. 30920 - Ba 8 214.98 * 13.42
• 56 *
animal over a 4-day period here. This would imply that ACTH
requires a longer period of time than growth hormone to make its
effect observable.
A second explanation could lie in the fact that this compound
is more rapidly destroyed than natural ACTH and therefore may
have been rendered inactive before it could depress cartilage growth*
The third explanation could lie in the structure of the
compound* The synthetic molecule is much smaller than natural
ACTH, and consists only of the 1-24 amino acids, v/hich,
however, it is claimed are the active components of the natural
ACTH* it is, however, possible that die growth inhibiting proper¬
ties may be associated with the amino acids sequence 25 - 39,
which has up till now been regarded as being concerned simply with
species specificity and not to be essential for the biological activity
of the hormone*
The first and second hypotheses could be proved or disproved
by repeating the experiment. If, a higher total dose, administered
more frequently over a prolonged period did net diminish cartilage
width, it would seem that the third hypothesis was the most feasible.
7. The effect of anterior pituitary hormones on the tibial
epiphyseal cartilage of rate in which atrophy of the gastrocnemius
muscle has been experimentally induced.
Introduction
There is practically no information available at present on
the relationships between muscular atrophy, bone growth and
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hormone treatment although Simpson, Evans and. Li (1949) observed
muscular hypertrophy accompanied by bone growth in hypophy-
sectomised rats following treatment with growth hormone.
The present study was undertaken in order to determine the
action of individual anterior pituitary hor.non es on the tibiae of rats
in which muscular atrophy had been induced by section of the nerve.
In this way it was hoped to ascertain whether muscular atrophy
would modify the tibial response to hormone administration, and
whether this response would be affected by the time at which the
hormone was administered. In the series of experiments recorded
here in non-hypophy-sectomi&ed animals, the hormones were
administered either prior to or immediately following nerve section,
or after muscular atrophy had occurred.
hiaterialc and Methods
The rats were of the Wistar strain and had a mean initial
weight of 56 g (range 49 - 72 g)i male and female rats were used in
equal numbers wherever possible. In all groups apart from the
unoperated animals (lulled on day of operation), atrophy of the
gastrocnemius muscle was produced by cutting the n»rve on one
side. The nerves of right and left legs were sectioned in equal
numbers. In order to prevent reirmervation of the muscle during
the post-operative period a portion of the nerve (mean length 15 mm.)
was removed.
The animals were subdivided into three main groups which
were treated in the following way:-
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Group A - animals were treated for 9 days prior to and 2
days after operation and killed on the 12th post¬
operative day.
Group B - animals were treated for the 11 days immediate¬
ly post-operative and killed on the 12th day.
Group C - animals were rested immediately after operation
and treated from, the 9th - 21 si day, being
killed on 22nd day.
Apart from the unoperated animals, rats were injected
with one of the following
1. C. 9% saline -0.5 mis/day
2. Growth hormone - NUI - GH - - 2 p.glday
3. Adrenocorticotrophic hormone (ACTK) - *Zinc Corticctrophin1
Organon - 2 i, u. I day
4. Thyroid-stimulating hormone (TSH) - NIH - TSH - Bl - 1 i. u. /
day
5. Follicle-stimulating hormone (FSH) - NIH - FSK - SI - 1 mg./
day
At death the tibiae were dissected out and stored in 10%
formol saline until the ca.rtilage width could be measured. All
cartilage- width measurements were made according to the modi¬
fied method of Greenspan, et al. (1950).
R e suits
The results have been summarised in Tables 16 and 17 and
Fig, 6.
TABLE 16.
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246 I 41 J 13
250 J 20 J 9
195 * 36 * 16
242 J 83 J 29
260 - 29 5 9
246 - 35 J 16











190 J 61 J 19
251 - 32 - 10
218 + 50 - 16
184 I 61 I 19
274 x -43 r 13











202 j 33 i 10
228 I 31 7 10
193 - 56 - 19
209 7 31 I 10
240 7 29 J 9











202 J 67 J 30
214 J 24 x 11
220 - 33 - 15
189 I 61 t 27
251 x 12 ? 5











192 J 54 J 13
276 - 59 r 19
199 - 30 - 12
196 J 45 7 14
279 7 39 7 12




Uhoperated = sni&als killed on day of operation.
Group A as animals treated fof 9 days prior to, and 2 days
after, operation and killed on 12th post¬
operative day.
Group B = animals treated for 11 days immediately post¬
operative and killed on 12th day.
Group C = animals treated from the 9th to 21st day post¬
operatively and killed on 22nd day.
TABLE 17.
Effect of honrcne traatasat on the tiftlae of rats with
a.rtifieiaJ.lv Induced atrmihv nf tha m.gtmenMlus amsaln .











































































Ifaoperated = animals killed cn day of operation.
Group A = animals treated for nine days prior to and 2
days after operation and killed on 12th post¬
operative day.
Group B a animals treated for 11 days immediately post¬
operative and killed on 12th day.
Group 0 = animals treated from the 9th-21st day post¬
operatively and killed on 22nd day.
Pig. EFFECT OF HORMONE TREATMENT W THE TIBIAE OF HATS WITH
ARTIFICIALLY INDUCED ATROPHY OF THE GASTROCNEMIUS MUSCLE
UNOPERATED i.e. ANIMALS .KZLUBD OK MY OF OPERATIC.
GROUP A i.e. ANIMALS TREATED FOR 0 DAYS PRIOR TO,
AMD FOR 3 HAYS AFTER OPERATION AND
KILLED ON THE I2TII POSTOPERATIVE DAY.
GROUP a i.e. ANIMALS TREATED FOR 11 DAYS IMMEBIATELY
POSTOPERATIVE AND KILLED OH THE 12TH
POSTOPERATIVE DAY.
GROUP C I.e. ANIMALS TREATED FROM THE STH - 21ST
POSTOPERATIVE DAYS AND KILLED ON THE
22ND DAY.














The unoperated animals, i.e. those killed on the day c£
operation, have a mean cartilage width of 242 + 29p.* The mean
width (innervated leg) of none of the sub-groups is significantly
different from that of the unoperated group; neither can a differ¬
ence between the cartilage widths of the innervated and denervated
limb £ be observed within any of the sub-groups.
ACTH, Growth Hormone, and FSH
The results observed following treatment with ACTH,
Growth Hormone and FSH were surprisingly similar. In spite of
the apparent difference in the cartilage widths of innervated and
denervated limbs observed in ACTH group A and group B, and in
Growth Hormone group A and group B, none of the groups showed a
significant difference. The cartilage widths of the ACTH group A
animals were narrower than those of the matching controls (P < 0.05
denervated leg; P < 0, 01 innervated leg and P < 0.1 innervated
leg v. unoperated limbs); as were also those of the growth hormone
group A treated animals (P < 0.02 denervated leg and P < 0.001
innervated leg.) A similar reduction in cartilage width can be
seen in the FSH treated group A animals (P d. 0,05 denervated leg;
P d,Q. 001 innervated leg and P < 0. 001 innervated leg v. unoperated
limbs).
TSH
No difference in epiphyseal cartilage width was observed
between the innervated and the denervated legs of the TSH treated
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group A and C animals, although the cartilage width of the dener-
vated leg was considerably less than that of the innervated leg in.
the group B. When the TSH treated groups are compared with
their matching controls, the cartilage width of the TGH group B -
denervated legs is less than that of the appropriate control
(P < 0.05), as is also that of the TfH - group P - innervated leg
(P C 0.01).
Discussion
The experiment was designed in order to ascertain whether
atrophy of the gastrocnemius muscle affected tibial epiphyseal
cartilage width, and whether the response was modified in any way
by treatment with individual anterior pituitary hor ones. Hormone
treatment was given i) prior to nerve section ii) in the immediate
post-operative period, and iii) after atrophy was established, in
order to fix in time any interaction of hormone treatm ent and the
establishment of muscular atrophy, i. e. to find out if the epiphy¬
seal cartilage of the tibia is more sensitive to hormone treatment in
the days immediately prior to nerve section, during the period of
atrophy induction, or after atrophy is well established.
From the reEults reported here it would appear that section
of the sciatic nerve, with resulting atrophy of the muscle, did not
modify the width of the tibial epiphyseal cartilage in normal rats
treated with saline in the above manner when examined 12 and 22
days after nerve section, although muscular atrophy was by this
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time well established.
The general lack of response amongst the rats treated with
hormones was somewhat surprising, especially when compared with
the results obtained on muscle weight. The reduction in cartilage
width noted in all but one of the hormone treated group A type ani¬
mate is extremely difficult to explain. In this connection it is of
interest to note that the administration of both ACTK and growth
hormone caused a marked diminution in cartilage width of both
Innervated and denervated limbs. This eatabolic effect is quite
contrary to the more usual marked increase in cartilage width
following growth hormone treatment (Hecks et al 1941), although
it ha3 been observed following the administration of A CTH (Becks
et al 1944). In fact a lack of response by these animals could
have been explained more easily, as it could have been ascribed to
the treatment schedule: in these animals, hormone treatment was
discontinued 9 days before death. Any effect, therefore, could hav*
worn off by the time the tibiae were removed. On the other hand,
this suggestion does not explain the non-response observed in
groups B h C, as in these groups hormone treatment was not
discontinued until the day preceding death. It in possible, however,
that despite the massive doses of hormone used in this experiment,
these were not sufficiently large to superimpose their usually
marked effects on rats with intact hypophyses.
Finally, it is just possible that positive responses may have
been masked by the large standard errors encountered; the wide
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range observed it probably uue to cue fact that rats with intact
hypophyses were useti in tnis stuay, and whue the initial weight
range was not excessively wide, it is very poesiole that the growth
. ' ' ■ ; ...
rats* axao. perforce t&e c&ruiage wiatn of xnaiviauai rat&* was very
, . > - ' . ■ , ' ' , • ■ ' ■ " j. ':
different.
: 1 ■ I i' " ; - - i '
Over the last two uecaaes the tibiai test has been the most
widely acceptea bioassay -uetaou for growth hormone. in spite of
various modifications, tue procedure nae not been appiicaoie to
clinical problems. Gemzeil, neij^enekjoia ana ttrom (1966) and
Gemz,ell (1969) have nowever, reported tue presence ox a growth
'
promoting substance, which fcaey considered to be growth hormone,
in fractionated plasma samples from acromegalic subjects. While,
.
one would expect growth hormone to be present in the blood of
active acromegalic, recent work has shown that it would be most
unlikely for the levels to 0e high enough for it to oe detected by the
tibial test, in the worn presented herein, it has oeen shown that a
• • "
daily injection of 6 ^-tg./ rat for 4 days produces a rmai mean carti¬
lage width which is not significantly greater than chat shown by
animals have received only U. 9vo saline. This figure for the sensi-
'
tivity of the ubiai test should be compared with the work using
radio-immuno-assay methods which nave shown the level of growth
hormone in acromegalic blood to be in the region of 0.1 jug./ml.
plasma (Glick, ec al. , 1963). As one would expect the levels in
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normal subjects and other disease states to be rather less than the
acromegalic figure, this means that the tibial assay is virtually
useless for clinical estimations.
The assay is however of value in the comparison of differ¬
ent preparations of pituitary growth hormone, in particular of
preparations from different species. It has been found that the
epiphyseal cartilage of the rat appears to respond to growth hormone
of widely divergent origin, including a wide variety of mammals
(li, Papkoff and Jordan, 1959) and other vertebrates such as a
fish (the shad), frogs and chickens (Solomon and Greep, 1959).
Although the rat tibial epiphyseal cartilage plate apparently exhibits
a non-specific response to growth hormone, Solomon and Greep
(1959) claim that when equal weights of crude pituitary extracts
were tested, the rat cartilage was apparently more sensitive to
amphibian and mammalian extracts than to those obtained from
piscine, avian and reptilian pituitaries. This is only to be
expected and an interphylur difference has also been shown for
prolactin, Forsyth (1964) claims that a human growth hormone
preparation which appeared to have a very low prolactin concen¬
tration (about 4 i.u./mg.) when tested by the pigeon crop assay
proved to have a much higher concentration (about 15 i,u./mg,)
when tested in the rabbit. It is probable, that, in the experiments
reported here, the very marked variation in potency of the different
pituitary extracts noted, is due, not so much to iiater-species dif-
ferencies as to variations in the methods of extraction and
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purification used. It has been noted that the material (all of human
origin) prepared and obtained direct from Raben (Boston) had a
consistently low activity, although material (also of human origin)
initially prepared by his method and then further purified for use in
clinical and immunological work had a consistently high biological
activity (Cambridge, ICRF & MRC). Similar differencies in the
potencies of the bovine and ovine pituitary growth hormone prepar¬
ations were also observed; it was interesting to note the very high
biological activity of Kwa*s 'soft1 bovine preparation, which was
simply prepared by submitting a pituitary homogenate to high
speed centrifugation and separation on a Sephadex column. It is
tempting to contrast this very high activity wife the generally low
activity of the Raben preparations and to ascribe the difference to
fee extraction methods. It is probable, feat, the Raben method,
which includes extraction of the pituitaries with hot glacial acetic
acid (70°C.), is a very harsh chemical procedure when compared
to the relatively gentle Kwa method, and that it is accompanied by
a certain amount of denaturation of protein which will result in a
material with a relatively low biological activity.
In 1959, la et al. observed feat when fee same weight
(5 jag. /day) of growth hormone from a number of mammals was
administered to the hypophysectomised rat, there was a marked
difference in the cartilage width and body weight responses to fee
different growth hormones. After 4 days the tibial widths were
approximately the same (indicating apparent equipotency) for all the
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growth hormones, but after about 10 days a divergence in the body
weight response became noticeable. At about this time the body
weight of animals receiving primate, i. e, human and monkey,
growth hormone appeared to reach a plateau, and although treatment
was continued for 90 days failed to show any further response, while
the animals receiving bovine and whale growth hormone continued
to respond i, e. increase in weight, throughout the entire period,
Differences between the body weight and cartilage width responses
were also observed in the experiments reported here. The differ¬
ence was most marked following the administration of combined LH
and F5H, these hormones had no effect on cartilage width i, e, bone
growth, but caused a marked stimulation of whole body growth as
measured by an increase in total body weight. While, the difference
noted, following the administration of growth hormone and the two
levels of combined hormones, could be ascribed to a differential
response, it is more probable that a synergistic effect of the com¬
bined hormones cn tibial width has been masked. From the results
obtained it is obvious that a near maximal tibial stimulation was
produced by a daily dose of 1 mg, growth hormone, but that the
body weight increase was by no means maximal. It was also
interesting to note that, in the experiment designed to test the
optimal injection period, that while maximal cartilage width stimu¬
lation occurred within 4 days, body weight was still increasing after
14 days.
The tibial test has also been applied to the assessment of the
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general growth properties of two new compounds. It was interest¬
ing to note that, while the synthetic polypeptide Ciba 30920 - Ba
with known ACTH-like activity did not have an inhibitory effect on
cartilage width, the pituitary inhibitor I. CI. 33, 828 did show a
marked depressant action on the cartilage. Since, Li (1962) had
shown that a synthetic B 1 - 19 amino acid chain had ACTH-like
effects and could stimulate cortisone production by the adrenal and
similar properties had been shown for the B 1 - 24 synthetic poly¬
peptide Ciba 30920 - Ba )Schuler et al., 1963) it was surprising
to find that this prodiict had no apparent effect on cartilage width.
The mode of action of naturally occuring ACTH on cartilage growth
is still somewhat obscure. It has been suggested that ACTH acts
on the adrenal cortex to stimulate the production of cortisone
(a known growth inhibitor, Ragan et al 1949} Sobel, 1958) which
then acts on the cartilage (Becks et al. 1944). Becks and his co¬
workers foitnd that in pituitary intact rats, ACTH did not cause
cartilage regression in adrenalectomyed animals, however, the
results of an experiment in which marked cartilage depression was
observed following the administration of ACTH to rats which had been
both hypophyeectomised and adrenalectomy ed were inconclusive due
to the very high mortality encountered in both the control and treat¬
ment groups (see page and Table 9). It is, however, possible
that this was a real effect, indicating that the inhibitory effect of
ACTH on cartilage growth is a direct effect, rather than one media¬
ted through stimulated adrenal production of cortisone} and that this
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action is located somewhere in the fi 25 - 39 amino acid chain which
has so far, been considered to be concerned only with species
specificity and is absent from the structure of the synthetic compound
thus suggesting that the lack of depressant activity of this compound
on cartilage growth is due to the absence of a specific growth
inhibitor located scrra where in the f3 25 - 39 position.
On the other hand it was equally surprising to find that the
dithiocarbamoylhydrasine derivative (I.C.I. 33,828) had a very
marked depressant action on cartilage growth. It had been shown
to inhibit pituitary gonadotropic action (Paget et al. , 1961 i Bell
et al. , 1962), but it was not known whether the compound had a
general or a specifically gonadotropin inhibitory action on the
pituitary. If it was a general inibitor, it could act by inhibiting
growth hormone release from the pituitar" in much the same way
as some of the monoamine oxidase inhibitors prevent the release of
pituitary growth hormone (7, or, Didcketein and Sulman, 1965). If,
however, its action on the pituitary was specifically one of gonado¬
tropin secretion inhibition, it would seem unlikely to have an effect
on cartilage growth, unless it was one of general toxicity. Brown,
(1963) observed that the compound produced marked signs of toxicity,
and as the animals in the experiment presented here showed a
tendency to lose weight it is possible that some of the effect of this
compound on tibial epiphyseal cartilage width was simply a reflection
of the general toxicity of Compound 33, 828. However, the experi¬
ments presented here do not elucidate the mechanism of action of
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these two new products.
.
It has long been thought that a relationship existed between
some muscular diseases and the pituitary gland (for references see
Adams, Denny-Brown and Pearson, 1962; Herman, 1953 and Shy,
■
I960). Muscular atrophy is followed by a general withering of the
•» '
affected limb and it was thought that application of the tibial test to
. - .
an experiment in which muscular atrophy was artificially induced in
rats might provide some useful information about bone growth in
this condition. It appeared, however, that under the conditions
of this experiment, bone growth was not affected, even though
.
the animals became very lame. Hormone therapy in these
animals did not appear to have an appreciable effect on cartilage
growth.
It would appear, therefore, that the future use of the tibial
assay lies in 1) the standardisation of new growth hormone prepar¬
ations, 2) the assessment of ,growthl promoting or inhibiting
properties of synthetic compounds and 3) its application to the
.
elucidation of the physiological effects of protein hormones in the
experimental animal.
SUMMARY
1. The tibial assay method for growth hormone has been established
and some of the conditions of assay examined.
2. Specificity teste which included observations on the effect of the
anterior pituitary hormones ACTH, FSH, LH, Prolactin and T3H
feeding experiments and the effect of adrenalectomy on the width
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of the tibial epiphyseal cartilage in hypophyeectomised imma¬
ture rats, have been studied.
3. The potency of 13 pituitary growth hormone preparations
(3 of bovine, 1 of ovine and 9 of human origin) has been
estimated in terms of the International Standard.
4. The effects of a dithiocarbamoylhydrazine derivative Compound
33, 828 (ICI) and of a synthetic polypeptide Ciba 30920 - Ba on
the cartilage width of hypophyeectomised immature female rats
have been investigated.
5. The effect of hormone administration on the condition of the
tibial epiphyseal cartilage in pituitary intact immature animals






The first suggestion that immunological techniques might
be applied to the field of endocrinology was that of Ltavitsky and
Arquilla (1953) who were investigating the presence of insulin
antibodies in the blood of patients showing a marked insulin resis¬
tance. In 1956, Arquilla and Stavitsky prepared an insulin anti¬
serum in rabbits and applied immunological methods to the assay
of purified insulin. Although Ferguson and Boyden (1953) recorded
the formation of high titre antisera to BGH in sheep, which could
be detected by the tanned cell technique, it was not until 1958 that
Read and Stone reported, they had set up a haemagglutination
system to beef growth hormone which mig X be used as a possible
method of assay for the hormone. This was followed by a large
number of papers recording attempts to prepare antisera to other
hormones (for references see Jhapter 1). The majority of these
workers hoped to establish simple, specific quantitative assay
s
methods for the hormone, but in addition many investigators on
HCG were looking for a simple, quick and foolproof pregnancy test
which would also be cheap to perform. In the early 1960*8 Ortho
Pharmaceutical Ltd. brought out a commercial pregnancy diagnosis
test based on an agglutination reaction between an HCG antiserum
and suitably HCG-fcagged latex particles.
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The aim of the work reported herein, was firstly, to
establish a sensitive assay method for human growth hormone
which could be applied to clinical problems, and secondly, to
establish a quick, specific and sensitive assay method for HCG
which could be applied to the quantitative measurement of the
hormone in urine and blood samples.
MATERIALS AND METHODS'
1. Hormones
The hormones employed in this section were used for three
purposes, namely a) raising antisera in rabbits, b) specificity
tests and c) assay experiments.
a) Hormones vised for raising antisera.
Bovine growth hormone - Armour 'Eomar A1,
Human growth hormone - Raben 6.
Follicle-Stimulating hormone - NIH - Si,
Luteinising hormone - NIH - SI.
Human Chorionic Gonadotrophin - Organon •PregnyV
Pregnant mare serum gonadotrophin - Organon 'Gestyl*.
All the above hormones except for the two Organon prepar¬
ations (Pregnyl and Gestyl) have been described in the Tibial Test
Section (see pages 23 - 29 ). Both the Organon preparations had
been standardised in terms of the appropriate International Standard
prior to distribution.
t>) Hormones used in specificity tests.
In addition to the hormones quoted above, the following
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hormones which have also been described in the Tibial Test Section
(see pages 23-29 ) were also used in specificity tests:-
Bovine growth horraone - NIH - B2
Ovine growth. hormone « NIH - S3
Thyroid-stimulating hormone - NIH - Bl
Adreno-corticotrophic hormone - Armour 'Acthar*
c) Hormones used in assays,
i. - Standard Preparations
Beef growth hormone - Armour 'Somar A*
Human growth hormone - Raben 6
Human chorionic gonadotrophin - International Stand¬
ard
ii - Test Materials
Beef growth hormone - NIH - B2
Human growth hormone - Raben 6
Human pituitary extract - a crude pituitary extract





have been obtained by further separation of the
extract on a DEAE-cellulose column.
Human chorionic gonadotrophin - Organon 'Pregnyl*
2. Preparation of Diluent
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In view of the fact that serum proteins from different
animal species may crossreact, it was considered necessary to
restrict the number of species involved as far as possible. It
was therefore, decided, in view of the fact that the antiserum was
prepared in rabbits, a phosphate buffered saline (1/15M: 0.9% N-Cej
pH 6.4) containing 1% normal rabbit serum (NRS) should be used as
the diluent.
In early pilot experiments the NRS used was prepared in the
laboratory, however, in later experiments the DIFCO preparation
war employed. Following exhaustive tests with a number of red
cell preparations, both control and antigen-coated, it was found
that in no case was the addition of the cells to a phosphate buffered
saline containing 1% NRS (Bifco) followed by either spontaneous
agglutination or haemolysis of the cells even when the tubes were
left for 2-3 days at + 4*C. The Difco NRS preparation was,
therefore, considered to be satisfactory for routine work.
3, Preparation of Antis era in Babbits
A specific antiserum can only be prepared from a pure
antigen. The application of immunological techniques to hormone
assay has therefore, only become possible since the preparation of
pituitary hormones of high purity.
Protein hormones are of themselves only weakly antigenic
and in order to obtain an antiserum of high titre, they have to be
injected in a suitable adjuvant. The adjuvant is used to assist in
the formation of antibodies, firstly, by slowing down the rate of
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abeorption and therefore of destruction of the antigen, and secondly,
by stimulating the antibody producing mechanisms. It was found
that the light mineral oil mixture known as Freund's Incomplete
Adjuvant (F.I. A.) recomn:ended by Read did net give a measurable
antibody titre following the administration of growth hormone to
rabbits. With a commercial preparation (Difco) of Freund's
Complete Adjuvant (F. C.A.) which, however, consists of F.I. A. t
Idlled mycobacteria, reasonably high titres could be obtained after
a series of 3 or 4 injections.
In view of the fact that hormone preparations are seldom
completely pure, there is a danger of selective fixation of the anti¬
body, i, e, the production of antibodies in greater concentrations
to the contaminants than to the main antigen present. Lack of
pure antigens is the main factor affecting the specificity of the
antiserum. However, if contaminating antibodies are present, it
is possible by simple absorption techniques to reduce their concen¬
tration considerably. The cleanliness and specificity of the anti¬
serum can then be confirmed by irnmuno-diffusicn and immune-
electrophoretic techniques.
a) Immumsation with beef and human growth hormone.
Healthy young male or female rabbits of about 9-12 months,
preferably with long pendulous ears and large ear veins, were chosen
In all cases they were acclimatised to their new surroundings for
3-4 weeks, prior to the commencement of the injection schedule.
* 75 -
An emulsion consisting of 2. 5 rag. hormone dissolved in
2.5 ml. 0.9% saline and 2.5 ml. F.C.A. was prepared. Half of
this preparation was injected intraperitoneal!'/ and the remainder
eubcutaneously in the back of the neck. The injections were
repeated at intervals of 2 weeks. Fourteen days after the third
injection, approximately 5 ml. blood were removed from the ear
vein, and tested by the double dilution method, in order to obtain a
rough estimate of the antibody titre. If the tifcre was above 1 :
3,000, the animal was bled again; 30 - 40 ml. being withdrawn
from, a 2. 5 kg. rabbit. If the titre was below 1 : 3,000 injections
were continued at 14 - day intervals until a satisfactory level was
reached.
b) Immunisation with Human Chorionic Gonadotrophin (HCG).
The preparation of HCG used was 'Pregnyl'j 300 i.u.
were dissolved in 2. 5 ml, 0.9% saline arid an emulsion prepared
using an equal volume of F. C. A. Animals were then treated as
described for growth hormone.
c) Immunisation with Pregnant Mare Gerura Gonadotrophin
(FMSG).
The preparation used was ,Gestyl,» 3,000 i.u. were
dissolved in 2. 5 ml. 0. 9% saline and an emulsion prepared using an
equal volume of F.C.A. Rabbits were then treated as described
above.
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d) Immuniuaticn with Follic le -Stlmulafcing Hormone (FSH).
The preparation used was NKi - FSH - S - 1* 25 rag. were
dissolved in 2. 5 ml* 0* 9% saline and an emulsion prepared using
an equal volume of F. C, A, The rabbit was then treated as des¬
cribed above* Injections were discontinued* when 3 months after
commencement of treatment, no antibodies could be detected.
e) Immunisation with Luteinising Hormone (LH).
The preparation used was NIH-LH-S-1 ; 10 rng. were
dissolved in 2* 5 ml. 0. 9% saline and an emulsion prepared using
an equal volume of F* C* A. The rabbit was then treated as above.
Injections were discontinued, when 3 months after commencement of
treatment* no antibodies could be detected.
4* Bleeding
The rabbit was firmly wrapped in a warm towel to prevent
struggling. The ear was closely shaved, washed with alcohol and
wiped with liquid paraffin* The ear was warmed* rubbed and the
median vein dabbed with xylol to increase the flow of blood through
the ear. The marginal vein was clamped with a bull-dog clip and a
email longitudinal cut made in it with a Haggendorn needle. The
blood was collected in a 50 ml. centrifuge tube, allowed to clot and
then left for some hours at + 4^C. for retraction of the clot*
5. Purification of antic era. (Hayashidaj
As much serum as possible was pipetted off into a clean
centrifuge tube, and. both this tube and the original tube containing
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the clot were spun in the cold for 30 min. at approximately 2, 300
rcf. The serum fvoa each tube was pipetted off into clean contain¬
ers, ; the serum from the tube containing the clot being respun.
If (his serum was not badly haemolyised the two batches were
combined before further purification; otherwise the two samples
were treated separately.
The antiserum was then incubated at 56°C. for 30 minuter
to destroy the complement (a thermola bile factor which causes the
lysis of red cells) and cooled.
The non-specific serum protein antibodies were then
absorbed out. The antiserum, was mixed with normal human serum
(or normal serum from the species of origin of the antigen) diluted
with 0. 9% saline in the proportion 0. 05 ml. 10% normal serum
to £.0 ml. antiserum, incubated at 37°C. for 1-2 hours, and
left at + 4°C. overnight, centrifuged in the cold at 2, 500 ref, for
20 minutes, and the supernatant collected. This was repeated
until no further visible precipitate was formed.
Other hormone antibodies can be absorbed out in the same
way, using the appropriate absorbents.
Finally, non-specific cell antibodies were absorbed out by
mixing and standing for 30 minutes at room temperature with an
equal volume of washed, packed red cells (of the type to be used in
the agglutination reaction).
Serum was finally stored in 0. 5 ml. aliquot c at - 20®C.
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6. Immune - Diffusion (Kohn)
Qxoid 5.0 cm. cellulose acetate discs were used as the
supporting medium. Spots were marked on the discs with a soft
pencil to indicate the pattern of antigen and antibody application.
The usual antigen - antibody distance was 1-1.5 era.
The discs were soaked in a veronal buffer solution, by first
floating the disc the buffer surface until the lower surface of the
disc was completely wetted and then submerging the whole disc.
(Quick immersion, without floatation causes airpockets which spoil
the discs.) The discs were then blotted to remove excess moisture
and placed on pin supports in a moist chamber.
A drop of antigen or antibody solution was applied to the
appropriate spot with a fine capillary tube and allowed to dry into
the surface of the disc. When all the samples had been applied and
allowed to dry in, the discs were immersed in a bath of Whitmore
White Oil 120 using the flotation technique described above.
The discs were left in the oilbath (at room temperature)
until the diffusion reaction was completed, usually between 1-3
days. The discs were then removed from the oil bath washed free
of oil with a detergent such as Teepol, and stained with either 0.2%
Ponceau S or 0. 001% Nigrosin.
The discs can be stored dry or cleared by flotation in the
White Oil, which leaves the strip glass clear and in a suitable
condition for photographic purposes.
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7. Preparation of Antigen-Tagged P,ed Ceils.
Boyden'e report in i 951 that proteins could be absorbed onto
the surface of sheep red. cells which had been pretreated with tannic
acid, and that these protein-conjugated cells could be agglutinated
by highly diluted specific antisera, opened up a new area in which
immunological techniques could be used. Over the next decade
more methods of preparing protein-conjugated ceils were developed.
It was reported by Renvick (1959) that Boyden'a method was
equally applicable to human red cells. As sheep erythrocytes were
not available from a guaranteed constant source, or easily obtain-
■
able, human erythrocytes of an 0 Kir -hre nature were used in all
experiments.
The various methods o£ conjugating growth hormone with
red cells used in this work are detailed below.
a) Tannic Acid Method - Boydcn, b.V. (I9bi)
' ' * - ....... ..... - ■.
Blood was collected under sterile conditions into an equal
'
volume of Alsever's solution (a citrate/dextrose anticoagulant).
While the blood was not used until at least 3 days alter collection,
it could be kept in this solution at +4°C. for 3-4 weeks without
undue haemolysis,
v. ... .. .. •
_
The cells were then washed three times with 0.S5% saline,
and packed by light centrifugation. To each miiUitre of packed
erythrocytes was added 40 ml. pH 7. 2 phosphaie buffered saline.
Equal volumes of this red cell suspension and 1: 20, 000 tannic acid
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solution were incubated for J.0 - 15 minutea at 37°C» The cells
were tlxen lightly (c. 500 rcf) packed and the supernatant poured
off. The cells were washed once and resuspended in the original
volume of pH 7.2 buffered saline, (Cells can be stored at this
point for 2-3 days at + 4°C.) Tubes containing 0.1 mg. growth
hormone in 25 ml. pH 6*4 phosphate buffered saline were made up
and 5. 0 mi. tannic acid red cell suspension was added. The
tubes were well mixed and allowed to stand at room temperature
for 15 minutes. The cells were very lightly packed (c. 300 rcf.)
and the supernatant discarded. The cells were washed once with
10 ml. l'vo N. R.S. in pH 6.4 phosphate buffered saline (N. R.S.
1 : 100) and resuspeaded in 5. 0 ml. N. R.S. I : 100,
Control cells were prepared in the same way using pH 6.4
buffered saline without hormone. Antigen-tagged cells were used
on the day of preparation.
b) Tannic Acid - Forrnalinlsed Red Cells - Fulthorpe, A.J.
(1957).
Blood was collected and the red cells washed, and tanned
ana sensitised co antigen according to the Boyden method.
After the final washing the sensitised cells were resuspend-
ed in a minimum volume of 0. 85% saline and then added to an
isotonic 0.05 M sodiumbou-ate /succinic acid buffer (pH 7.5)
...... . " " -—w
containing 1% iSf. R.S. and 20% formalin. The cell mixture was
then left at +4°C. fox' 3 days to allow formalinisation to occur.
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During this period the cell mixture was frequently shaken so as to
minimise cell clumping. At the end of this period, the superna¬
tant was removed and the cells reeuspended in 1% N.R.S., this was
repeated every 2 days for a week to remove all traces of free
formalin.
Cells treated in this way are supposed to remain unchaa ged
and with a constant sensitivity for about 4 months,
c) Formalin-Tanaic Acid Treated Erytrocytes (FTTH1)
Weinbach, R, (1958).
Blood was collected under sterile conditions into an equal
volu i.ie of Alsever's solution. The cells were washed 3 times with
normal saline,
Formalinisation of the cells was carried out by mixing equal
volumes of an 8% v/v cell suspension and a 3% formalin solution
which had been neutralised to pH 7. 0, The mixture was shaken for
24 hours at 37°C. with two changes of formalin solution during this
period. The cells were then thoroughly washed to remove all traces
of formalin and then suspended in pH 7. 2 phosphate buffered saline,
1.0 ml. packed cells to 9.0 ml. saline.
Fqual volumes of the formaliniced cell suspension and a
• • . V" - " • • ' - - . ... .v -
1 : 20,000 (w/v) tannic acid solution were mixed and incubated at
37°C. for 30 minutes. The cells were washed once with pH 6.4
phosphate buffered saline to remove any traces of tannic acid and
made up to a 107a suspension with a pH 6.4 phosphate buffered saline.
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Fqual volumes of antigen solution (0.1 rug. growth hormone
25 ml. ; 100 i.u. HCC-/1 ml. ) in pH 6.4- phosphate buffered
saline and the 10% tannic acid - formalinised red cell suspension
were mixed and incubated at 56°C. for 1 hour. The cells were
washed twice with the pH 6.4 buffered saline and made up to a 10%
(v/v) suspension in normal saline containing 1% N. U.S. and 1 :
10,000 (w/v) merthiolate.
Control cells were prepared in the same way using pH 6.4
buffered saline without hormone.
In this form, the cells will keep for several weeks at +4°C.
Before use, the required a: ount should be washed and resuspended
in fresh saline (with 1% N. P-.S.) to form an approximately 2% cell
suspension.
d) Formalinised Red Cells - Csicmas, L. (i960)
Blood was collected, into an equal volume of Alsever's
solution. The red cells were then washed. 5 times with 10 volumes
of normal saline. The washed packed red cells were resuepended
in not less than 8 volumes of a pH 6.8 phosphate buffered saline.
Into a 2. 5 cm, cellophane dialysis sac was poured 0.25
volumes (of the above cell suspension) 40% formaldehyde solution.
This bag was placed in the bottom of a flask and the cell suspension
poured over the formaldehyde sac. The flask was shaken gently
at room temperature for about 2 hours. The sack was then
opened and the contents mixed into the cell suspension. Shaking
of the flask was continued for another 12 - 18 hours, care being
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taken to prevent too much foaming of the flaekfe contents.
The contents of the flask were then carefully decanted
through a gauze filter to remove the cell debris. To the filtered
cell suspension was then added 0.5 of its volume buffered saline.
The cells were then washed 6 times with saline. The packed
forraalinised cells were then suspended in an equal volume of
buffered saline and stored at +4°C.
e) Formallaised Erythrocytes * Faucomiier, B. (1958).
Blood was collected tinder sterile conditions into an equal
volume of Alsever's solution. The cells were washed once and
resufcpended in a phosphate buffered saline to form a 25% cell
suspension.
Coal gas (source of carbon monoxide) was passed through
the cell suspension for 30 minutes. Following gassing, a 0.2
volume formol solution (30% formaldehyde : 2x concentrated buffer
1 : 1) was added to the suspension, mixed in by gentle shaking and
incubated for 2 hours at 3?°C. The cells were tlxen washed 3-5
times with 10 volumes buffered saline to remove excess formalin
and resuspended in buffer (25% cell concentration).
Treatment with carbon monoxide and formalin was repeated
twice and the cells finally stored at +4°C. as a 25% cell suspension.
Before coating with antigen, the cells were lightly centri-
fuged and 2.0 ml. packed cells were resuspended in 8.0 ml. buffer.
To tliis suspension was added 10.0 ml. buffer containing 0. 1 mg.
antigen and thoroughly well mixed. The antigenic®!! mixture
was then stored at +4°C. in 1. 0 ml. aliquots. Before use each
1.0 ml. aliquot was diluted to 20.0 ml. and the resultant cell
suspension used in the haemagglutination reaction.
Control cells were prepared in the same way using, however,
buffer without antigen.
f) Pyruvic Aldehyde Treated Erythrocytes - Ling, N. R.
Blood was collected into an equal volume of Alsever's
solution. The cells were washed 7-10 times with 10 volumes of
normal saline. After washing the packed cells were resuspended
in an equal volume of saline.
Normal saline and 25% pyruvic aldehyde solution were
raised in the ratio 3 : 1.6 and the pH of the solution adjusted to
approximately 7.0 with 10% sodium carbonate. To the neutralised
pyruvic aldehyde solution were added 0.7 volumes of a 0. 15 M
phosphate buffer pK 8.0 and 1.0 volume of the 50% red cell
suspension. The mixture was stored at +4°C. for 2 days with
occasional stirring.
The cells were then thoroughly washed with normal saline
to remove excess pyruvic aldehyde and stored as a 10% suspension
(with 0.1% aside) at -r4°C.
Antigen could then be attached to the cells by either the
Boydea method or in the following manner. 1 vol, of the 10% cell
suspension was cencrifu&ed, washed once and resutpended in 0.6
vol. dilute buffer containing antigen (saline : water : 0.15 M
phosphate buffer pH 6.0 10 : 10 : 1) and incubated for 1 hour at
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50°C. After incubation the cells were washed 3 times with diluent
(N. U.S. 1 : 100) and finally resuspended in 0. 2 vol. diluent con¬
taining 0.1% sodium aside.
Control cells were prepared in the same manner except that
buffer without antigen was used. Prepared cells were diluted 20
times before use.
3. Haemagglutination Reaction
It has long been known that blood cells will agglutinate when
added to an alien serum. Since the first years of this century
Landsteiner and his colleagues have applied this fact to the identi-
fication of the blood groups of human serum, and from this has
developed the haemagglufcination reaction as it is known today. It
depends on the principle that
Antigen will react with Antibody > Agglutination
on Cells In Serum of Cells
Serial dilutions of antiserum were made using 1normal
rabbit serum as diluent. Y hen all dilution; had been made 0.02 ml
prepared antigen-coated red ceils v:ere added to acb. tube
(containing 0. 2 ml. diluted antiserum). Tim c ontents were mixed
thoroughly by gentle shaking and the tubes allowed to stand at +4°C.
overnight. The cell patterns were read the next morning. The
titre of the antiserum was taken as the greatest dilution of the
antiserum in which a positive agglutination pattern was observed.
• • • • Ti ■
. . ,VR:r. . -
The agglutination patterns observed in a typical haemag-
glptinaticn reaction are recorded in Table 19. J
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9* Hemagglutination - Inhibition Reaction
This modification of the haemagglutination reaction depends
on the following principles:-
Antigen in reacts Antibody . . .
Test Solution with in Serum ( nt serum)
I
Combined Antigen Agglutination
Antigen/Antibody plus on f or
Complex Ceils Nonaggiutination
The end-point of the reaction depends on whether the amount
of antigen in the test solution added to the antiserum is sufficient to
inhibit all the antibody present. If this is the case, then the cells
will not agglutinate* if, however, some antibody remains, this will
react with the 'antigen on cells' to cause agglutination of the cells.
The end-point of the assay was thus taken to be that dilution of
antigen which just fails to inhibit agglutination.
Serial dilutions of standard antigen and the test solutions
were prepared. .An equal volume (0.2 ml.) of diluted antiserum
- . . - , ... . ... ...
was then added to each tube, the contents were mixed thoroughly by
gentle shaking and allowed to stand for 1-2 hours at room temper¬
ature; 0. 02 ml. prepared red cells were then added to each tube,
the contents again mixed well and the tubes left to stand overnight
at +4°C. The cell patterns were read next morning. These were
the reverse of those seen in the haemagglutination reaction in that
no agglutination was seen in the tubes containing high concentration
of antigen.
When the agglutination - nonagglutination balance point had
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been ascertained, the dilutions of antigen which will give a 0.1 log
dose interval between these points were calculated. Ten tubes
for each of these antigen dilutions were then set up and antiserum
and prepared erythrocytes were added as described above.
Following the overnight settling period the number of positive and
negative results at each dilution were noted and the results analysed
using a 4 - point quanta! assay system (Gaddura, 1933 ana 1933 b -
see Appendix )
The agglutination patterns observed in a typical haemagglu-
tination - inhibition reaction are recorded in Table 24.
10. Preparation of Latex Particles
Polystyrene latex particles 0.81 jx (Liico) were diluted 1 :
10 with water and filtered through "Whatman No. 40 paper and stored
at +4°C. The suspension was again filtered immediately before
antigen coating.
2. 0 jig. antigen in 9. 9 ml. 0. 06 M dorensen's phosphate
buffer pH 7.4 were mixed with 0. 1 ml. of the dilute latex suspen¬
sion and allowed to stand for 15-30 minutes before use.
A commercial preparation of HCG-coated latex particles
was also used. They were supplied by Ortho Pharmaceutical Ltd.
11. Latex Agglutination - Inhibition Reaction
The latex agglutination - inhibition reaction is based on the
same principles as the haemagglutiaation - inhibition reaction. In
this reaction, however, the end-point-turbidity of the supernatant -
indicates the degree of latex particle agglutination and can be
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estimated quantitatively with a spectrophotometer.
Serial dilutions of standard antigen and the test preparations
were made. An equal volume (0. 5 ml. ) diluted antiserum was
added to each tube, the contents well mixed and the tubes incubated
in a water bath at 37°C. for 1 hour. Then 1.0 ml. thoroughly
shaken prepared latex particle suspension was added to each tube!
the tubes were reshaken and again incubated at 37°C. for 2 hours.
Following incubation the tubes were centrifuged at 1500 rcf for 2
minutes, speed and time of centrifugation were critical.
Following centrifugation, the supernatant was carefully
removed and an aliquot transferred to a glass micro-cuvette, the
percentage light transmission at 650 mu was measured using a
Unicam SP 600 spectrophotometer.
Results were calculated from a standard curve using the
simplified 4 - or 6-point quantitative bioassay procedure (Gaddum,
1953). The percentage light transmissions observed in a typical
standard curve and assay are shown in tables 30 and 31.
Results
The results presented herein will be considered under the
four main headings 1) Antisera, 2) Red Cells, 3) Latex Parti¬
cles and 4) Hormone Assays.
The first section comprises results pertaining to the
production and preparation of the hormone antisera. It also records
the levels of antibody titre reached and the results of specificity
tests.
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The results of experiments designed to establish the
suitability of different preparations of red cells for use in haemag-
glutination reactions are contained in the second section.
In the third section are reported the results ob tained from
v-/
some preliminary experiments on latex particles.
The results of all the hormone assays per formed by immune
methods are grouped together under the fourth heading 'Hormone
Assays1. This section has been further subdivided into
i) the results obtained using the haemagglutination - inhibition
method for growth hormone and ii) results obtain ed with the
latex particle agglutination - inhibition method for human chorionic
'
gonadotrophs.
1. ANT IS ERA
A. Haemagglutination Titres
The final anti-hormone haemagglutination titres obtained
are summarised in table 18, and a typical estimate of antibody
titre is shown in table 19.
a) Anti - bovine pituitary growth hormone.
An antiserum to the bovine pituitary growth hormone
(Armour - Somar A) was successfully raised in one rabbit. The
haemagglutination titre reached was 1 : 51,200.
b) Anti - human pituitary growth hormone.
An antiserum to the human pituitary growth hormone
(Raben 6) was successfully raised in four rabbits. The titres
reached were 1 : 102,400 (1), 1 : 51,200 (1) and 1 : 25,600 (2)
TABLE 18
Pituitary hormone antibody titres (in rabbits)






Growth 'lorraone BOS 1 1 t 51,200
human
Growth Hormone HGH 1 1 i 25,600
HGK 2 1 8102,400
mn 3 18 25,600
HGH 4 1 : 51,200
Human Chorionic
Gonadotropin HOG 1 1 I 6,400
HOG 2 1 i 51,200
HCG 3 ll 6,400
HCG 4 1 ! 6,400
HCG 5 18 800
Ovine Follicle-
Stimulating
Hormone PSH 1 Nil
Ovine
Luteinising
Hormone LH 1 Nil
TABLE19
Typicalhaemagglutin tionpat erobservedduringest m tion©£ntib dytit f antiserusrai edgain thumangrowthhor o e. Serum Dilution1:10024:81 600326482561 512 0:1024 NRSwith Antigen«...•*» Cells NGH3with Antigen+4♦ Cells HGH3with Antigen4♦+\<► Cells HGH3with Control„ Cells +indicatescellwhichhavgglu inated -Indicatescellswhichhavotgglut nated
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respectively.
c) Anti-human chorionic gonadotrophin.
An antiserum to the human chorionic gonadotrophs (Pregnyl)
was successfully raised in five rabbits. The titres reached were
1 : 51,200 (1), 1 : 6,400 (3) and 1 : 800 (1) respectively.
d) Other hormone preparations.
Attempts to raise antisera to luteinising hormone (NIH ~ L.H-
... ;■ i* I
SI), follicle - stimulating hormone (NIH " FSH - Si) and pregnant
mare serum gonadotrophin (Gestyl) were unsuccessful.
B. Specificity of Antisera.
All the specificity tests were carried out with absorbed
anfcisera; irnmuno-diffusion on cellulose acetate discs was the
method used for checking specificity.
a) Anti" bovine pituitary growth hormone.
Between 42 and 48 hours after application of the samples to
the immuno-diffusion disc6, a clear precipitin reaction between the
j
anti - bovine (Armour - Somar A) growth hormone serum and the
.
two bovine pituitary growth hormone preparations (Somar A and
NIH - BGH - 2) could be distinguished. Even up to 96 hours after
application of the samples, precipitin lines (indiccitiag an immuno-
reaction) did not materialise between the antiserum and the following
hormones (used as antigens)
HGH - Raben 6-0.5 trig/ ml.
HGH - Raben 12 - 0. 5 mg/ml.
SGH - NIH - S3 - 0. 5 mg. /ml.
FSH - NM - SI - 0. 5 mg. /ml.
LH - NIH - SI - 0. 5 mg. /ml.
TSH - NIH - B1 - 0. 5 mg/ml.
ACTH - •Acthar* - 70 i. u. / ampoule.
b) Anti-human pituitary growth hormone.
A clear precipitin reaction between the anti-human growth
hormone (Raben 6) serum and two pituitary extracts (Raben 6 - HGH
and a crude human pituitary extract prepared in the laboratory in
Edinburgh) was visible 48 hours after the commencement of the
immune-diffusion reaction. Even 96 hours after the application of
the samples immuno-reactions had not apparently occurred between
the antiserum and the following antigenic substances
Human serum
BGH - Armour, Somar A - 0. S mg./ml.
FSH - NIH - SI - 0. 5 mg. /ml.
EH - NIH - SI - 0.5 mg. /ml,
TSH - NIH - Bl - 0. 5 mg./ml.
ACTH - lActhar* - 70 i.u. / ampoule.
PMSG - lGestyl' - 1000 i.u./ml.
HCG - 'Pregnyl* - 4000 i.u./ml.
c) Anti - human chorionic gonadotrophin
By 48 hours after the commencement of the immuno-dif-
fusion reaction a marked precipitin reaction between the antisera
and the human chorionic gonadotrophin (Pregnyl) was visible. At
least 2-3 (and possibly more) precipitin lines were visible. When
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the five antisera were tested together with normal rabbit serum
against the HCG preparation, a continuous precipitin band (showing
that the antisera possessed a common antibody) lay between the
antisera and the HCG, but did not extend in front of the NRS. There
were no visible precipitin lines between the NRS point and the HCG
position. None of the five antisera appeared to possess antibodies
to the PMSG (Gestyl) 1500 i.u./ml.
2. CELLS
Cell preparations (both antigen-coated and control cells)
were tested for spontaneous agglutination or haemolysis in buffer,
diluent (i, e, buffer + 1% NRS) and normal human serum. Control
cells were also tested for spontaneous agglutination and haemolysis
in the diluted prepared antisera. The design of a typical test and
the observations made therein are shown in table 20,
A, 'Boyden* Cells,
Spontaneous agglutination and/ or haemolysis of either
antigen-coated or control cells prepared according to the Boyden
technique rarely occured in tubes containing either buffer or diluent.
Agglutination of both coated and control cells frequently
occured when cells were added to tubes containing untreated human
serum. In one experiment, 9 human sera (5 male and 4 female)
were tested for their ability to cause spontaneous agglutination of
the Boyden type cells. All the sera caused agglutination at a
dilution of 1 : 10 while 2 sera diluted 1 : 80 were still able to cau3e
agglutination of the cells. There appeared to be no relationship
TABLE 20
Results from a Typical Red Cell Test using Cells prepared
according to the methods of Boyden and Fauconnier.
Cell Preparation Buffer Diluent Antiserum





•Boyden' type m _ +
Antigen-coated «• - +
Cells - - +
— m +
•Fauconnier* type H +
Control Cells ± + H
- ± ±
H «■» ±
•Fauoonnier* type + + +
Antigen-coated + + +
Cells + + +
+ + +
H indicates presence ©f haemolysis
+ indicates presence of agglutinated cells
- indicates no agglutinated cells present
. < 1
Each type of cell was tested in quadruplicate; each symbol,
therefore, indicates the result ©f a single tub®.
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between the known blood group of the serum and its ability to
agglutinate the cells (see Table 21),
If, however, the test sera were Erst, incubated for at least
30 minutes (to destroy complement) and then absorbed with fresh
'
untreated red cells, no agglutination or haemolysis of the cell® was
observed at a 1 : 5 dilution of the sera.
• ' ' ' ' -• : • •
B. 'Fulthorpe* Cells.
No haemolysis was observed but haphazard spontaneous
I ' lilS ■ £ ;' , ' ij
agglutination of both control and antigen-treated cells in both buffer




Similar results to those obtained with the Fulthorpe method
•. ' " ' ' - ' ' ' ' • - '••• -. •" • - - • - • - ' -
were obtained. It appeared that this method of formalising cells
was not suitable for use in haemagglutination reactions.
D. 'Cszimas* Cells.
Following formalinisation by the Cszimas method the cells
were so crenellated as to be totally unusuable,
.
E. 'Fauconnier* Cells.
Following formalinisation by the Fauconnier method the cells
were of a good colour and not crenellated, but, both control and
antigen-treated cells showed spontaneous agglutination in diluent.
F. 'Ling* Cells.
Cells prepared according to the Ling method were of good
appearance and net crenallated. Control cells were not agglutinated
TABUS 21
Estimates of serum dilution litres at which spontaneous
agglutination of aritigentagged 'Boyden1 type cells
occurs in normal untreated sera.








1 M B -fve is 10
2 M A -re 1»10
3 ¥ 0 -ve Is 20
4 M A —ve It 20
s M 0 +ve 1:40
6 F 0 -ve Is 40
7 F 3 -ve 1:40
3 F 0+ ve 1»80
0 U 0 +ve Is SO
M a* male, F = female.
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when added to buffer or diluent. Antigen-treated cells did not
show spontaneous agglutination in buffer or diluent, neither did
they agglutinate in antiserum. All attempts to coat the Ling cells
with growth hormone failed.
G. Specificity- of the Haemagglutination - Inhibition Reaction.
Using cells sensitised to HGK according to the Boyden
technique, no cross reaction has been observed to the following
hormones up to the concentrations quoted
BGH - Armour 'Somaj A1 - 100 ug, / tube
BGH - NIH - B2 - 100 ug./tube
Prolactin - NIH - S3 - 100 ^ig./tube
TSH - NIH - B1 - 100 ug./tube
FSH - NIH - SI - 100 pg./tube
LH - NIH - SI - 100 pg./ tube
HCG - 'Pregnyl* - 500 i.u./tube
PMSG - ,Geetyll - 500 i.u./tube.
The addition of ACTH (Armour 'Acthar') to the reaction
mixture caused marked haemolysis of the ceils.
3. LATEX PARTICLES
A. Suspension Iviedium for Latex Particles.
As will be seen from Table 22 and fig, 1 there is a direct
relationship between the concentration of latex particles and the
percentage of light transmitted. For any given concentration of
uncoated latex particles there is virtually no difference in the
percentage of light transmitted whether the particles are suspended
TABLE 22
Estimations of the Percentage Light Transmission of different
Concentrations of Latex Particles in Water and in Urine.
Percentage Latex
Particle Concentration
Percentage Light Transmission at 650 mju.
Water Fresh Urine 3 month old urine
0.5 0 0
0.25 0.8 0.1 1.3
0.125 3.1 4.3 3.9
0.0625 13.5 14.1 14.4
0.0312 35.8 35.3 34.8
0.016 50.3 57.1 58.0
0.008 77.0 75.0 74.0
0.004 87.5 85.0 84.8
0.002 @3.3 93.0 92.1
0.001 96.7 98.0 93.8
.
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in water or in fresh or 3 month old urine.
£• Specificity of the 'Latex -A gglutination - Inhibition Reaction
The results of a specificity test are shown in Table 23 and
fig. 8. It will be seen that the prior addition of between 3. 1 and
200 ug./tube of FSH and L.H to the anti-HCG serum did net inhibit
the agglutination of the coated latex particles. This indicates that
these two pituitary gonadotropic hormones do not interfere with
the assay and that the pituitary LH which has similar biological
properties to HCG does not have common immuno-properties.
4. HORMONE ASSAYS
i) Haemagglutination-1-nhibition Method
A. Typical Growth Hormone Assay ! ■.
The results of a typical 4-point qaantal assay are shown in
Tables 24 and 25. The slope of the dose response curve is steep
and a very narrow log. dose interval (0.1) can be used. The /\
figure (0. 043) is very low indicating a high degree of precision in
the assay and the fiducial limits are relatively narrow (92 - 114%).
There was no significant deviation from parallelism between the
dose response curves of the standard and the unknown.
B. Growth Hormone Standards and Pituitary Extracts.
The results of 12 quantal assays are shown in tables 26 -
28. They were all of a 2 + 2 design and all were statistically valid
i. e. the slopes of the standard and unknown curves were all parallel.
Using an antiserum, to BCH» estimations of the potency of a
growth hormone preparation NIH - B2 were made on three occasions
Fig. 8:- THE LATEX PARTICLE AGGLUTINATION-INHI3ITI0N ASSAY
FOR HUMAN CHORIONIC GONADOTROPHS. DOSE RESPONSE
CURVES FOR HQJ , NIH-FSK ASD NIH-LH.
FSH AND LH CONCENTRATION IN ^G.
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ResultsofatypicalGr wthHormoneImmun - say-emagglutination-InhibitionMsthod.
Frslajni.np.ryT§st9fraBr7&*iiwa
,•Ti"J)!>-.• ...•■
Hormone Concentration25012562,31.255.627.819,90 849 inug. Armour8®with Controlells-— ArmourBGHwith-—♦+ AntigenCells--♦+♦ NIH-B2with Controlells-- ---- NIH-B2with•♦♦♦♦♦ AntigenCells-—-♦♦♦♦♦ Quanta!AssayObservations StandardPreparation%ageagglutin ted 'Armour1Bdl4.0Ug.♦•♦♦♦♦♦«80 5.0ug.10 6.3pg,-♦20 8.0pg.10 TestPreparation NIH-BG—28.0ug.♦+90 10.0ug.-♦+♦9 12.6ug.-10 16.0jag.---- +indicatesthepres nceofagglutinatedcells -indicatestheabs nceofagglutinatedce ls.
TABLE 25
Besuita of a typical Growth Hormone Iantuno-assay •
Hoq -;agglutinat.Aon-Inhibition Method.
Concentration Total No.
Growth Honoone/ No. of Tubes of Tubes/
Preparation Tube in ug. Agglutinated Dose Level Probit
Armour BGH 4.0 8 10 6.28
(standard)
5.0 1 10 3.72
NIH - GH - 10.0 9 10 5.84
B2 (unknown)
12.6 1 10 3.72
log# dose interval 0.1
Relative Potency 1.02, 95$ Confidence Limits 92 - 114$,
4^-point assay design.
\ 0.043.
Deviation from parallelism is not significant#
TABLE 26
Replicate Estimations of NIH - GH - 32 in











2 4 2 1.02 92-114 0.043 Valid 0.546(0.50 - 0.62)
2+2 1.15 108-128 0.036 Valid 0.616(0.58 - 0.69)
2+2 1,00 90-UUL 0.045 valid 0.536(0.48 - 0.59)
The mean relative potency is 1.06.
Calculated mean activity of BIH - G3 - 32 is
0.57 i.u./fog. (Fid.Lim, 0.48 » 0.69 i.u./rag.)
TABLE 27
Duplicate Estimations of HQH - Raben 12 in terms

















0.177 (0.146 - 0.209)
0.195 (0.160 - 0.238)
TABLE 28
Estimations of the Growth Hormone Activity of
Fractions Separated from a Crude Pituitry Extract











Fraction 1 2 + 2 1,00 89-112 0.046 Valid 1.85 (1.65 « 2.07)
Fraction 2 2 + 2 0.98 81 - 118 0.072 Valid 9.05 (7.48 -10.90)
Fraction 2 2 + 2 1.00 89 - 112 0.076 Valid 9.25 (8.23 -10.36)
Fraction 3 2 + 2 1.01 89 - 116 0.050 Valid 0.93 (0.82 - 1.07)
Fraction 3 2+2 1.00 89-112 0.046 Valid 0.92 (0.82 - 1.03)
Fraction 4 2 + 2 1.04 88 - 122 0.054 Valid 0,038(0.032-0.046)
Fraction 4 2*2 0.92 77-111 0.063 Valid 0.034(0.028-0.041)
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(see Table 26). The values obtained, were respectively 0.546,
0.616 and 0.536 l,u,/mg. which gives a mean, estimate of 0.57 i. u.
mg. This value, although somewhat lower than the estimate of
potency made by the tibial test (0.745 i. u./mg. ) is well within the
95% confidence limits of the tibial estimation.
Using an antiserum to KG-H, estimations of the potency of a
growth hormone preparation Raben 12 were made or. two occasions.
(See Table 27). The values obtained were respectively 0.177 and
0.195 i.u./mg. which gives a mean estimate of 0. IS6 i.u./mg.
This value, although slightly higher than the estimate of potency
made by the tibial test (0. 146 i. u, / mg.) is well within the fiducial
limits of the tibial estimation.
Using an antiserum to HGH, estimations of the potency of
four samples obtained by fractionating a crude pituitary extract on
a deoxycellulose column were made (see Table 28 ), Where
estimations of potency have been made more than once, agreement
between the values on each occasion was good. In no case was
sufficient material available to confirm the results obtained by re-
estimating the potency using the tibial test.
C. Growth Hormone in Human Serum
No estimates of growth hormone could be made in fresh,
■
- ...... ., ■, . ... - :.y-
untreated human serum from 9 normal subjects because of non¬
specific agglutination in control tubes.
All estimates of growth hormone made in sera (from 24
normal subjects) which had been incubated at 56°C. (to destroy
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complement) and absorbed with fresh red cells (to remove non¬
specific agglutinins) showed that the level of growth hormone was
below the sensitivity of the method i. e. less than 20 - 50 m^ig. /ml.
serum, A brief comparison of the growth hormone levels obtained
herein and by other workers is shown in Table 29.
ii) L.acex Particle Agglutination-Inhibition Method
D. Typical Human Chorionic Gonadotrophin Standard Curve
Experiments were carried out to establish the form of the
HGG standard curve in a latex agglutination-inhibition reaction.
The results of a typical experiment are recorded in table 30 and
shown in graph form in fig 9. It will be seen that maximum
agglutination of the particles, which occurs when little or no antigen
is present, is accompanied by maximal light transmission, while
minimum agglutination, which occurs when an excess of antigen is
present, is accompanied by a high degree of turbidity and minimal
light transmission. The steepest part of the curve appears to lie
in the region of 1 - 10 i.u. HCG and for normal assay work the dose
levels of the standards were chosen from this region.
E. Assay of HCG Standards
The results of a typical 6-point quantitative assay are shown
in table 31. The slope of the dose response curve is reasonbly
steep and a log. dose interval of 0.301 was used. The A figure
is very low indicating a high degree of precision and the fiducial
.
limits are relatively narrow (90 - 114%). There was no signifi¬
cant deviation from parallelism between the dose response curves
TABUS29
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tiesuits of a Typical HOG Assay by Immuno-assay -
Latex Particle Agglutination - Inhibition Method.
Mean Percentage Range in Number
Concentration Light Trans¬ Spectro¬ of
Preparation in i.u. mission at 650mu photometer Obser¬
Readings vations
International 6.0 65.8 1.8 3
Standard
3.0 36.2 1.4 3
1.5 14-3 19.9 3
Unknown 6.0 57.6 2.0 3
'Pregnyl' 3.0 41-1 6.6 3
1-5 14-7 3.4 3
3 f 3 Assay design; Index of Precision X 0.044
Relative Potency 1.028 95% Confidence Limits 90.6 -
114.0%.
Validity i- Ho significant deviation from parallelism
(P > 0.05)
Ho significant curvature of dose response
curve standard (P > 0.1)
Ho significant curvature of dose response
curve unknown (P > 0.05)
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of the standard and the unknown, nor did the two curves show any-
significant curvature of the dcse response curve.
The results of replicate estimations of the potency of a
commercial HCG preparation "Pregnyi* are- shown in table 32.
There is good agreement between the relative potencies, (1.028 and
1. 020 respectively, ) obtained, which makes the commercial prepar-
ation virtually equipotent with the International Standard, i.e. the
, r ."""v""
results obtained here confirm the potency claimed for the prepetr-
■ ■
ation by the manufacturers.
F, .Assay of HCC in Urine
None of the estimates of the HCG content of pregnant urine
were statistically valid. All the assays showed highly significant
(P 0.005) deviation from parallelism between the dose response
'
curves of the standard and the unknown.
... ......,.
The results of a number of recovery experiments are shown
in table 33 ana fig 10. In no case was the dose response curve ox
the HCG in urine parallel with the dose, response carve of the HCG in
water.
It would appear, therefore, that this assay method cannot be
applied to the direct estimation of HCG hi urine, although apparently
satisfactory for the estimation of purified HCG preparations.
DISCUSSION
The application of immunological techniques has given
considerable impetus tc research in endocrinology. In theory,
immunological methods are highly specific, since a given antigen
TABLE 32
Estimations of HCG activity in 'Pregnyl' in terms
of the International Standard













* Valid - No significant deviation from parallelism
and no significant curvature of the dose response
curves.
TABLE 33
Estimates of the Percentage Light Transmission following
the Addition of Various Concentrations of HGG to a Number
of Urine Samples - Latex Agglutination - Inhibition
Method.
Mean Percentage Light Transmission at 650 mp
Concentration-













S 10.7 3.1 10.0 55.2 21.25
4 55.6 21.7 44*4 72.4 62.75
2 74.4 46.1 53.1 81.3 69.30
1 82.6 55.7
Fig. lQj- THE LATEX PARTICLE AGOLUTIKATION-INHIBITION ASSAY FOR
HUMAN CHORIONIC GONAUOTROPniN. RECOVERY OF HOG ADDED





will only react with its appropriate antibody and nothing else. In
practice, however, this does not always hold because it is often
extremely difficult to obtain a system in which only a single antigen
and antibody exists# Immunological techniques have been applied
in two main fields. They have been used firstly, to provide infor¬
mation about the potency of purified hormone preparations and
secondly, in the development of specific and sensitive methods of
estimating hormone levels in blood and urine.
The protein hormones are in themselves only weakly anti¬
genic, and so, to obtain a high litre antiserum, have to be injected
in a suitable adjuvant. That an adjuvant is necessary has been
shown by various workers including Elberg and Li (1950) and
Emmerson and Emmerson (i960) who were unable to demonstrate
the presence of antibodies to growth hormone following the
repeated administration (to rats) of bovine growth hormone given
without adjuvant. Although, Read (1958, i960 ab) claimed that a
satisfactory growth hormone antibody titre could be obtained using
the light mineral oil mixture known as Freuadb Incomplete Adju¬
vant, only two other groups namely, Irie and Barrett (1962) and
Hay&shida and Li (1958 abc) have used this method of raising
antibodies to growth hormone. Most wo rkere (including Brody and
Carlstrom, I960; Hunter and Greenwood, 1962; Lunenfield et al.,
1962; 1/IcGarry and Beck, 1963) prefer to use the stronger adjuvant
known, as Freund's Complete Adjuvant to raire antibodies to hormone
preparations. The results obtained in the present chapter appear
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to confirm this preference since the presence of antibodies could
not be detected foilowing treatment with F.I, A. , but high titres
were obtained when the hormones were administered in F.C.A.
The use of an adjuvant increases the danger of selective
fixation of antibody i.e. the production of antibodies in greater
concentrations to the contaminants rather than to the main antigen
present. It is, therefore, essential to purify the antiserum as
much at possible before use. In the present chapter the cleanli¬
ness and specificity of all the antisera prepared have been checked
by imrnuno-diffusion and cross -haemagglutinatioa reactions.
Kayashida and Li (1958 b) noted that prior to absorption an
antiserum to BGH showed cross-precipitation with ovine prolactin
and ^ - globulin, but that following purification no reaction to
prolactin, TSK, ACT:I, L»K, FSH and ^-globulin could be detec¬
ted. While the appearance of precipitin lines between an antiserum
and an antigen indicates the presence of an antigen-antibody system,
their absence does not necessarily mean that such a system does
not exist. The bands may not appear because one or both of the
components of the system may be so weak that the precipitin complex
may not be visible; or one of the components may be present in
such an excess that the antigen-antibody com .piex precipitate may
have dissolved in the component which is in excess. A more sen¬
sitive index of the presence of impurities can be the haemagglutiaa-
tion reaction itself. Cross-reaction in haemagglutination systems
may be demonstrated in. cne of two ways, 1) antiserum will
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agglutinate cells which have been tagged with •foreign1 antigens or
2) the agglutination reaction may be inhibited by a 'foreign* antigen.
In this context the term 'foreign' antigen is applied to any antigen
other than the one to which it was intended to raise antibodies.
i the criterion of absence of lines of identity, it was
shown that following preliminary purification both the antisera to
BGH and HGH appee red to be reasonably free of non-specific
antibodies (see p. §9;. No cross reactions with human pituitary
growth hormone, ovine prolactin, ovine FSH and LH, bovine TSH
and a commercial preparation of ACTH have been observed against
the BGH antiserum. Unlike Hayashida and Li (1959) lines of
identity between ovine growth hormone and the BGH antiserum were
not seen. There was apparent confirmation of the above results,
in that, no inhibition of the agglutination reaction was observed,
when any of these hormones (in amounts of up to 200 jig./tube)
was added to tubes containing BGH antiserum prior to the addition
of BGH-coated red cells, some haemolysis of the cells was noted
when ACTH was added to the system, this was probably due to the
presence of a non-specific haemolytic substance in the commercial
preparation used. When HGH -coated cells were added to the anti-
BGH serum no agglutination of the cells occurred. It would appear
therefore that a reasonably pure antigen-antibody system to BGH
had been obtained and that this was specie specific.
A similar apparently pure species specific antigen-antibody
system was also obtained for HGH. In spite of the apparently
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identical electrcphoretic patterns of ovine prolactin and human
growth hormone (observed by Ferguson and Wallace, 1961)
precipitin lines - indicating a common immuno-identity - between
sheep prolactin and the anti-HGH teru. n were not observed; a
similar finding has been reported by Kayachida arid Grunbaum, 1962.
As nc human prolactin was available it was not possible to confirm
the observation of Kayashida (1962) of a continuous band between
IIGH, human prolactin end an anti-HGH serum. It would seem
probable that this indicates a common immuno-chemical property
of the two hormones rather than a non-specific human protein as
there are no reports of the presence of a line of immunQ-ideatity
between normal human serum and. the anti-HGH serum.
Although there had been several reports in the literature
(Bourdell, 1961; Gold et al., I960; Moudgai and Li, 1961 ab anu
Segal et al., 1962) of the successful production of antibodies to
ovine FSH and LH, the single attempt reported heroin was unsucces¬
sful. As by this time it was obvious that all the endocrine antigen-
antibody systems were species specific and the aim of this work was
to set up methods for the assay of human F£K and LH, it did not
appear worthwhile to undertake further attempts to obtain antibodies
to the ovine hormone.
The HCG antiserum obtained was apparently free of anti¬
bodies to ovine FSH and LH, and to bovine GH and TSH. Like
Carlstrom and Brody (1962) no cross-reaction with PMSG was noted.
As no human LH (HLH) was available it was not possible to investi-
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gate the claim of Wide^ Roos and Gemzeli, (1961) and Goss and
Taymor (1962) of a cross-reaction between HCG and IiLH. In fact
Taymor, Goss and Buyteudorp, (1962) ascribe this cross-reaction
to the presence of a major antibody component which is common to
both HCG and HBH, More recently, Gosc and Bewis (1964) have
shown that while HCG and HBH possess a common antigenic group,
each has specific antigenic components which permit their immuno¬
logic differentiation, but do not affect their biological activity.
Goss and Taymor (1962) claimed that it was possible to adapt
the Ortho Pregnancy h uagnosis Kit to the assay of HLtH, by measur¬
ing the percentage light transmission of the supernatant. They
found that there was a proportional decrease hi the light transmitted
when HLiH was added to the tube, tire effective straight line dosage
was 15 - 50 ug. HLiH/ tube.
More recently Taymor, Buytendorp and Goss (1962) claim
to have measured the levels of HLH in human urine using this
method and that the results obtained agree well with those obtained
using the comparative bioaseay - the ventral prostate test. Their
immunological assays have been performed, not on untreated urine,
but on urine which has been extracted according to the method of
Albert (1955).
In the experiments reported here attempts were made to
convert the Ortho Pregnancy Biagaosis Kit into a quantitative assay
for HCG. As will be seen from the results obtained it proved to
be a very precise method of estimating the potency of reasonably
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pure preparations with a sensitivity comparable to that found by
the bioaseay method depending on the increase in weight of the
prostate in intact immature rats. However, attempts to apply the
method to the measurement of HCG in urine failed because of lack
of parallelism between the standard and the unknown. Even in
' " ' .... ....... f. .
recovery experiments, when known amounts of HCG were added to
urine from male and non-pregnant female subjects, the dose
response curves of HCG in water and of the same concentrations of
HCG in urine were not parallel. It would appear therefore that the
addition of urine to the reaction mixture interfer in some non¬
specific manner with the agglutination and mbsequent precipitation
of the latex particles. It is not clea.~ whether this interference is
a pH effect or linked in some way with the ionic concentration and
the specific gravity of the urine. Singer and Plots (1956) noted
that spontaneous agglutination of coated particle;, ogcured between
PH5.5 and 3. 0, while a total inhibition cf reaction occured between
pH 10 and 12.6. To eliminate this pK effect, the pH of all urines
examined in this study was adjusted to between pH S. 0 and 0. 5
before preliminary centrifugal ion, although, Goblin (1962) claims
that urine pH is not critical. It would appear that pH is not
critical for uncoated particles, as, in some preliminary experi¬
ments, for a particular particle concentration, there was very little
difference in the percentage light transmitted (see table 22), whether
the particles were suspended in distilled water or in pH adjusted
urine.
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Although it has not been found possible to use this method
for the quantitative estimation of HCG in urine (Goes and Taymor,
1965 use it in a semi-quantitative form to give rapid estimates of
HGG levels in pregnancy) this does net invalidate its use a) for the
quantitative estimation of potency of purified preparations of HCG
and b) for the diagnosis of pregnancy. As a pregnancy diagnosis
kit the conditions of the assay have been so weighted that it only
very rarely gives a false positive result. Approximately 2% false
negative results are obtained from either testing urine too early in
pregnancy, of from the use of a urine sample with a low specific
gravity. Correct results generally range from about 95 - 1097;
(Ortho Research Foundation, Goldin, 1962; Henry and Little,
1962; Raj et aij, 1963 amongst others and compare favourably
with the results obtained by the more conventional pregnancy tests.
It was hoped that tire use of latex particles would eliminate
some of the difficulties encountered in the standard haemagglu-
tination reaction. In the latex particle system the amount of
agglutination occuring can be measured quantitatively and accurate¬
ly by estimating the residuary turbidity of the solution while, direct
methods for the accurate estimation of red cell agglutination do not
exist.
Although coated latex particles are unfortunately sensitive
to alterations in salt concentrations and the specific gravity of;
the fluid in which they are suspended, they are inert and therefore
should not be affected by the non-specific antibodies which fre-
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quently upset haemagglutinaticn reactions. Following the finding
that Boyden type cells, both control and antigen-coated, were
agglutinated when added to either normal human serum or plasma,
two courses were open. Either the serum or the plasma must be
purified in some way to remove the interfering agglutinins or
another type of coated (indicator) cell, which was not affected in
this way, must be used in this system.
From the literature it appeared that treatment of red cells
with formalin had the effect of net only strengthening the ceil and
making it mere resistant to non-specific agglutinins but also of
preserving the cell, i.e. coated cells could be prepared in advance
and used for upwards of 3 months. / number of different methods,
all claimed to give good results, were tried. In one instance
(Csizmas) the cells were so crenallated following forrnalinifcation
as to be totally unusable, in spite of the author*? claim that no
crenellation occurred. Cells treated according to the methods of
Fultborpe and VCeinbach were dark, sticky and showed a totally
haphazard agglutination reaction in both diluent arid buffer. The
best results were obtained with those prepared according to the
method cf Fauconnicr, in which the cells were gassed with carbon
monoxide before formaliniaation. Cells prepared in this way were
of good colour and were not. crenellated, but even these showed
frequent spontaneous agglutination in diluent which made them
useless as indicator cells in the haemagglutiaation reaction.
Butt et al. (1961) claimed good results in an. HCG system
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using cells prepared according to the method of ding. In this
method pyruvic aldehyde was substituted for formalin. Cells
prepared according to this method were not crenellated, and did not
show spontaneous agglutination in buffer and diluent. Unfortunate¬
ly all attempts tc tag these cells with growth.hormone failed. As
the various attempts to prepare a better cell for use in the system
had failed, the only alternative left was to attempt to clear tae
sample of unwanted antigens.
The simplest method of clearing the serum sample was
firstly to destroy the comjjement content by heating, and secondly,
to absorb the serum with the red cells to be used in the assay.
Fresh cells had to be used, because uncoated tanned cells would
remove all the protein including the growth hormone from the
sample. Following this procedure the non-specific agglutinants
appeared to have been removed. It now, however, appeared that
the growth hormone level cf normal serum was below the level of
sensitivity of the assay i.e. less than 10 - 50 mpg./ml. serum.
This very low (below the sensitivity of the method) result was
very puzzling in the light of the values for normal serum (range
SO - 480 mjig. / ml. serum) reported by other workers at this time
(see Table 29), although Kaplan and Grurnbach (1962) using
similar heat treated and absorbed serum reported the growth
hormone levels in normal and hypopituitary subjects to be less
than 20 inpg. /ml. i. e. belov, the sensitivity of the method. It
was some time before it was accepted that these apparently
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reasonable results (normals <500 mug. I ml; acromegalics 7 500
mjig./ml. serum) were in fact over estimates of growth hormone
activity. These results became suspect because of the high levels
reported in clinical conditions such as pituitary dwarfs and hypophy-
sectomised subjects (range 100 - 200 mpg./ml. and 20 - 290 myig,l
ml. respectively), when low or undetectable levels would be
expected. It was thought that these false high values were due to
the presence of non-specific inhibitors in the test sera; a view
apparently confirmed by the findings of Dorninguea and pearson
(1962) who used unextracted serum and showed values in the same
range from normal subjects, hypophyeectomised subjects, hypop-
ituitary dwarfs and acromegalics. When the serum samples were
extracted, values below the sensitivity of the method were obtained
in the case of the first three groups.
It would appear therefore, that the failure to apply this
method to clinical problems lies in its lack of sensitivity, not in
its performance. This method gave good, reproducible and
precise results when used for assaying the hormone content of
pituitary extracts and where the potency of a pituitary preparation
has been estimated by both the haemagglutination-inhibition method
and the tibial assay, reasonable agreement exists between the
results obtained by the two methods.
More recently, radio-immunological assay methods have
been developed. The estimated potency of some pituitary extracts
; *
.
(ICRF 6, ICRF 6 - peak I and ICRF 6 - peak II) as measured by the
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Hunter radio-immuno-electrophoretic method agreed with the
results obtained by the tibial test (see Pages 50-51 ). The
values for human plasma (range 0-50 mug./ml.) published by
Utiger et al. (1962) using a modified precipitin test are less than
most of the published values for the haemagglutination-inhibition
method, but greater than the values obtained by Hunter and Green¬
wood, 1962 (range 2.4 - 5.6 mpg. I ml. plasma) and Glick et al.,
1963 (range 0-15 mug. I ml. plasma) who have used a modified
electrophoretic technique. It is interesting to see that the more
sensitive radio-immunological assay methods have confirmed the
normal growth hormone level in blood to be less than 10 mjig. I ml,
which is the lower limit of sensitivity reached in the experiments
reported here. It is probable that the radio-imnrtmo-electro¬
phoretic techniques which are precise and not too laborious will
become the methods of choice in the clinical field, despite the fact
that they are time consuming.
SUMMARY
1. Specific antisera have been raised to the following hormones :-
bovine and human growth hormone and human chorionic
gonadotrophin.
2. The haemagglutination - inhibition assay method for growth
hormone has been established and some of the conditions of
assay examined.
3. The potency of two pituitary growth hormone preparations and
four pituitary fractions has been estimated by this method.
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4. The haemagglutmation-inhibition method was used to estimate
the growth hormone content of human sera from 24 normal
subjects.
5. The Ortho pregnancy diagnosis kit was modified to give a
quantitative method of estimating HCG, and the specificity of
the method examined.
6. The potency of 'Pregnyl' was determined using this method.




RAT GONADAL PYRUVIC ACID
INTRODUCTION
Ciaesson, Dicssfaiusy, Hillarp and Hogberg, 1948 and
Ciaesson, Hillarp and Hogberg, (1953) have shown that subsequent
to the administration of gonadotrophins there is a marked decrease
in esterified cholesterol and fatty acids and a marked increase in
phospholipids in the rabbit ovary. Little or nothing is, however,
known about the precursors of cholesterol in the ovary or testis;
their normal levels or the effects of gonadotrophins on them. In
1964, Bell efc al. developed a sensitive method for the bioassay of
luteinising hormone depending on the depletion of ovarian choles¬
terol in the intact immature rat pretreatea with PMSG and HCG.
It seemed possible that an investigation of the endogenous levels
of some of the precursors of cholesterol might provide information
about the mechanism by which LH affects cholesterol and might
provide a further biological parameter which could be used for the
assay of LH. The aim of this section of the thesis is to present
the results obtained.
In recent years the biosynthetic pathway of cholesterol has
been fully elucidated (see p. 19 and fig. 1 ). A simplified outline
of the metabolic pathway to cholesterol is as follows
Pyruvate ——^ Acetylcoensyrae A Mevalonic Acid
——^ Cholesterol
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Methods of estimating mevalonic acid are complex, time consuming
and not suitable for incorporation into bioassays, and for this
reason no attempt has yet been made to study the endogenous
levels of this substance. Attempts to measure acetate as an index
of the acetylcoenzyme A level in the ovary failed because the
techniques suitable for extensive application were not sensitive
enough to detect the presence of acetate even in ovaries pre-
treated with PMSG and HCG.
Pyruvic acid readily forms a coloured hydrazone with
2, 4-dinitrophenylhydrazine, and methods of estimating pyruvate
using this property of the compound are reasonably sensitive and
easy to perform. The method of Katsuki et al. (1961) was finally
chosen and the results obtained with this procedure are described
herein.
A very sensitive enzymic method which depends on the
reaction
Pyruvate + NADHo + H+ > Lactate + NAD+
is also available, and the data presented here was obtained with
the method of Rueher et al. (1963).
In the present section, the results of an investigation under¬
taken to study the endogenous pyruvic acid level in the ovaries and
testes of immature rats, is reported. The effect of gon&dotrophic
stimulation on the pyruvate levels of the ovary is also described.




1. 0. 1% dinitrophenylhydrazine solution - 100 mg, DNPH (BDH -
reagent grade) are dissolved in 100 ml. 2N HCl with the aid of
gentle heating.
2. 0. IN sodium carbonate - 5. 3 g. anhydrous sodium carbonate
(BBH «* AR grade) and 0. 84 g. sodium bicarbonate (BDH - AR
grade) are dissolved in distilled water and the volume made up
to 1 litre.
3. Ethyl acetate - ethyl acetate (M & B - reagent grade) was
redistilled and the fraction collected from boiling point 74 - 77°C
was used.
4. Petroleum ether - petroleum ether (BDH - AR grade) was
redistilled and the fraction collected from boiling point
60 - 80°C. was used.
Method (Katsuki et al., 1961)
1. 4.0 ml. deproteinised tissue preparation and 1.0 ml. DNPH
solution are placed in a 10. 0 ml. stoppered, graduated,
conical centrifuge.
2. The tube was shaken and incubated for 10 minutes in a 25 - 30°C
water bath.
3. 5. 0 ml. ethyl acetate was then added, the tube again shaken and
nitrogen bubbled through the mixture for 2 minutes.
4. On standing, two layers became apparent and when completely
separated the lowers aqueous layer was discarded.
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5. The ethyl acetate layer was washed twice with 2-3.0 ml.
distilled water.
6. 5. 0 ml. petroleum ether and 2. 0 ml. carbonate solution were
then added, the tube was again shaken and nitrogen bubbled
through the mixture.
7. After standing, the tipper ethyl acetate layer tvas discarded .
8. The carbonate layer was then washed-three times with 4. 0 -
5.0 ml. of a 1:1 mixture of ethyl acetate and petroleum ether.
9. Nitrogen was then bubbled vigourously through the carbonate
solution until the odour of ethyl acetate could no longer be
detected.
10. The carbonate extract was made up to 10.0 ml. with more
carbonate solution and the absorbancy measured at 355 mji using
a DNPH blank. Silica cells with a 1. 0 cm, light path were used.
11. 5.0 ml. 2N NaOH were added to 5.0 ml. of the carbonate extract
and the absorbancy measured at 417 myu
12. The value of the pyruvic acid content of the sample was then
calculated from standard curves.
13. Blanks were prepared in the same way, 4.0 ml. of deprotein-
ising agent being substituted for the 4.0 ml. deproteinised
sample.
Eight samples could be carried through the method at one time.
Modifications to the Method
1). Deproteinising Agent.
The type of deproteinising agent used la this procedure is of
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importance. Kateuki ct al. (1951) recommended the use of meta-
phosphoric acid for this purpose. They found that trichloracetic
acid gave unsatisfactory results because it interfered with the
final extraction of pyruvate dinitrophenylhydrazone. On the other
hand Neigh (1933, 1957} found that a freshly prepared tungstic acid
solution was the best tissue extractant and deproteinising agent for
pyruvate.
Pyruvic acid standards were made up in both 10% metaphoo-
phoric acid and in freshly prepared tungsfcic acid (8 ml. N/12 H SO4
: 1 ml, 10% Na tungstate) and taken through the procedure for the
extraction and estimation of pyruvate. The results obtained (read
against the appropriate DNPH blank) are shown in table 34 and
figure 10.
From these it can be seen that the two curves follow each
other closely and when the central part of the two curves was
analysed on the basis of a 6-point Gaddum assay (see Appendix),
they were found to be parallel and to show no significant curvature.
In all the experiments reported using the DNPH method
tungstic acid was used as the deproteinising agent.
?.), Absorbancy measurements.
The pyruvic dinitrophenylhydrazone has a faint yellow colour
. \
in dilute carbonate solution with a maximum absorbance at 355 myi.
If sodium hydroxide is then added there is a colour change to red
and the point of maximum absorbance is altered to 417 mp. Satsuki
and his colleagues suggest that it is better to measure the absorbance
TABLE 3I
Standard Curves - Comparison of the optical density of
pyruvic acid standards mad® up in metapfaosplioric acid and





Metaphospfaoric Acid Tumgstie Acid
O.D. 355 mji. O.D. 417 m. 0.D.355 ay* Q.D.417 mji.
0.125 0.094 0.044 0.088 0.042
0.25 0.201 0.090 0.155 0.067
0.50 0.519 0.210 0.353 0.149
1.00 0.713 0.300 0.687 0.280
2.00 1.368 0.560 1.344 0.550
Fig.lit- COMPARISON OF THE OPTICAL DENSITY OF PYRUVIC ACID
STANDARDS MADE UP IN METAPHOSPTiORIC ACID AND IN
TUNGSTIC ACID AT 355 AND 4L7IIU WAVELENGTH.
1-6-
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of solutions at 417 mp, as interference by coloured impurities in
the sample was then largely avoided. The red colour io not
however very stable and samples must be read within 10 - 20
minutes of the addition of the sodium hydroxide.
Pyruvic acid standards were therefore made up in both
metaphosphoric acid and freshly prepared tungstie acid and taken
through the procedure. The absorbancy of the solutions was
measured at both 355 mp and following hydroxide addition at 417 mp.
The results obtained are summarised in table 34 and in figure 11,
At both 355 mp and 417 mu the curves relating the optical
densities of the pyruvic acid standards in both rnetaphosphoric acid
and in tungstic acid follow each other closely, and fee central parts
were found to be parallel and to show no significant curvature.
However when the afosorbaacy curves at 355 mp and 417 mp are
compared it can be seen that while they follow the same pattern of
increased optical density with increasing concentrations of pyruvic
acid, the curves are no longer parallel. The steeper dose response
curve is obtained when the absorbancy is measured at 355 mp.
3), Cuvettes and Spectrophotometer.
Fused silica quarts cuvettes were used throughout. Initially
the carbonate extracts were diluted to 10 ml. with more carbonate
solution and the abaorbance measured using 1 cm light path cuvettes
with a 4 ml. capacity. It was thought that it would be possible to
make the assay more sensitive if microcuvettes of less than 1 ml,
capacity were used. Pyruvic acid standards were made up in
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tungstic acid in concentrations ranging between 0. 125 and 16.0 jpg/
sample. The aboorbancy of these samples was measured in either
the diluted form in the large cuvettes or undiluted in the micro-
cuvettes, The results are summarised in table 35 and in figure 12.
It can be seen that the two curves are of identical form and
parallel. The use of microcuvettes increases the sensitivity ©f the
method by a factor of about eight.
All measurements of absorbancy were made in a Pye
spectrophotometer model Sp. 500.
4). Modifications to the method adopted.
a. Tungstic acid as deproteinising agent.
b. Microcuvefctes.
c. Undiluted carbonate extract.
B. Eazymic Method
Reagents:-
1). 5 M potassium carbonate - about 69g. KgCOg (BDH • AR grade)
are dissolved in distilled water and made up to 100 ml.
2). Methyl orange indicator (0.05% w/v) - 50 mg. methyl orange
are dissolved in distilled water and made up to 100 ml.
3). Perchloric acid (6% w/v) - 13 ml 70% HC 10..• (BDH - AR grade)
re diluted to 250 ml. with distilled water.
4). 0.4 M triethanolamine buffer, pH 7. 6 - 18. 6g, triethanolamiae
hydrochloride (BDH - reagent grade) are dissolved in 200 ml.
distilled water, 18 ml. 2N NaOH (BDH - volumetric solution)
and 3. 7g. of the disodium salt of ethylene-diamine-tetra-
TABUS 35
Standard. Curves - Comparison of the optical density of
pyruvic acid standards in standard and microcuvettes at


















Fig.12:- COMPARISON OF THE OPTICAL DENSITY OF PYRUVIC ACID

























acetic acid (BBH - reagent grade) are then added and the volume
made up to 250 ml.
5). Reduced diphcsphopyridine nucleotide (NADH) - 7 rng. of the
diaodium salt (BDH) are dissolved iii 1.5 ml, distilled water
-3
to give an approximately 5x10 M /3 NADH2 solution.
...
. ' '
6). Lactic dehydrogenase (LDH) - a 10 mg/ml protein solution with.
an enzymatic activity c£ 75U/mg. (supplied by Koch-Light
.......
Laboratories) is diluted 1 : 10 with 2.1 M ammonium sulphate.
.
(BDH - AR grade)
All solutions were stored in a refrigerator at +4°C., the
NADH2 solution was freshly prepared each week, the others were
kept as long as no bacterial contamination occurred.
Method:-
To a Silica yuartz cuvette with a 1.0 m. light path a
.
3. 0 - 4. 0 ml. capacity was added.
'
1. 2.0 ml. deproteinised sample.
. ^ .... ...... ..
2. 1.0 ml. 0.4 M triethanolamine buffer.
3. 0. 04 ml. NABH2 solution.
* - - • • • - •
The concents of the cuvette were well mixed and of this
solution two measurements of the optical density against a blank
containing 3. 0 ml. buffer + 0. 03 ml. indicator were made at 340 mji
at three minute intervals. Then 0. 01 ml. of enzyme solution were
pipetted onto a small glass spatula and stirred into the solution and
the optical density again measured 3 and 6 rain, after the addition of
the enzyme. The amount of pyruvate present can then be calculated.
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Calculation
The concentration of pyruvate in the sample is estimated
from the equations
fiE x V
jiraoles pyruvate/ assay mixtureg x d
or
■-—~— ~ jamoles pyruvate/ gram tissue
where * decrease in optical density (O. D. ) following
the addition of lactic dehydrogenase
V s volume of assay mixture.
£ = extinction coefficient of DPNK which is 6,3
cm. ^/u mole at 340 mp for a light path of 1
d = the light path,
and A » weight of tissue in the assay sample, which
= g. tissue x ml. extract taken for assay
total ml* extract
('total ml. extract1 means the volume of
extractant used plus the correction for the
volume of water contained in the tissue. For
this purpose it is assumed that the water
content of tissues is 15%, In the experiment
reported here the correction for the water
content of the tissues was neglected, as a
5, 0 ml. extractant volume was used on
tissue weights ranging from 20 - 200 mg.
the error introduced fay neglecting this
factor was not more than 3%. )
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Modifications to the Method:-
The only modification to the enzymatic method which has
been introduced, is the approximately twenty-fold increase in the
volume of tissue extractaat used. This is discussed in the section
on tissue preparation (see p. 122 - 124)
METHODS OF TISSUE PREPARATION
A. Tissue Freezing
It is generally accepted that pyruvic acid is rapidly destroy¬
ed in tissues by autolytic procedures and Neish (1953) has recom¬
mended that the animal should be anaesthetised and the appropriate
tissue be frozen in situ, before removal to a container precooled
in a mixture of acetone and dry ice. In the present investigation
it was found difficult to free the ovary from the surrounding fat,
capsule and fallopian tube following quenching in situ. In view of
the fact that an ovary could usually be dissected out, cleaned and
quenched within one minute of removal from the rat, it was decided,
therefore to check if freezing of the tissue was obligatory.
Twelve rats which had been treated with 50 i.u. PMSG prior
to the experiment were anaesthetised, one ovary from each animal
was quenched and frozen, the other ovary was not frozen, but put
into the deproteinicing solution as rapidly as possible. Material
from the rats was pooled and the results are shown in table 36.
The difference of 3.4 mji moles noted between the pyruvate
level in frozen and in unfrozen tissue is less than the standard
deviation (+ 16. 5) of the mean of the five separate observations
TABLE 36
Estimation of pyruvic acid concentration in ovarian material
•which has been frozen and not frozen before extraction with


























made o£ the pyruvate level three days after treatment with 50 i.u.
PMSG (see p. 127). It therefore seemed unlikely that any marked
deterioration in pyruvic acid levels had occurred and for this
reason freezing of the ovarian tissue was diecontinued.
B. Volume of Protein Extractant.
1) In the diiiitrophcnylb.ydrasine method.
Although it had been shown that there was no difference in
the recovery of standards made up in metaphosphcric acid and in
tungstic acid, it seemed relevant to repeat the experiment using
tissue pyruvic acid rather than the pure compound. The ovaries
from 7 rats which had been pretreated with 50 i.u. PMSG at age 21
days and with 25 i.u. HCG on the third day after PMSG, were
removed 11 days after the administration of the HCG, One ovary
from, each rat was extracted by metaphosphoric acid and the other
extracted by tungstic acid. The results obtained with each
extractant are shown in Table 37.
Tt can be seen that the results 12. 7 mjx moles/100 mg.
ovarian tissue extracted by mctaphosphoric acid and 14.1 myi moles/
100 mg. ovarian tissue extracted by tungefic acid were not signi-
• - - •» • ... ■. .... . . .........
ficantly different. It was, therefore, decided to upe tungstic acid
as the protein extractant of choice.
Neish recommended the use of 9.0 ml. tungstic acid to 1.0 g»
tissue as the optimal tissue to protein extractant ratio. Ae ovarian
material was somewhat scarce, it was decided to estimate the
TABLE 37
Estimation of pyruvic acid concentration in ovarian material
which has been extracted with mataphosphoric acid and with


















2 * 1 0.96 82 - 11$ 0.078
fungstic add 1*.12 2 ♦ t 0.99 82 - 120$ 0.095
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pyruvate level in ovarian material wMch had been extracted at the
following ratios
a). 0.1 g. tissue : 8.0 m 1. tungstic acid.
b). 0.1 g. tissue : 1.0 ml. tungstic acid.
Pooled ovarian material from rats which had been treated with 50
i.u. PMSG two days before was used for this experiment. The
results are summarised in table 33.
It can be seen that there was little difference in the results
obtained when different volumes of tissue extrariant were used. It
would appear therefore that increasing the volume of tissue extrac-
tant used does not adversely affect the extraction of pyruvate from
the material, but does reduce the lower limit of sensitivity of the
procedure and was therefore used in future experiments.
2). In the envymie method.
Bucher et al. (1963) recommends that 2.0 g, tissue should
be extracted with 6. 5 ml. 6% perchloric acid. It is apparent from
the text that this ratio has been chosen in order to simplify the
final calculation. It was assumed that to increase the volume of
perchloric acid used per gram of tissue would not materially inter-
fore with the extraction of pyruvate from the tissue.
A 24 day old rat was killed and the liver dissected free. The
liver was then homogenised in 6% perchloric acid in the following
ratios
1). 0.1 g. tissue : 6.5 ml. perchloric acid.
2). 0.2 g. tissue : 6.5 ml. perchloric acid.
TABLE 38
Estimation of pyruvic acid concentration in ovarian material















0.1:8,0 3A.8 2 ♦ 1 0.75 65 - 88$ 0.079
0.1:1.0 85.9 2 + 1 0.76 61 - 91% 0.098
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3). 2.0 g. tissue : 6.5 ml. perchloric acid.
The results are summarised in table 39.
It can be seen that there is little difference in the estimated
level of pyruvic acid when liver tissue is extracted in ten or twenty
times the recommended volume of extractant. It was decided,
therefore, to use a constant (5. 0 ml.) volume of perchloric acid
for the extraction process, and to correct for tissue weight in the
final calculation.
C. Method of Tissue Preparation Adopted.
1) In the dinitrophenylhydrazine method.
Immature female rats were anaesthetised, and the ovaries
rapidly dissected free and cleaned. The ovaries were weighed to
the nearest rag, and then homogenised in freshly prepared tungetic
acid. The volume of acid used was adjusted to the weight of the
available material (1. 0 ml, : 0.1 g. ), The homogenised solu¬
tion was then filtered through T/hatman no. 50 paper. The clear
filtrate obtained represents the •deproteinised solution* on which
the pyruvate estimations were made.
2). In the enzymic method.
Mortars containing a little sand and 5.0 ml. of an approx¬
imately 6% (w/v) perchloric acid solution were prepared. Immature
female rats were killed by cervical dislocation. The ovaries were
rapidly removed, cleaned, blotted and weighed in pairs on a torsion
balance to the nearest rag, Paired ovaries were then ground in a
TABLE 39.
Estimation of pyruvic acid concentration in liver tissue
which has been extracted with different volumes of 10a

















mortar and left to stand for approximately 10 rain, before the
contents were transferred to a conical centrifuge tube. The centri¬
fuge tube was then spun in the cold for 5-7 min. at approximately
2, 500 rcf. The clear supernatant was decanted and 4. 0 ml. were
transferred to a 10 ml. conical flask, 0. 01 ml. methyl orange
indicator (0.05% w/v) was then added and the solution neutralised
with an approximately 5M potassium carbonate solution. Following
neutralisation the conical flasks were left in a tilted position in the
refrigerator for at least 10 min. Most of the supernatant was then
poured off carefully. This was the extract or 'deproteinised
solution* on which the enzymic estimations were made.
Experimental Design.
1. Rate
Animals from a closed colony were used throughout these
experiments. The rats were from Wistar strain, and usually
varied in age from 21 - 24 days, in some experiments where large
numbers of animals were required rats of up to 30 day6 in age were
used. The body weight at the commencement of an experiment was
usually within the weight range 25 - 35 g.
2. Pretreatment
The hormones used in pretreatment were:
a). Pregnant mare serum gonadotrophin (PMSG) - 'Gestyl*
b). Human chorionic gonadctrophin (HCC) - *Pregiiyl*
and were supplied by the courtesy of Organon.
The hormones were dissolved in distilled water and adminis-
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tered eubcutaneously, the injection volume being kept constant at
0.5 ml.
Rats receiving PMSG alone were given cither a single
injection of 25, 50 or 100 i.u. or two injections each of 50 i.u.
The second injection was administered 1, 2 or 3 days after the
fir tit.
Rats receiving both PMSG and HCG were given 50 i.u.
PMSG followed 3 days later by 25 i.u. HCG.
3. Sampling*
Experiments were usually longitudinal in design, i. e.
estimations were made at daily intervals following hormone
administration. When estimations were made by the DNPH method
pooled material from groups of 3 -6 rats was usually used; although
for the estimations on untreated rat ovaries, the material from
approximately 50 rats had to be pooled. When the ensymic method
was used, estimations could usually be made on the combined
material from a tingle pair of ovaries.; however for the esti¬
mations on ovarian material from untreated animals, the ovaries
from 2-7 animals were pooled.
4. Calculation of Hesuits
In the DNPH method results were calculated from standard
curves. The statistical evaluation of the results wat carried out
according to the simplified, three - point, four - point and six -
point assay procedure described by Gadehim (1953 b).
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.
In the enzymic method results were obtained directly from
the appropriate formula (see page 119) and the standard deviation
for each group calculated.
The results obtained by the two methods were then compared
by the student 't* test, (see Appendix).
RESULTS
A. Linitrophenylfaydrag ine method.
Experiment 1. To establish the pyruvic acid concentration
in the seminal vesicles and the ventral lobe of the prostate in
immature male rate.
The accessory gland material from approximately 50 rats
aged between 21 and 30 days was pooled for this experiment. The
results are shown in table 40. The estimated value of 2.84 mjx
moles/ 100 mg, tissue for the seminal vesicle tissue cannot be
accepted as a correct estimation as the assay was statistically
invalid. This level does however appear to be of the same order
ae that obtained for the prostate tissue (3.45 rrm moles/ 100 mg.)
this assay being valid.
Experiment 2, To establish the pyruvic acid concentration
in the ovaries of untreated immature female rats.
The pooled ovarian material from approximately 50 rats agec
between 21 and 3G days was used. The results of this experiment
are shown in table 40. The assay was statistically valid and the
estimated level 3.75 mu moles/100 mg. in of the same order as
TABLE 40.
Estimation of pyruvic acid content in gonadal and accessory


























2*2 0.97 93 - 102 0.100 lea
Ovarian 3.75 2*2 1.06 93 - 121 0.370 X@3
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that found in the immature male gonadal accessory gland material.
Experiment 3. To ascertain the effect of different concen¬
trations of PMSG on the ovarian pyruvic acid level,
A group of 36 rats was divided into 3 groups at weaning and
each group was then injected with one of the following:- 25, 50 or
100 i,u. 'PMSGI rat. The results of this experiment are contained
in tables 41 - 43 and summarised in table 44,
It can be seen that except on day 5, the pyruvic acid levels
in the ovarian material was much the same for all doses of PMSG,
The very high level 40. 9 mu moles/100 mg. for the material from
rats injected with 25 i. u. PMSG, 5 days previously is probably an
artifact due to the use of a three-point assay for the statistical
analysis of the results. If the pyruvic acid level is estimated by
directly reading from the standard curve, a value of 31.1 my moles/
100 mg. is obtained. While this figure is still markedly higher
than the comparable values for rats treated with 50 and 100 i. u.
PMSG, i.e. 23.1 and 25. 9 my moles/ 100 mg. respectively, the
difference can be ascribed to the error inherent in the use of single
estimations in bioassay.
It would appear that, while, stimulation of ovarian growth
by PMSG is accompanied by a marked rise in the level of pyruvic
acid in the ovary, increasing the concentration of PMSG between
25 and 100 i. u. does not further increase the pyruvic acid concen¬
tration in the ovary.
Experiment 4. To establish the ovarian pyruvic acid level
TABLE 41.
Estimation of pyruvic acid concentration in ovarian tissue



















3 33.84 2 + 2 1.193 103 - 133$ 0.063 Xes
4 17.73 2+1 0.626 20 - 99$ 0.248
5 40.91 2 + 1 1.152 82 - 162$ 0.159
6 28.18 2 + 1 0.792 64 " 98$ 0.089
TABLE 42.
Estimation of pyruvic acid concentration in ovarian tissue

















3 29.54 2*2 1.040 92 - 117% 0.066 les
4 20.34 2+2 0.718 55 - 0.091 Xas




0.878 76 - 10$ 0.087 Xes
TABLE 43
Estimation of pyruvic acid concentration in ovarian tissue

















3 27.95 2 + 2 0.985 82 - 117$ 0.096 Tes
4 23.50 2 + 2 0.827 69 - 99$ 0.066 les
5 25.91 2+1 0.914 68 - 117$ 0.186
6 28.98 2+2 0.816 67 - 100$ 0.102 les
I
TABLE 44
Comparison of the pyruvic acid concentration in ovarian tissue
following treatment with various concentrations of PMSG.
Dinitrophenylhydrasin e Determinations.
Days after
mix moles pyruvic acid/100 mg. ovarian tissue







4 17.73 20.34 23.50
5 40.91 23.18 25.91
6 28.18 31.14 28.98
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in immature rats consequent to the administration of a single
injection of 50 i.u. PMSG.
This experiment was repeated a number of times and the
results are contained in table 45 and summarised in table 48 and.
figure 13. It will be seen that following an injection of 50 i.u.
PMSG, there is a marked rise in the pyruvic acid content by the
second day after the injection, which then proceeds to fall and
appears to plateau at about 2.0 myt moles/100 rag, ovarian tissue
by the fifth to sixth day after the injection.
Experiment 5. To establish the ovarian pyruvic acid level
in immature rats which have twice been treated with 50 i.u. PMSG.
In this experiment the second injection of PMSG was
administered three days after the first. Rats were killed on the
first and third days after the second injection. The results of
this experiment are contained in table 46 and summarised in table
48 and figure 13.
It will be seen that immediately following a second injection
of 50 i.u. PMSG there appears to be no further increase in the
pyruvic acid level of ovarian material. One day after a second
injection of PMSG the mean pyruvic acid level was 28.4 + 11.2
mu moles/100 mg. tissue which is not significantly different from
the mean level 24.4 + 5.1 mu moles/100 rag. for tissue from rats
which had been treated with a single dose of PMSG four days before.
It is» however, possible that following a second injection of PMSG
there is a reduction in the pyruvic acid content of ovarian material
TABLE 45
Estimation of pyruvic acid concentrations in ovarian tissue
following a single injection of 50 i.u. FMSG.Dinitrophenyl-
hydrazine Determinations.
Days mu moles
after pyruvic Assay Relative Fiducial \ Validity
50 i.u. acid/ Design Potency Limits A
FMS 100 ag.
\ ■ ' V 1 i; 1
2 04.8 2 ♦ 1 0.75 65-88 0.079
65.9 2 ♦ 1 1.16 95 - 142 0.095
70.6 2 + 1 1.24 101 - 153 0.095
85.9 2 ♦ 1 0.76 61 - 91 0.098
3 29.3 2+2 0.77 57 - 105 0.073 Yes
43.1 2 + 1 0.76 67-37 0.046
23.5 2+2 0.83 73 - 94 0.066 Yes
20.4 2+2 0.72 0.127 Hot
29.5 2 + 2 1.04 92 - 117 0.066 Yes
39.8 2+2 1.05 78 - 139 0.073 Yes
43.2 2 + 1 0.76 67 - 86 0.046
4 16.2 3+3 1.15 99 - 133 0.127 Yes
25.9 2 + 1 0.91 80 - 103 0.074
28.2 2 + 1 0.99 86 - 115 0.089
29.3 2+2 1.03 83 - 129 0.122 Yes
26.6 2+2 0.94 25 - 351 0.072 Yes
20.3 2 + 2 0.72 55 - 84 0.091 Yes
5 14.8 3+3 1.04 92 - 105 0.058 Yes
23.2 2 + 2 1.30 155 - 180 0.233 Yes
6 20.0 2 + 2 1.41 94 - 215 0.180 Yes
24.4 2+2 1.72 156 - 193 0.243 Yes
22.8 2+2 1.6 37 - 188 0.172 Yes
31.1 2+2 0.88 76 - 103 0.087 Ye 3
TABLE 46.
Estimation of pyruvic add concentration in ovarian tissue
following a second injection of 50 i.u. FMSQ, 72 hour3 after
















Limits % X Validity
1 44*8 2*1 0.79 71-87 0.051
26.4. 2*1 0.93 82 - 105 0.074
19.7 2 + 2 0.69 54- 84 0.107 Tes
22.8 2*2 0.83 69-97 0.093 Yes
3 11.3 3*3 0.79 64-99 0.139 Yes
H.2 3*3 1.00 79 - 125 0.151 Yes
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as three days after a second injection the mean level had fallen
to 12. 8 + 2. 0 inji iTiolee/100 mg, which is significantly lower than
the mean level 24. 6 + 4. 7 mjx moles/ 100 mg. fcr the comparable
day (the sixth) after a single injection of PMSO.
Experiniei-t 6. To establish the ovarian pyruvic acid
level in immature rats which havss bean treated with both PMSG and
HCG.
The HCG (25 i.u./rat) was administered three days after
the injection of 50 i.u. PMSG. This experiment was repeated a
number of times and the results are contained in table 47 and
summarised in table 48 and figure 13.
It will be seen that the administration of both hormones does
not appear to greatly alter the pyruvic acid level in ovarian mater¬
ial. One day after the injection of HCG the mean pyruvic acid
level was 24.8 + 6.9 mp moles/100 mg. tissue which is virtually
the same as the mean level 24.4 + 5.1 mn moles/ 100 mg. tissue
from, rate which had been treated with a single dose of PMSG four
days before. Two to three days after the HCG injection the
ovarian pyruvic acid level appears to level off at about 10-15 mja
moles/100 mg. tissue, which is significantly lower than the
comparable levels obtained for rats treated with PMSG alone.
B. Fnzymic Method.
Experiment 7. To establish the pyruvic acid concentration
of the testis of immature male rats.
Separate estimations were made on each teetis. The
TABLE 47.
Estimation of pyruvic acid concentration in ovarian tissue
following an injection of 25 i.u. HCG, 72 hours after the















































































4 11.0 3 + 3 0.77 47 - 125 0.164 Yes
5 8.5 2 + 2 1.19 74 - 243 0.212 Yes
6 17.4 3 + 3 1.22 95 - 153 0.137 Yes
7 14.5 2 + 2 1.02 55 - 198 0.233 Yes
8 7.4 2 + 2 1.04 76 - 152 0.231 Yes
9 12.7 2 + 2 0.89 74 - 108 0.103 Yes
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»v 4 76.8 i 10.1 4
3 7 32.7 - 16.5
' ' '
£ ' ' ' ' '
4 6 24.4 - 5.1 4 28.4 - 11.2 6 24.8 - 6.9
5 2 19.0 * 5.9 2 13.6 * 7.1
6 4 24.6 I 4.7 2 12.8 - 2.0 3 15.5 - 6.4
7 • • : ' .1 ; 1 11.0
8 1 8.5
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estimated value 9.4 + 3.4 mji moles/100 mg, tissue appears
reasonable when compared with the values obtained for other
gonadal tissues.
Experiment 8. To establish the pyruvic acid concentration
in die ovaries of untreated immature female rats.
In this experiment estimations were made on pooled mater¬
ial. The results are shown in table 49. An estimate of the pyru¬
vic acid content per pair of ovaries could not be made directly.
The mean weight of a pair of immature ovaries was 5. 3 mg. and
the estimated pyruvic acid content per 100 mg. was 18. 3 + 7.3 nijx,
moles. From these figures it can be deduced that thejpyruvic acid
content of a single pair of ovaries is about 1 my mole.
Experiment 9 To establish the ovarian pyruvic acid level
in immature rats consequent to the administration of a single
injection of 50 i.u. PMSG.
, .. ..
This experiment was repeated a number of times; three"
observations were usually made on each occasion. The results
..
are shown in table 50 and summarised in tables 57 and 59 and figure
14. It can be seen, that following a single injection of 50 i.u, PMSG
there is firstly a very marked rise in ovarian weight during the first
... * " • - -• ■- - '
three days, a plateau period from day 4 to day 6, and thereafter a
steady falling off in weight. This pattern is reflected in the
concentration of pyruvic acid per pair of ovaries but not in the
concentration of pyruvic acid per 100 mg. ovarian tissue. The
TABLE 49.
Estimation of pyruvic acid concentration in gonadal tissue




















• mean of 12 observations on separate testes
from 6 animals
♦ mean weight of pairs of ovaries from 50 rats
° calculated value
*
mean of 7 observations on pooled material.
TABLE 50
Estimation of pyruvic acid concentration in ovarian tissue





















1 7 16.0 - 2.9 12.3 - 3.4 72.9 - 27.4
2 9 36.6 - 10.3 18.4 - 5.8 49.6 - 5.9
3 18 73.2 - 20.2 20.4 - 6.8 28.6 - 8.1
4 11 82.5 - 25.5 16.5 ~ 2.8 22.5 - 5.8
5 11 84.7 * 28.4 12.2 - 6.0 14.7 * 5.3
6 12 79.8 - 27.1 10.6 * 2.5 14.9 - 5.9
7 12 57.5 - 27.0 9.6 1 4.5 17.3 - 7.6
8 6 50.6 - 15.6 10.9 - 3.5 18.4 - 5.1
9 3 36.7 - 14.3 8.1 — 3.0 22.1 - 0.9
10 3 20.7 - 5.5 7.3 - 4.6 35.1 - 4.5
11 3 25.0 - 2.6 5.6 - 3.5 21.8 - 11.1
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concentration per 100 mg, shows a four-fold rise in the first 24
hours after the injection followed by a steady fall in concentration
which levels off at about the initial concentration by the fourth day
after administration.
Experiment 10. To establish the ovarian pyruvic acid
level in immature rats which have twice been treated with 50 i.u.
PK1S.
In this experiment the second injection of PMSG was
administered one, two or three days after the first, Hats were
sampled daily after the second injection. The results of this
experiment are shown in tables 51 * 54 and summarised in tables
57 - 59 and figure 14.
It can be seen that a second injection of PMSG causes a
very marked increase in the ovarian growth, which is reflected in
the marked rise in the pyruvic acid content per pair of ovaries,
whether the PMSG is administered one, two or three days after
the first injection. A similar increase in the pyruvic acid content
when expressed per 100 mg. tissue was not noted. When the
•econd PMSG injection was given either one or two days after the
initial injection there was little difference between the pyruvic acid
content per 100 mg, of comparable ovaries from rats which had been
treated with one or two doses of PMSG. However, when the second
dose of PMSG was administered three days after the first injection
there was a marked depression in the pyruvic acid content per 100
mg. in the ovarian material from rate which had had two doses of
TABLE 51
Estimation of pyruvic acid concentration in ovarian tissue following













































Estimation of pyruvic acid concentration in ovarian tissue following


















1 6 110.5 + 25.1 23.8 ± 10.3 25.7 + 4.7
2 6 153.2 £ 18.5 29.4 + 3.0 19.2 ± 1.5
3 6 242.5 ± 28.8
- ,
32.7 + 7.7 13.4 + 2.7
TABLE 53
Estimation of pyruvic acid concentration in ovarian tissue following






























































































































































































PMSG when compared with the appropriate single dose material.
Exporime nt 11. To establish the ovarian pyruvic acid
level in immature rats which have been treated with both PMSG
and KCG.
The KCG (25 i.u./rat) was administered three days after
the injection of 50 i.PMSG. This experiment was repeated a
number of times, three observations were usually made on each
occasion. The results are contained in tables 55 and 56 and
summarised in tables 57 - 59 and figure Id.
It will be seen that in the first 24 hours following the
administration, of 25 i.u. HCG, the ovarian weight doubles and
•then almost immediately thereafter is maintained at about that
V •
\
level. The pyruvic acid content per pair of ovaries following the
administration of HCG shows a somewhat erratic pattern but on the
whole is considerably higher than the level of comparable ovaries
from rats which have been treated with a single cose of PMSG,
this is however simply a reflection of the higher ovarian weights
in rats which have had combined PMSG and HCG treatment rather
than PMSG alone. When the pyruvic acid content is expressed as
ray. moles per 100 rag, ovarian tissue there is a marked depression
in pyruvic acid immediately following the administration of HCG,
which plateaus in two to three days to a level considerably lower
than that seen in animals treated with PMSG alone.






Estimation of pyruvic acid concentrations in ovarian tissue following




















1 5 160.5 + 61.5 22.51 ± 12.2 14.3 + 4.7
2
1 -/
6 161.0 ±48.4 15.15 ± 4.2 9.5 + 1.5
3 5 106.4 ± 26.1 15.25 ± 10.6 7.8 ± 6.0




4 192.7 ± 32.1 18.15 + 1.0 10.4 + 1.6
6 180.5 ± 26.2 28.64 ± 15.3 16.0 + 11.7
3 3 153.7 ± 25.1 20.57 ± 6.4 13.4 + 3.3
0 3 157.3 ± 19.9 15.73 ± 1.2 10.0 ± 1.2
10 4 157.7 + 15.7 25.71 ± 8,8 18.2 + 8.4
11 3 173.0 ± 15.6 17.34 ± 1.4 10.0 + 0.8
X
TABLE56
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Second injection 50i.u.PMS 24hrs.after firstinjection
Second injection 50i.u.PMS 48hrs.after firstinjection
Second injection 50i.u.PMS 72hrs.after firstinjection
Second injection 25i.u.HCG 72hrs.after firstinjection
innmoles/ 100mg./ tissue mean+S.D.
rnumoles/ 100mg. tissue mean+S.D.
mpoles/ 100mg. tissue mean±S.D.
muoles/ 100mg. tissue taean+S.D.
muoles/ loomg. tissue mean£S.D.
1 2 3 4 5 6 7 8























27.4 5.8 8.1 5.8 5.3 5.8 7.6 5.1 0.9 4.5 11.1
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Fig.14:- PYRUVIC ACID LEVELS IN THE OVARIES OF IMMATURE RATS
PRIOR TO AND FOLLOWING TREATMENT IVITH PREGNANT MASS
SERUM GCNADOTRQPHIN (PMSG) AND HUMAN CHORIONIC
GONADOTEOPHIN (HCG). ESTIMATIONS BY THE ENZYMIC
METHOD.
F i g. 14
133
Experiments 2 and 8
The results are compared in table 60. A significant 5 •
fold difference in the pyruvic acid level in untreated immature
ovaries was observed. It is probable that this difference in
values can be discounted. For a discussion on this point see page
135,
Experiments 4 and 9»
The results of these experiments are compared in table 61.
It will be seen that on the second and sixth days after the adminis¬
tration of PMSG, the difference in the results obtained by the two
methods was significant, but on the third, fourth and fifth days
thereafter the difference was quite clearly not significant. While
the difference in values for the second and sixth days is statistically
significant, the concentrations obtained by the DNPH method are
less than twice the values obtained by the enzymic method and can
probably be discounted for the following reasons :~>
a), a smaller number of estimations were made by the DNPH
method, and
b). seasonal animal differences due to the estimations by the two
methods being made at different periods of the year.
Experiments 5 and 10
Only two comparisons could be made in this category, and
these are shown in table 62. It will be seen that one shows a
significant difference between the results obtained by the two
methods, while the other does not. When the results for the third
TABLE 60
Comparison of estimations of pyruvic acid content
in the ovaries of untreated immature rats

















3.75 18.30 6 5.31 0.01 - 0.001 Significant
TABLE 61
Comparison of estimations of pyruvic acid concentration in
ovarian material following the administration of 50 i.u. PMSG,















2 76.8 49.6 11 6.18 < 0.001 Significant
3 32.7 28.6 25 0.76 0.4 - 0.5 Not significant
4 24.4 22.5 15 0.66 0.5 - 0.6 Not significant
5 19.0 14.7 13 1.34 0.2 - 0.3 Not significant
6 24.6 15.0 14 2.93 0.01- 0.02 Significant
TABLE 02
Comparison of ovarian pyruvic acid content following the
administration of two injections of 50 i.u. PMSG,

















1 23.4 16.6 10 2. 22 0.05 - 0.1 Not significant
'3 12.8 9.2 5 3.16 0.02 -0.05 Significant
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clay are considered the actual difference between the two means is
seen to be quite small, but as the standard deviations obtained in
this experiment were exceptionally low, the difference between the
,
two means becomes statistically significant.
Experiments 6 and 11.
Following the administration of HCG, results were obtained
on aayc 1, 2, 3 and 11 by the two methods. These are compared
in table 63, where it can be seen that on the first and eleventh days
after HCG, the results obtained by the two methods show signifi¬
cant differences. As in the previous experiments, it is probable
that a major factor in the causation of apparently statistically
significant differences between the two methods, ic the low stand¬
ard deviation shown by the results obtained by the enzymic method.
Comment.
It would be reasonable to say that the results obtained by
the two methods are comparable. While 50A of the comparisons
apparently show a significant difference in the results obtained by
the two methods, at least half of these have quite low actual
differences which would probably not be significant, if the group
means had shown higher standard deviations. Excepting the values
obtained for untreated immature ovaries, the higher value is never
as much as twice the lower result. Other contributory causes are
probably animal differences and the low number of replicate esti¬
mations by the DNPH method.
TABLE 63
Comparison of estimations of ovarian pyruvic acid content,
following the administration of 50 i.u. PR1SG and 25 i.u. HOG,
obtained by the DNPH and enzymis methods.
Days Pyruvate Degrees t P Difference
after concentration of




1 24,3 14.3 & 2.83 0.02 - 0.05 Significant
2 13.6 9.5 6 1.54 0.1 - 0.2 Not significant
3 15.5 7.8 6 1.60 0.1 - 0.2 Not significant
11 12.8 10.0 4 ' 3.73 0.02 - 0.05 Significant
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DISCUSSION
The difference in the results for the pyruvic acid concen¬
tration per 100 mg, ovarian tissue obtained by the dinitrophenyl-
hydrazine method when compared with thor.e obtained by the enzymic
method is not significant in most cases. As the two methods
involved are totally different in concept and performance, this
implies that the values obtained are reasonably comparable and
therefore probably represent a true assessment of the pyruvic
acid level.
The greatest discrepancy in the results appears in the value
for immature untreated ovarian material for which the values
obtained are 3. 75 and 18,3 mp moles/100 mg. for the dinitrophenyl-
hydrazine and the enzymic methods respectively. This 5-fold
difference is somewhat disquieting but can probably be discounted
for the following reasons:-
1) Only one assay was carried out on this material by the
dinitrophenylhydrazine method due to the large number of
animals required per assay.
2) The range in values 9, 3 - 27.6 nip moles by the enzymic method
is very wide.
3) Seasonal variation - estimations by tlie DNPH method were made
in the spring and early summer, by the enzymic method in the
autumn and winter months.
Similar reasons probably account for the discrepancy noted.
- Ite
two days after PMSQ stimulation, The difference here is,
however, considerably less and may also in part be accounted for
by differences in ovarian weight.
Despite these differences in the values for the immature
ovaries it is obvious that, initially, prior to hormonal stimulus the
pyruvic acid level is relatively low. It is therefore interesting to
note that, in the first 24 hours after PMSG stimulation, there is an
approximately 5-fold increase in pyruvic acid concentration. This
high value then rapidly fads off and about four days after PMSG
administration has fallen to a level which is of the same order as
the initial concentration. It is postulated that this initial rise is
connected with tne marked increase in ovarian growth which is
caused by the administration of PMSG, However 'the increase in
ovarian growth continues for about three days when it reaches a
plateau and then progressively decreases from the seventh day
onwards, while a continued rise in pyruvic acid was not seen. It
was then thought that perhaps the rise in pyruvic acid concentration
only occurred during the initial phase of a growth spurt and so
attempts were made to increase the pyruvic acid concentration by
further increases in ovarian weight obtained by either the adminis¬
tration of a second injection of PMSG- or of I-iGG,
it was, however, found that in the first few dayt following
the administration of a second dose of PMSG, whether the second
injection was given one, two or three days after the first, there
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was no significant difference in the ovarian pyruvic acid concen¬
tration between animals which had received one or two doses of
PMSG. It was noted that following the administration of HCG that
there was a further significant depletion ex ovarian pyruvic acid*
It would appear therefore that renewing the ovarian growth is not a
cause of ovarian pyruvate build up, but, rather of pyruvate deple¬
tion.
One finding rioted in the laboratory, which may have some
bearing on this problem is that the ovary and uterus of untreated
immature rats are usually deeply imbedded in fat. following the
administration of PMSG and during the consequent ovarian growth
period, this fat disappear:; and by the third to fourth day after
PMSG the ovary it completely free of surrounding; fat. It is known
that during periods of fasting free fatty acids form the main meta¬
bolic fuel of the heart (Olson, I962),aad Garland, New ..holme and
Handle (1962) have shown in hi vitro experiments that the addition
cf free fatty acids to the medium diminishes the uptake and oxidation
of pyruvate by rat heart and diaphragm muscle. It is therefore
reasonable to suggest that the administration of Pi,ISC with conse¬
quent high ovarian activity stimulates in some way the mobilisation
of the surrounding fat depot and that, the pyruvate build up noted is
in fact the consequence of pyruvate sparing, due to the use of the
surrounding fat as the preferred metabolic fuel. The plateaued
level noted three to four days after PMSG administration thus
.
reflects a basic turnover level reached vfa en the surrounding fat
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depots nave been, exhausted. The -even lower level noted following
the administration ox HCG probably reflects an even higher turn¬
over rate ia pyruvate consequent to the increased metabolic rate
which occurs auring the ovarian luteinising process following HCG,
SUMMARY
1. Two methods for the estimation of pyruvic acid have been
established. One is dependant on the formation of a coloured
hydrazone, the other on the enzyxnic conversion of pyruvic acid
to lactic acid*
2. Both metnods have been used to estimate the pyruvic acid
content of ovarian material from immature- rats, both prior
to and following treatment with PMSG and HCG.




It is over thirty years since Evans and Simpson (1931)
reported the first quantitative method for the assay of pituitary
growth hormone. In the succeeding decades many workers have
tried to develop more sensitive methods ©f assay and as purer
hormone preparations became available, the specificity of the
methods has been studied. Over the last ten years, sensitive
and specific immunological techniques have been applied to the
assay of growth hormone. Initially, it was not known whether the
biologically active growth promoting principle was the same as
the immunologically active material, and few investigators have
reported the results of comparative assays. The growth hormone
content of serum could not be measured by both the tibial test and
by immunological methods, because of the relative lack of sensiti¬
vity of the former, however, comparative estimates of potency of
standard growth hormone preparations have been made by the two
methods. In the present study the results of such a comparison
are reported (see Chapters 2 and 3).
In the tibial section (Chapter 2), the potencies of a large
number of growth hormone preparations of pituitary origin were
measured by this method, and in Chapter 3, the potencies of one
bovine and one human growth hormone preparation were again
estimated, but this time by the haemagglutination-inhibition assay.
It was shown that there was reasonable agreement between the two
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estimates of potency for these preparations, the indices of discrim¬
ination were 1. 32 and 0. 82 for the BGH and the HGH preparations
respectively* It is interesting to note the differences between the
two methods. The response in the tibial test is a graded one and
is characterised by having a relatively low slope and high standard
deviation, while the response of the haemagglutination-inhibition
assay is of an all-or-none type and consequently has a very steep
dose response curve. These differences are high lighted by
static tieal analysis, which indicates that the tibial test is a
relatively imprecise method having high lambda figures and vexy
wide fiducial limits, while the immunological technique is very
precise with low lambda figures and narrow fiducial limits.
In this study, it has-been shown that the index of discrim¬
ination for the two assay methods is approximately unity. There¬
fore, it would appear that the biological and immunological activity
of growth hormone as measured by the tibial test and the haemag-
glutiaafcion-inhibition were respectively contained in different
chemical groupings of the same molecule and that the two methods
were measuring the same substance. This study has also shown
•
, •; , " •' • ' . • t v i, . . ' . " -
that from a statistical viewpoint, the haemagglutination - inhibition
method is a more precise assay system for the quantitative assay of
purified growth hormone.
Recently, there has been considerable controversy as to
whether the haemagglutination-inhibition method for growth hormone
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determination as described by Read (I960 ab), is in fact a suitable
method for the measurement of the hormone in body fluids. The
present investigation has shown that the procedure meets the re¬
quirements of practicability as suggested by Borth (1957) in that
it is cheap, rapid and requires little skill of the operator. There
is also extremely good agreement between replicate estimations
(see Chapter 3). Providing that the necessary steps to remove
interfering substances are taken, the method appears to be specific
and other anterior pituitary hormones do not interfere with the
results obtained (see Chapter 3). The high degree of specificity
shown by the immunological method is in marked contrast to the
lack of specificity shown by the tibial test and the method depending
on the increase in total body weight in rats (see Chapter 2).
The immunological technique has other advantages over the
bioassay methods in its greater sensitivity and its extensive dose
response curve. While, its ultimate limit of sensitivity appears
to be about 10 mug. / tube, preliminary scanning experiments can
cover a range of up to 1 nag. I tube. The method is therefore much
more sensitive than the tibial test for which the dose response curve
extends over the range 5 - 250 pg. / rat. The two-fold form of the
haemagglutinatioea-inhibition assay (see Chapter 3, table 24).,
with its extensive preliminary scanning experiment followed by the
narrow range accurate assay made this a very useful tool for esti¬
mating the growth hormone content of a purified preparation whose
approximate potency was completely unknown. Such preparations
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are extremely difficult to measure by the tibial test as valid esti¬
mates can only be made when approximately the same effective
doses of the standard and the unknown preparation© are administered
1. e. ideally the final relative potency of the assay should be
approximately unity, the amount of the unknown used being adjust¬
ed to this end.
As was to be expected, the agreement between replicates
using the immunological assay was excellent (see Chapter 3, tables
26 - 28), and considering the inherent inaccuracies of the tibial
test agreement between replicates here was also good (see Chapter
2, rabies 11 and 12). Despite the apparent advantages of both
these methods it is therefore most unfortunate that neither of these
assays is sufficiently sensitive to be used for the estimation of
growth hormone in human body fluids. Provided that the haemag-
glutination-inhibitioa assay is correctly set up, it has been shown
in Chapter 3 that the growth hormone content of human serum cannot
be measured and is therefore less than 10 mjig. /ml. an estimate
which is in agreement with the more recent findings of Click et al.
(1%3) and Hunter and Greenwood (1964) who have used radio-
imrmmological assay techniques. However, it is worthy of note
that even with the more sensitive method, growth hormone levels
are frequently below the limit of sensitivity in normal subjects.
Attempts to modify the Ortho Pregnancy Diagnosis Kit for
quantitative clinical use were also unsuccessful. Several worker©
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(for references see Chapter 1) have shown it to be am excellent
method for the diagnosis of pregnancy. It is probable that this is
due to the fact that as a qualitative test it has been weighted to give
a positive reaction only when very high concentrations of HCG are
present, and so interference by non-specific agents is relatively
unimportant. However, when attempts have been made to quan-
titate this method, the presence of these non-specific substances
becomes increasingly important. It is still a matter of controversy
as to what is the precise form of these non-specific agents. It has
been suggested that as the endpoint measured was the percentage of
light transmitted through the test sample, that this interference
Is due to the presence of some non-specific light absorbant substance.
Since the test samples were urines (which naturally contain substan¬
tial amounts of ehioraagens and non-specific absorbants), this
■
. ' -x--,.• ,
.... r.
appeared to be a reasonable hypothesis. If, however, this is the
explanation, then, the use of the same urine as the blank should
compensate for, and thus neutralise any such absorbant effects
in the test sample. Even though this was the procedure used here,
interference was still noted. The work presented here, has thus
shown that the presence of chromagens in the test samples was not
the major cause of interference, although it may yet prove to be
a minor contributory factor. Although, all samples were brought
to a pH of 8. 0 - 8. 5 (the near optimal pH figure quoted by Singer
and Plotz, 1956) before use, interference still occurred, and so the
work presented here (see Chapter 3,) has shown that pH was not a
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major cause of interference, a finding which confirms Goldin*s
observation (1962) that urine pH was not a critical factor during
pregnancy diagnosis tests, It is probable that the specific gravity
of the sample plays a relatively important part; some workers
(Goldin, 1962; Henry and Little, 1962) have observed either
inconclusive or false results when urines with a specific gravity
of less than 1, 015 were tested, If the specific gravity had proved
to be the most important cause of interference, this could have been
overcome by concentrating the sample to some extent. However,
it now seems certain that the most important factor is the ionic
concentration of the sample, Singer and Plots (1956) noted that
there was marked spontaneous agglutination of latex particles
when the electrolvte concentration, was less than 0.3% and greater
than 1.25% sodium chloride, and advised suspending particles in a
buffer containing 3.85% NaCl. It would, however, be a somewhat
complex procedure to stabilise the electrolyte concentration of
urine at the optimum level, and for this reason attempts to develop
a quantitative direct assay for HCG in urine using a modified form
of the latex pregnancy diagnosis test do not seem to be worthwhile.
It is interesting to note that Gosb and T&ymor (1962) claimed
satisfactory results using urine which was first extracted by the
kaolin-acetone method of Albert (1955) prior to r©suspension of
the extract in the buffered saline.
Although the two immunological methods examined here
have proved to be unsuitable for clinical use, they are both of value
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and complementary to the bioassay methods for growth hormone
and HCG, when estimates of the potency of standards or pituitary
extracts are required. Read's haemagglutination-inhibition method
for the assay of growth hormone could easily be used instead of the
tibial test in laboratories which require only occasional estimates
of the potency of purified growth hormone preparations, either
for the purpose of checking the potency of standards or for the
standardisation of pituitary extracts. The only special require¬
ments for this assay are a high titre antiserum (which can be
readily prepared and stored until required at - 20°C, ) and a source
of sheep or human red cells (both of which are readily available,)
The method is much cheaper and more practicable than is the
tibial test in which large numbers of hypophysectomieed weanling
rats are required. It is also easier to perform replicate estima¬
tions of potency by the immunological method. As hypophys ecto-
mised animals are not required for the bioassay of HCG and the
sensitivity of the two methods is approximately the same, there is
no great advantage in using the immunological methods for quantita¬
tive work except in laboratories which have no animal house and
only require occasional estimations. It can, however, be used in
a supplementary form to confirm the potency of new standards in
places which habitually use bioassay methods.
Although, the relatively simple immunological assays of the
haemagglutination-inhibition and latex particle agglutination-inhibi¬
tion types had initially shown great promise, the data presented
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(Chapter 3) has shown that they are not suitable for clinical work.
With this in mind, and following the successful development of the
ovarian cholesterol depletion assay for LH (Bell et al. , 1964),
attention was turned towards the measurement of ovarian pyruvic
acid, (See Chapter 4.)
Little is known about the level of pyruvic acid in the ovary,
Neieh (1953) has shown the presence of fairly high concentrations
of pyruvic acid in rat blood and brain tissue. He also measured
the pyruvic acid concentration in tissue from the lungs, liver,
spleen and kidney, but did not investigate the gonads. Pyruvate
is known to be an important general metabolic precursor and it has
been shown to be a precursor of mevalonic acid and hence of
cholesterol (Cornforth, I960). Methods of estimation were known
to be reasonably sensitive, specific and practicable. However, as
was pointed out by Neish (195?) although pyruvic acid is the most
stable of the oC- keto acids found in animal tissues, it is advisable
to carry out estimations as rapidly as possible to avoid post-mortem
autolysis.
The results presented here (Chapter 4) proved to be very
interesting. As was to be expected, the level in immature untreat¬
ed ovarian material was very low. Estimates were made by two
methods and the values 3. 75 mp moles/100 mg. (DNPH method) and
18.3 mp moles/100 mg. (enzymic method) which are equivalent to
0.33 and 1.61 mg/100 g. respectively are of the same order as the
values quoted by Neish (1953) e.g. 0.16 - 1. 21 mg. /100 g. for lung
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tissue. Following the gonadotrophs stimulation consequent to the
administration of PMSG there was a marked rise in pyruvic acid
concentration which then fell off rapidly. There was no further
increase in pyruvic acid concentration when ovarian growth was
further stimulated by the administration of a second dose of PMSG
or HCG; in fact a relative depletion of pyruvic acid was observed.
It seems that the most likely explanation of this curious pattern
of pyruvic acid response to gonadotrophs stimulation lies outwith
the ovary itself.
It was observed, during the course of these experiments
and by other workers in the laboratory in Edinburgh, that initially
the immature ovary was surrounded by a mass of fat, which was
difficult to remove, but following the administration of PMSG and
HCG, as the ovary grew, this fat depot was used up and had dissa-
peared Z - 3 days after the administration cf HCG, incidentally
making the ovary much easier to clean. It is suggested therefore,
that the pyruvic acid build up occurs in the ovary during the initial
growth period following a single injection of PMSG, because the
surrounding fat was being preferentially metabolised for energy
requirements and that when this was exhausted, pyruvic acid was
then used as a precursor thus causing the falling off in pyruvic acid
concentration noted.
It seems unlikely that the initial rise in pyruvic acid con¬
centration observed here was due to either a simple growth effect
or to the development of follicles in the ovary. If this was the
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explanation one would expect the increase to be either further
enhanced or at least maintained following the administration of a
second dose of PMSG. The marked depletion which does in fact
occur can however, be explained by the fat mobilisation theory.
Ovarian growth is very rapid following the administration of either
HCG to the PMSG primed ovary or of a second dose of PMSG. Thus
the fat depot would be exhausted even more rapidly and the pyruvic
acid called on as a precursor earlier, thus depleting the reserves.
An alternative explanation of the marked depletion of pyruvic
acid which occurs may lie in the observations of Ssarka, Mayer and
Evans (1933). Pyruvic acid is known to be metabolised to lactic
acid and these workers noted that in their in vitro experiments
ovarian material from rats which had been treated with PMSG at
least 4 days before, converted 1 molecule of oxygen to 2. 55 mole¬
cules of lactic acid, while untreated animals showed a conversion
rate of only 1 : 1.36, although the total oxygen consumption by
material from both groups, was virtually the same. It is thus
possible that the marked fall in pyruvic acid levels (from the third
day onwards after PMSG administration) observed in the experiments
presented herein (Chapter 4) reflects an increased rate of conver¬
sion of pyruvic acid to lactic acid.
Fven the approximately six-fold rise in pyruvic acid (to
about 6. 5 jig! 100 mg,), which followed the administration of a single
injection of PMSG, did not raise the ovarian pyruvate concentration
to the level of cholesterol (up to 1000 y.gl 100 mg,, Bell et al., 1964)
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seen in the ovary. This implies that while pyruvic acid is a
precursor of cholesterol, its turnover rate it so rapid that none is
stored by the ovary. The basic ovarian pyruvic acid levels are
so low and difficult to measure that it would not be possible to
detect any further gonadotrophs effect and for this reason no
attempt was made to develop the findings obtained as a possible
assay method for either FSH or LH. However, the data presented
here provides further information about the effect of the gonado-
trophic hormones on intermediary metabolism in the ovary.
Although bioassays are intended to give quantitative infor¬
mation about the substances they are measuring, they can some¬
times be usefully adapted to supply qualitative information. The
data presented here (see Chapter 2) has shown chat the tibial test
can be used in this way. It has been shown that in the hypophy-
sectomised rat, the alteration in the width of the proximal epiphysis
of the tibia known as the tibial test is simply a relatively sensitive
but non-specific index of the growth of the animal. Using this
qualitative form of the tibial test, the growth promoting or inhibit¬
ing properties of new compounds have been investigated. The
dithiocarbamoylhydrazine derivative studied herein has been shown
to have a marked growth inhibitory action, while this may weli be a
pbenomonen of the dosage used, it could be a reflection of the
recently proved general toxicity of the compound (Brown, 1363).
Similarly the lack of effect of the ACTH-like synthetic polypeptide
could be a dosage effect, although it might reflect a real loss of
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buological activity. A clinical problem (muscular atrophy) was
also investigated using the tibial test in this way. The work
presented here has shown that surgically induced muscular atrophy
of the gastrocnemius muscle does not affect cartilage growth and
that treatment of these pituitary intact animals with substantial
doses of the anterior pituitary hormones did not modify cartilage
growth although it had some effect on the atrophied muscle. It
would appear, therefore, that lamness due to muscular disease is
not accompanied by a shortening of the bone. The lack of effect
of administered anterior pituitary hormones on bone growth in
these animals was surprising, but growth effects may have been
masked by the use of pituitary intact rats rather than the hypophy-
sectomised animal of the standard growth hormone tibial assay.
Thus the work presented here has shown that even though
new assays have been developed and old ones modified, there is still
a need for more sensitive procedures which can be applied to
clinical problems and that attempts to study the physiology of fee
hormones involved remain an important field for future investigation.
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SUMMARY
1. The Tibial Test for growth hormone has been established;
its conditions g£ assay and the specificity of the method have
been investigated.
2. The tibial test has been applied to the estimation of the
potency of a number of pituitary growth hormone preparations
from different animal species and to an assessment of the
effects on cartilage growth of two synthetic compounds and of
artificially induced muscular atrophy.
3. Antisera have been raised to bovine and human growth hormone
and to human chorionic gonadotrophin, and the specificity of
the antisera examined.
4. The Haerr .agglutination-Inhibition method for the determination
of both bovine and human growth hormone was established;
the conditions of assay and the specificity of the method have
been examined,
5. The haemaggluunation-inlubitioa method has been applied to
the estimation of the potency of a bovine and a human pituitary
growth hormone preparation and of four human pituitary
fractions. It has also been applied to the estimation of the
growth hormone content of sera from normal human subjects.
6. The Ortho Pregnancy Diagnosis Kit has been modified to
provide a quantitative method for the estimation of purified
HCG preparations.
7. This latex particle agglutination-inhibition method has been
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applied to the quantitative estimation of HCG in urine.
8. Two methods for the estimation of pyruvic acid* one
dependant on the formation of a coloured hydrasone, the other
on the enzymic conversion of pyruvic acid to lactic acid, have
been established.
9. Both these methods have been applied to the determination of
the pyruvic acid content of ovarian material from immature
rats, both prior to and following the administration of
PMSG and HCG.




All the assay procedures which depended on a graded or a
measured effect (i.e. tibial assays, latex agglutination-inhibition
assays and the estimations of pyruvate by the dinitrophenylhydraaine
method) were of a three-point, four-point or six-point design as
described fey Gaddum (1953a). The assay procedures dependant
on an all - or - none or quantal response (i. e. haemagglutination-
inhibition assays) were of a four-point or six-point design as
described by Gaddum (1933, 1953a). The calculations of the rela¬
tive potency, the fiducial limits of error and the index of precision
for both types of assay have been carried out according to the sim¬
plified formulae of Gaddum (1953b).
One of the most commonly used methods for estimating the
precision of bioassay procedures is the calculation of the index of
precision ( A )• which provides an estimate of the standard deviation
of the logarithms of the individual effective doses. For assays
dependant on measured effects this is calculated from the formula
where s is the mean standard deviation of the responses, and b
is the slope of the dose response curve.
In quantal assays where the response is submitted to probit
fcrauodormation before calculation, and b, w/hile, still the slope of
the uoee response curve, has a somewhat different meaning, the
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index of precision is calculated from the formula
A 4
The precision of a given assay is considered to be high
when s is small and b is large, i. e. the lower the figure for
the more precise the assay. In practice, an assay is consid¬
ered to be very precise when the index of precision is less than
0,2, while an assay with a ^ figure greater than 0,2 is described
as having a low precision.
The validity of the four-point and six-point assays was also
tested according to the methods of Gaddum (1903b), An assay
was considered to be valid when no significant difference between
the slopes of the log dose-effect curves of the standard and unknown
preparations could be demonstrated. While, an absence of parall¬
elism between the slopes of the standard and the unknown can be
taken as a positive indication of lack of identity between the standard
and test preparations, the presence of parallelism between the two
slopes cannot be taken as irrefutable evidence that the two prepar¬
ations are identical.
The statistical method of Gaddum (1953b) was also used to
determine the linearity of the log dose response curves of the
standard and the unknown preparations in six-point assays. Ideally
the response observed for the middle dose should lie midway between
the responses observed for the high and low doses. A significant
deviation from the straight line indicates that the response measured
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is not being altered in a regular manner and invalidates the results
obtained.
The fiducial limits or 95% confidence limits as they are
sometimes called, are the limits within which the potency may be
expected to lie in 95% of assays, Vhere there is a good overlap
between the fiducial limits of separate assays using the same
standard, it is reasonable to assume a common identity for the
unknown preparations, "Where there is no overlap in the confi¬
dence limits, it can be considered that there is a qualitative dis¬
similarity between the preparations. Fiducial limits can also
be used to compare different assay methods. Where comparable
relative potencies with overlapping confidence limits are obtained
from different assay methods for the same preparation, it can be
argued that the methods are measuring the same substa nee.
In some experiments (tibial tests and pyruvate estimations)
the standard deviation of a response was calculated according to the
method of Gaddum (1953b), For the tibial test where the standard
deviations are large, it has been the convention to express the
results as the mean + the standard error of the mean. The
standard error of the mean is in fact the square root of the variance
(or standard deviation squared) divided by .he number of observa¬
tions? this was also calculated according to the method of Gaddum
(1953b).
When comparisons of results were required, the student 't*
test as described by Gaddum (1953b) was used. This test indicates
whether the discrepancy between two sets of results can be
accounted for by the errors of the test, and is used to ascertain the
significance of the difference between the means. It is an estimate
of the variance of the difference of the means; the significance of
this value is determined by consulting a table of't* (Fisher and
Yates, 1957),
The Index of Discrimination was used to compare the results
obtained by the tibial test and the haemagglutinatior-inhibition assay
for growth hormone. It is the ratio of the results obtained by the
two methods and was calculated according to the method of Caddum
(1955) i, e.
Relative potency by tibial test
Index of Discrimination *
Relative potency by immuno-assay
When the index of discrimination is unity, it is assumed that the
active principle measured by the two teste is identical. If,
however, the value is widely divergent from unity then a qualitative
difference between the two assays is thougai to exist.
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